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II. Abstract 
 
Cyclic peptides have potential as scaffolds for novel pharmaceuticals, however their 
chemical synthesis can be challenging and as such natural sources are often explored. 
Several species of cyanobacteria produce a family of cyclic peptides, the cyanobactins, 
through the ribosomal synthesis of precursor peptides and post-translational tailoring. 
The patellamides, a member of the cyanobactin family, are cyclic octapeptides 
containing D-stereo centres and heterocyclised amino acids. A single gene cluster, patA 
- patG, contains the genes for the expression of the precursor peptide and the 
enzymes responsible for post-translational modifications including a heterocyclase, 
protease, macrocyclase and oxidase. Biochemical and structural analysis on the 
patellamide and related cyanobactin pathways has been carried out. 
   The crystal structure of PatF, a proposed prenyl transferase, has been determined, 
highlighting that it is likely evolutionary inactive due to changes to key residues when 
compared to active homologues. This is in agreement with the knowledge that no 
naturally prenylated patellamides have been discovered to date. 
   The crystal structure of the macrocyclase domain of PatG has been determined in 
complex with a substrate analogue peptide. The structure, together with biochemical 
analysis has allowed a mechanism of macrocyclisation to be proposed, confirming the 
requirement of a specific substrate conformation to enable macrocyclisation. 
   Using isolated enzymes from the patellamide and related pathways, a small scale 
library of macrocycles made up of diverse sequences has been created in vitro and 
characterised by mass spectrometry and in certain cases NMR. In order to further 
enhance diversity, macrocycles containing unnatural amino acids have been created 
using three approaches; SeCys derived precursor peptides, intein-mediated peptide 
ligation and pEVOL amber codon technology. 
   Finally, two oxidase enzymes from cyanobactin pathways have been purified, 
characterised and confirmed active for thiazoline oxidation.  Native X-ray datasets on 
crystals of the oxidase CyaGox have been collected and phasing trials are on-going.  
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1. Introduction 
 
1.1  Cyclic Peptides, RiPPs and Cyanobactins 
 
1.1.1 Cyclic Peptides 
 
Cyclic peptides have long been of interest to the biotechnology and pharmaceutical 
industries as novel therapeutics. They already have diverse applications in biology 
including antibiotics (e.g. Daptomycin [1], [2] Figure 1.1 A), immunosuppressants (e.g. 
Cyclosporine A [3] Figure 1.1 B), anti-cancer drugs (e.g. Somatostatin [4] Figure 1.1 C), 
and also as various probes and tools in biotechnology [5] (Figure 1.1).  
 
 
 
Figure 1.1: Chemical Structures of Cyclic Peptides. Chemical structures of (A) the antibiotic Daptomycin, (B) the 
immunosuppressant Cyclosporine A, (C) the anti-cancer drug Somatostatin and (D) the antibiotic 
Gramicidin S.  
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Cyclic peptides possess several properties that make them interesting pharmaceutical 
entities. They are considerably more stable (less prone to breakdown) than linear 
peptides due to their conformational rigidity and their lack of N- and C- termini means 
they are less prone to degradation by exo-proteases. They have increased 
bioavailability as the absence of the charged termini facilitates their movement across 
lipid membranes [6]. In some cases, stability is further increased by the presence of 
internal bonding between side chains e.g. disulfide bonds between cysteine residues 
[7]. As drug molecules, cyclic peptides often occur beyond the molecular weight limits 
defined by the Lipinski “rule of five” guidelines for small molecule compounds [8], 
however their size and increased chemical diversity can offer improvements in potency 
and specificity [9]. The use of peptides also bridges the chemical space gap between 
small molecules and biologics (e.g. antibodies). 
 
The chemical synthesis of cyclic peptides is particularly challenging due to cost and low 
yields [10] and achieving diversity is difficult due to limitations in chemical composition 
[11]. As a result, there is interest in examining the biosynthesis of natural cyclic 
peptides and harnessing the potential for utilising these processes to generate novel 
diverse compounds [12] [13] 
 
Many cyclic peptide molecules used in therapies today are derived from natural 
sources, e.g. Cyclosporine A from the fungi Tolypocladium inflatum [3], Daptomycin 
(Streptomyces roseosporus) [1] [2], or derivatised from a natural source e.g. the 
antibiotic Gramicidin S (Figure 1.1 D), a cyclic derivative of Gramicidin (Bacillus brevis) 
[14]. Marine organisms are one such natural source which provide a significant 
numbers of cyclic peptides [15].  
 
 
1.1.2 Ribosomally Synthesised and Post-translationally Modified Peptides (RiPPS) 
 
Ribosomally synthesised and post-translationally modified peptides (RiPPs) are a class 
of peptidic natural products which are derived from a ribosomally synthesised 
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precursor peptide and matured through a range of post translational modifications 
[16]. RiPPs cover a diverse range of natural products and can be sub-characterised into 
over twenty groups; exemplars include lanthipeptides [17], bottromycins [18], 
microcins [19], linear azol(in)e-containing peptide (LAPs) [20], amatoxins and 
phallotoxins [21], cyanobactins [22] and cyclotides [23] (Figure 1.2). Across the RiPP 
family, a range of biological activities have been established including antibiotics [18] 
[24], toxins [21] and anti-HIV activity [25]. 
 
 
 
Figure 1.2 Chemical Structures of RiPPs. Chemical structures of (A) The lanthipeptide NisinA [24], (B) The LAP 
Plantazolicin [26] [27],(C) Bottromycin A2 [28] and (D) the amatoxin -amanitin [29]).  
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All RiPPs have a common general biosynthesis with a precursor peptide ribosomally 
synthesised containing a leader peptide (or in rarer cases a follower peptide) prior to 
one or multiple core peptides and in some cases is also followed by a C-terminal 
enzyme recognition sequence (Figure 1.3) [16]. The full length peptide undergoes post 
translational modifications with enzymes that interact with the leader sequence and 
then subsequently modify the core peptide. This process therefore uncouples 
recognition from catalysis, potentially to allow hypervariable core peptide sequences 
to be modified by the same set of enzymes. Following modification, the core peptide is 
proteolytically excised to yield the mature RiPP [16]. In several subcategories of RiPPs 
the peptide is cyclised to form a macrocycle (e.g. cyanobactins [22] and cyclotides 
[23]). 
 
 
 
Figure 1.3: Schematic of RiPP Biosynthesis. General schematic of RiPP biosynthesis with a ribosomal 
precursor peptide tailored by enzymatic post-translational modifications. The enzymes 
act through recognition of the N-terminal leader and in some cases C-terminal 
recognition sequences. These sequences are subsequently cleaved leaving the mature 
compound. Figure adapted from Arnison et al (2013) [16] 
 
One recent example of the RiPPs ability to decouple binding from catalysis is shown in 
the study of the NisB, a dehydrogenase from the nisin lanthipeptide pathway [30]. 
NisB catalyses the dehydration of serine and threonine residues to dehydroalanine and 
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dehydrobutyrine respectively in the precursor peptide NisA, one of the early steps in 
the biosynthesis of the complex molecule NisinA (Figure 1.2 A) [31]. The dehydration is 
known to occur via the glutamylation of the serine and threonine side chains followed 
by a glutamate elimination step [32]. The study determined the crystal structure of the 
NisB in complex with the precursor peptide NisA showing the distinct peptide binding 
and glutamylation sites (Figure 1.4) [30].  The distinct binding and catalytic sites is an 
uncommon feature of enzymes in general but is highly prevalent among the RiPP 
enzymes [16]. 
 
 
Figure 1.4 Structure of NisB in Complex with Substrate NisA. Dimer structure of NisB in complex with 
NisA with glutamylation domain represented in green, elimination domain in magenta and the NisA 
leader sequence in red (secondary molecule shown in paler equivalent colours) [30]. All protein 
structure figures in this thesis were created in Pymol unless otherwise stated [33]. 
 
This thesis is primarily concerned with the cyanobactin family of RiPPs, which will be 
discussed in detail. 
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1.1.3 Cyanobactins 
 
The cyanobactins, a member of the RiPPs, are a superfamily of cyclic peptides 
(macrocycles) produced by both free-living and symbiotic cyanobacteria [22]. The 
cyanobactins are derived from a precursor peptide which is post-translationally 
tailored by a range of enzymatic reactions to form cyclic peptides containing 
modifications such as D-stereo centres, heterocyclised amino acids, disulfide bonds 
and prenylation. The size of these peptides ranges from six to at least twenty amino 
acids [22], [34]. The post-translation modifications are carried out by a range of 
enzymes including proteases, heterocyclases, oxidases and prenyl transferases. 
Bioinformatic comparisons of the related cyanobactin pathways show a high degree of 
homology between the related enzymes [35]. 
 
Figure 1.5 represents the diverse range of cyanobactins including tenuecyclamide 
(N. spongiaeforme) [36], anacyclamide (Anabaena sp.) [34], trichamide (T. erythraeum) 
[37] and trunkamide [38] , ulithiacyclamide [39] and patellamide [40] (all Prochloron 
sp.). The cyanobactins are of particular interest as they have been shown to have 
diverse biological effects including anticancer (e.g. Ulithiacyclamide A [41], [42]) and 
trunkamide A [43]), anti-parasitics (e.g. Venturamide A [44]) as well as reversal of 
multi-drug resistance (e.g. Dendroamide A [45]). In addition, the cyanobactins are 
produced using a defined set of tailoring enzymes and so are attractive for 
bioengineering [46].  
 
The high degree of homology between enzymes involved in cyanobactin production 
across the specific pathways potentially allows for enzyme exchange in order to lead to 
more diverse novel products. Additionally, modification of the gene encoding the 
precursor peptide in the core peptide region could lead to novel sequences and thus 
novel cyclic compounds. 
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Figure 1.5: Chemical Structures of Cyanobactins. The chemical structures of cyanobactins from the 
following families (A) Tenuecyclamide, (B) Anacyclamide, (C) Trichamide, (D) Trunkamide, (E) 
Ulithiacyclamide and (F) Patellamide. (Adapted from Sivonen et al. [22]) 
 
The patellamides are one of the most studied cyanobactins and therefore represents 
an excellent model system for exploitation and bioengineering. 
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1.2 Patellamide Biosynthesis 
 
The patellamides are a cyanobactin family produced by Prochloron sp., cyanobacteria 
that exist symbiotically with the marine sea squirt Lissoclinum patella [47]. L. patella, 
along with its obligate symbionts, is commonly found in tropical oceans, such as near 
the Palau Islands or at the Great Barrier Reef, both in the Pacific Ocean [40] [48].  
 
The patellamides are macrocyclised octapeptides containing heterocyclised residues 
(Thr/Ser and Cys) giving rise to oxazolines and thiazolines, the latter of which can be 
further oxidised to thiazoles [49] (Figure 1.6).  Additionally, D-stereocentres are found 
adjacent to the thiazoles. 
 
 
 
 
Figure 1.6: Chemical Structure of Patellamides. The chemical structures of (A) Patellamide A and (B) 
Patellamide D. 
 
 
The first patellamides, patellamides A-C, were isolated in 1981 by Ireland et al. and 
originally believed to be produced directly from the sea squirt, hence the naming 
convention [40]. It has since been discovered that Prochloron sp. are the true source of 
production [47]. Since the first discovery, several new patellamides have been 
discovered (patellamides D-G) [42] [50] [51] [52] [53].  
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The patellamides show considerable chemical diversity and as such their activity is 
dependent on their cyclic nature, the heterocycles present, and the amino acids side 
chains which make up the macrocycle. Variation in any of these properties, even subtle 
changes, can have large consequences on their function [49]. Lissoclinamide 4, a 
related cyanobactin, shows an increase of two orders of magnitude in cytotoxicity 
against T24 bladder carcinoma cells compared to lissoclinamide 5, despite varying only 
by the presence of a thiazoline as opposed to a thiazole, its oxidised analogue. [42] 
[54]. 
 
Although the patellamides function for the organism is unknown, they could 
potentially be produced as a defence mechanism to protect its environment from 
other bacterial species. The patellamides have been tested for a range of biological 
activities and been found to be cytotoxic to leukaemia cells and also having the ability 
to reverse multiple drug resistance [40] [55]. To date the basis of patellamide mode of 
action is not well defined but there is data to suggest that proteins associated with 
DNA, RNA and protein synthesis are all targets [49]. Patellamide D is however known 
to target the ATP-binding cassette multidrug efflux pump P-glycoprotein (P-gp) [55] 
which regulates the distribution and bioavailability of drugs [56]. Inhibition of this 
protein could play a role in cancer therapies where chemotherapeutic resistance has 
occurred.  Previous structural studies on the mouse P-gp protein have identified the 
binding sites for cyclic peptide inhibitors containing heterocycles and it is likely that 
Patellamide D interacts in a similar manner [57] [58]. The inhibitors are bound in the 
transmembrane portion of the protein (Figure 1.7).  
 
Patellamides are produced in vivo through a biosynthetic pathway (discussed in detail 
in following pages), however it is possible to synthesise them chemically. Garcia-
Reynaga and VanNieuwenhz (2008) [59] carried out the total synthesis of Patellamide 
A, an overall 18 step process (including the utilisation of the work of You et al. (2003) 
[60] to achieve the starting material) with an overall yield of approximately 25 % 
(Figure 1.8). This multiple step process gives a reasonably low yield, particularly when 
it can be considered that Patellamide A is one of the more symmetrical compounds 
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(mirror image with exception of serine/threonine) which allows for some of the initial 
starting materials to be used for both the initial Ser and Thr containing 4-mers. As a 
result of this, it is likely that when more diversity is required in the patellamide, the 
synthesis would require additional steps and reduce the efficiency of the yield further. 
As such, the chemical synthesis is a plausible yet lengthy strategy for producing 
patellamides and patellamide-derived novel compounds. 
 
 
 
Figure 1.7: P-glycoprotein in Complex with Cyclic Peptide. (A) Crystal structure of mouse P-glycoprotein 
(alpha helices - red, beta sheet - yellow) in complex with the hexamer cyclic peptide 
QZ59-SSS containing heterocycles (spheres, cyan) PDB Code: 4M2S (B) Chemical 
structure of QZ59-SSS.  
 
 
1. Introduction   
 11 
 
 
 
Figure 1.8: Chemical Synthesis of Patellamides. 18 step total chemical synthesis of Patellamide A as 
described by Garcia-Reynaga & VanNieuwenhz (2008)
 
[59] including the initial steps of 
You et al. (2003) [60]. The overall reaction has a yield of ~25 %.  
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Patellamides are biosynthesised ribosomally as a precursor peptide which undergoes 
several post-translational modifications through a range of enzymatic (and potentially 
non-enzymatic) reactions. A single gene cluster (Figure 1.9) of Prochloron sp. has been 
identified which encodes both the precursor peptide (PatE) and the tailoring enzymes 
(PatA, B, C, D, F, G) [47]. Studies of the gene cluster when heterologously expressed in 
E. coli have shown that PatA, D, E, F and G are essential for patellamide production and 
their absence leads to no detectable products. The absence of PatB and PatC however 
still results in patellamide products [47] [61] [62]. 
 
 
 
Figure 1.9: Schematic of Patellamide Gene Cluster. The gene cluster responsible for encoding the seven 
proteins of the patellamide biosynthetic pathway with seven genes patA-G. 
 
 
PatE, the 71 amino acid precursor peptide, consists of a 37 amino acid leader sequence 
followed by two eight residue core peptides each flanked by N- and C-terminal 
cleavage/macrocyclisation recognition signals of five and three amino acids 
respectively (Figure 1.10). The composition of the core peptide can be hypervariable 
and it is this core peptide that goes on to constitute the patellamide [47]. In some 
cyanobactin families, the precursor peptide contains up to four core peptides (e.g. 
Tenuecyclamides [62]). 
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Figure 1.10: Sequence Schematic of the PatE Precursor Peptide. The PatE precursor peptide 
highlighting the leader sequence (blue), the N-terminal cleavage recognition signals (red), 
the variable core peptides (white) and the C-terminal cleavage signals (green). 
 
PatA (77 kDa) consists of an N-terminal subtilisin-like protease domain and a C-
terminal domain of unknown function (DUF). The protease domain is responsible for 
N-terminal cleavage of the core peptides [63]. PatB (9 kDa) and PatC (7 kDa) currently 
have no defined function [61]. PatD (89 kDa) is a three domain protein responsible for 
heterocyclisation of specific amino acids within the core peptides [64]. PatF (36 kDa) 
currently has no defined function but equivalent enzymes in related pathways have 
shown that the PatF family is responsible for the prenylation of specific amino acids 
within the core peptide [65]. Finally, PatG (131 kDa) consists of three domains, an N-
terminal oxidoreductase domain, a subtilisin-like protease domain and a C-terminal 
DUF [63] [66]. The oxidoreductase domain is likely to catalyse the oxidation of 
thiazolines to thiazoles, however this has yet to be confirmed, while the protease 
domain carries out C-terminal cleavage and macrocyclisation of each core peptide [63]. 
In addition, the epimerisation of two C positions adjacent to thiazolines also occurs 
and may be an enzymatic or a non-enzymatic process.  
 
The order in which these reactions occur is not yet fully defined, although it is clear 
that certain reactions probably occur before others, as will be discussed.  
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1.2.1  Heterocyclisation 
Note: A selection of the work in this section has been carried out by the Naismith 
group including myself. This was achieved during the PhD research period but not 
within the scope of this thesis. All work has been published and references for this 
work are noted with an asterisk. 
 
PatD is an ATP-dependent heterocyclase enzyme which catalyses the formation of 
oxazolines and thiazolines from threonine/serine and cysteine residues respectively 
(Figure 1.11, 1.12). Each heterocyclisation event results in the loss of one water 
molecule which can be observed by a reduction in mass of 18 Da [64]. The binding of 
the PatE precursor peptide to the PatD is mediated through the 37 amino acid leader 
sequence of the PatE and removal of this sequence abolishes the majority of the 
heterocyclase activity [64]. The C-terminal cysteine of the core peptide will still process 
without the leader sequence as long as the C-terminal recognition sequence remains 
present [67]* [68]. 
 
 
Figure 1.11: PatD Catalysed Heterocyclisation of PatE. Schematic of the heterocyclisation of the PatE 
precursor peptide by the heterocyclase enzymes PatD highlighting cysteine (C), serine (S) 
and threonine (T) heterocyclisation within the core peptides to thiazoline, oxazoline and 
2-methyl-oxazoline respectively. 
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Figure 1.12: PatD Reaction at a Molecular Level. Chemical structure schematic of the substrate amino 
acids cysteine, serine and threonine and their heterocyclic products upon reaction with 
PatD and ATP. 
 
Within the cyanobactin family there are variations in the type of activity each 
heterocyclase adopts. TruD, an analogue from the trunkamide pathway, and LynD, an 
analogue from the aestuaramide pathway, are reported to only heterocyclise cysteine 
residues and both leave threonine and serine residues in their native state [64] [69]*. 
This is intriguing considering the high homology of TruD and LynD to PatD; 88 % and 76 
% identity respectively (Figure 1.13). The variation between the three enzymes may be 
a result of chemical selectivity, however one study on PatD and TruD has suggested 
that this is primarily down to regiospecificity [64]. Two positions within the core 
peptide (positions 1 and 5 from C-terminus) were found to be more liable to 
heterocyclisation by TruD, while PatD could act on at least five positions (positions 1, 
3, 4, 5 and 7). The order in which the heterocyclisations within the precursor peptide 
occur has been determined using the heterocyclase TruD and was found to process 
from the C-terminus backwards [67]*. 
 
The crystal structure of TruD (PDB entry: 4BS9) has been determined and the enzyme 
was found to consist of three domains; domain 1 (residues 2-85), domain 2 (residues 
86-321) and the larger domain 3 (residues 323-781) (Figure 1.14 A) [67]*. Two 
molecules of the protein interact to form a biologically relevant anti-parallel dimer 
(Figure 1.14 B) [67]*. Domains 1 and 2 were found to show structural homology to 
MccB, an adenylase from a microcin pathway [70], and both enzymes were found to 
contain two CXXC motifs along with bound structural zinc ion. These features are 
common amongst one class of adenylases [71]. The ATP binding site of MccB was not 
conserved in TruD meaning it was not possible to locate the enzyme active site. It was 
also not possible to identify where the leader sequence may bind in the structure. 
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Figure 1.13: PatD, TruD and LynD Sequence Alignment. Sequence alignment of the heterocyclases PatD 
and TruD from Prochloron sp. and LynD from Lyngbya aestuarii showing a high degree 
of homology. All sequence alignments were generated using ClustalW
 
[72] or Clustal 
Omega [73]
 
and the figures created with ALINE [74]. 
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Figure 1.14: Crystal Structure of TruD Heterocyclase Enzyme. TruD crystal structure to 2.95 Å resolution 
(PDB entry: 4BS9). (A) The asymmetric unit of domains one, two and three coloured 
magenta, cyan and green respectively. The zinc ion is shown as a grey sphere (B) The 
dimer representation of TruD which is biologically relevant showing the anti-parallel 
dimer interface occurring between domains one and two (symmetry molecule in 
darker equivalent colours) [67]*.  
 
The PatE leader sequence had been proposed to contain a helical structure from 
residues 13 - 26 [75] which would resemble that of the precursor peptide for microcin 
B17, where the helix plays a crucial role in peptide:protein binding [76], [77]. These 
original studies however were carried out in organic solvent and a more recent study 
has determined using NMR analysis of a 15N labelled PatE in aqueous buffer that there 
is no degree of secondary structure in the leader sequence [67]*.  
 
The recent determination of the crystal structure of LynD in complex with PatE and 
ATP (PDB entry: 4V1T) has allowed for the location of the peptide binding clamp and 
the ATP binding site to be determined [78]* (Figure 1.15). LynD is structurally very 
similar to TruD and forms the same dimer interface, however under binding of PatE 
the protein undergoes a conformational change. The PatE leader sequence binds and 
extends a beta sheet of domain 1 of LynD which in turn interacts with domain 3 of the 
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secondary molecule essentially bringing the two domains together and confirming the 
biological relevance of the dimer. The conformational change which occurs upon 
leader sequence binding results in the activation of the heterocyclase, subsequently 
allowing complete processing of the core peptide. 
 
 
 
Figure 1.15: Crystal Structure of LynD Heterocyclase Enzyme in Complex with PatE and ATP. LynD 
crystal structure to 2.14 Å resolution (PDB entry: 4V1T) in complex with PatE and ATP 
(broken down to ADP and PO4
-
). The dimer representation of LynD (green/pale green) 
with two copies of the PatE leader sequence (blue/pale blue), two molecules of ATP 
(red spheres) bound and two zinc ions (grey spheres). Domain 1 of the first molecule is 
brought together with domain 3 of the second molecule and vice versa [78]*.  
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The catalytic reaction of PatD is known to be ATP-dependent although the mechanism 
of this reaction remains unclear. McIntosh et al. (2010) initially proposed that 
heterocyclisation is driven by ATP through a molecular machine basis where there is 
no direct interaction between the heterocyclisation chemistry and ATP breakdown [79] 
(Figure 1.16). 
 
 
 
Figure 1.16: ATP Molecular Machine Mechanism for PatD: Proposed mechanism for PatD ATP depletion 
with ATP binding at a distinct site from the PatE causing turnover. Figure adapted from 
McIntosh et al (2010) [79]. 
 
Studies on the related RiPP biosynthetic pathway of thiazole/oxazole-modified 
microcins (TOMMs) then suggested that heterocyclisation occurs through a kinase 
mechanism where the peptide backbone carbonyl oxygen is phosphorylated by ATP 
[80] [81]. This then drives an O-elimination reaction which generates the final 
oxazoline/thiazoline (Figure 1.17). This releases H2O, ADP and phosphate, the latter of 
which was directly observed in experimental analysis. Unlike the patellamide pathway 
where heterocyclisation is carried out by a single enzyme, PatD, in the TOMMS 
pathway heterocyclisation is carried out by three enzymes working together, BalhC 
(scaffold protein), BalhD (catalytic protein) and BalhF (peptide binding protein) [80] 
[81] [82] [83]. There is high sequence homology between the third domain of PatD and 
BalhD suggesting that they will perform the same reaction therefore it would be likely 
that PatD also process via a kinase mechanism. 
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Figure 1.17 – Kinase Mechanism of Heterocyclisation. Proposed mechanism for heterocycle formation 
in the TOMMS pathway by BalhC/BalhD/BalhF with ATP phosphorylating the carbonyl 
oxygen followed by an O-elimination with the release of ADP, PO4
-
 and H2O. X = O or S. 
(Figured adapted from Dunbar et al., 2012, [80]) 
 
Next, a study on the TruD protein showed by an NMR approach that heterocyclisation 
potentially occurs via an adenylation mechanism through production of AMP and 
pyrophosphate from ATP during turnover and failed to observe ADP [67]* (Figure 
1.18). In addition, the crystal structure identified an adenylase fold in the second 
domain correlating with the NMR data (Figure 1.14). 
 
 
Figure 1.18: Adenylation Mechanism of Heterocyclisation. Proposed mechanism for thiazoline 
formation by TruD with ATP adenylating the carbonyl oxygen followed by an O-
elimination with the release of AMP, PPi and H2O. (Figure adapted from Koehnke et al, 
2013, [67]*) 
 
 
The adenylation mechanism appeared to be further backed up by a study on the E.coli 
YcaO domain, a close homologue of BalhD, which was, in the absence of substrate, 
shown to also hydrolyse ATP to AMP and PPi [82] 
 
Finally, like TruD, NMR studies on the LynD protein observed the production of AMP 
and pyrophosphate during heterocyclisation reactions with ATP [78]*. However, the 
crystal structure of LynD, PatE and ATP in complex cast doubt on to the proposed 
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adenylation mechanism [78]*. The binding of ATP in the active site (where in the 
structure ATP has actually hydrolysed to ADP and PO4
-) found that the nucleotide and 
the alpha phosphate were buried in a pocket whilst the gamma phosphate was 
exposed (Figure 1.19) [78]*. This would therefore favour a kinase mechanism through 
nucleophilic attack of the beta-gamma bond. Thus the two sets of data are conflicting.  
 
 
 
 
Figure 1.19: Nucleotide Binding to LynD. Structural binding of ADP and PO4
-
 to LynD showing structural 
shielding of the adenosine ring and the alpha phosphate by side chains of the enzyme 
whilst the beta and gamma phosphates are exposed. The phosphates are co-ordinated 
by three Mg
2+
 ions (grey spheres). (Figure adapted from Koehnke et al, 2015, [78]*)   
 
More studies will have to be carried out to fully elucidate the mechanism of 
heterocyclisation and the fate of ATP in this mechanism; however given current data, 
neither a kinase nor an adenylation mechanism appear to be entirely correct. 
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1.2.2 N-terminal Core Peptide Cleavage 
 
The N-terminal subtilisin-like protease domain of PatA (PatApr) catalyses the N-
terminal cleavage of the modified core peptide residue, resulting in the removal of the 
PatE precursor peptide leader sequence (Figure 1.20). This step must proceed after 
heterocyclisation due to the requirement of the leader sequence to bind PatD to 
enable heterocyclase activity [79]. 
 
 
 
Figure 1.20: PatA Protease Activity. Schematic for the action of PatApr which cleaves at the N-terminal 
of the modified core peptide (white box) upon recognition of the sequence ‘G (L/V) E (A/P) 
S’ (red box). 
 
PatApr contains the classic catalytic triad of subtilisin-like serine proteases [84], [85] 
with residues Asp23, His58 and Ser218 making up the active site. The cleavage site 
nomenclature uses P1-5 for residues N-terminal to cleavage site and P1’-P5’ C-
terminal. The N-terminal side of each core peptides contains the PatApr recognition 
sequence, consisting of a highly conserved five amino acids ‘P5 (G) P4 (L/V) P3 (E) P2 
(A/P) P1 (S)’. There does not appear to be any conservation at the P1’ or subsequent 
positions for protease activity, i.e. no restrictions on the first residue in the core 
peptide [63]. Like all subtilisin proteases [86], cleavage occurs through nucleophilic 
attack of the peptide bond after the recognition site by the catalytic serine (S218) 
following proton extraction by the catalytic histidine (H58) forming a tetrahedral 
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intermediate. The tetrahedral intermediate collapses, breaking the peptide bond and 
the C-terminal peptide is then released and protonated by His58 thus leaving an acyl-
enzyme intermediate. Finally, upon water addition a second tetrahedral intermediate 
is formed and its subsequent collapse releases the N-terminal peptide and returns the 
enzyme to its native state, ready to catalyse the next reaction (Figure 1.21).   
 
 
 
Figure 1.21: PatA Protease Mechanism. Schematic for the mechanism of action of PatApr showing 
classic serine protease characteristics. 
 
The crystal structure of PatApr has been determined and is consistent with known 
subtilisin like protease domains (Figure 1.22, 1.23) [66] [87] 
 
 
Figure 1.22: PatA Protease Domain Structure. A) Crystal structure of the PatA protease domain 
coloured by secondary structure elements (alpha helices in red, beta sheets in yellow) 
PDB Code: 3ZXX. B) Zoom view of the active site showing the classic serine protease 
triad with catalytic residues Asp23, His58 and Ser218 represented as sticks. 
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Figure 1.23: PatA Structural Alignment with Subtilisin. Structural alignment of the protease domain 
from PatA (red, PDB code: 3ZXX) with subtilisin (cyan, PDB code: 2ZRQ) shows a high 
degree of structural homology.  
 
The cleavage by PatApr is a relatively slow reaction (up to 48 hours) when compared to 
heterocyclisation by PatD (two hours) [63], [79]. This may be intentional to ensure that 
heterocyclisation can be driven to completion before removal of the leader sequence 
which reduces heterocyclisation activity [67]*. In all related cyanobactin pathways, a 
subtilisin-like protease domain (homologous to PatApr) is always present (Figure 1.24) 
however the N-terminal cleavage recognition sites on the precursor peptide upon 
which they act can vary quite significantly (Table 1.1). 
 
 
Table 1.1: PatA Protease and Homologue Recognition Sites. Variation of N-terminal cleavage sites 
within the cyanobactin precursor peptides which are recognised by the PatApr family of 
enzymes.  
Protease Organism N-terminal Cleavage Site 1 N-terminal Cleavage Site 2 
PatApr Prochloron sp. GLEAS GVEPS 
PagApr Planktothrix agardhii GLTPH - 
LynApr Lyngbya aestuarii GVDAS - 
TruApr Prochloron sp GVDAS - 
MicApr Microcystis aeruginosa GMDAS GADAS 
TenApr N. spongiaeforme var. tenue GVGAS GAGAS 
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Figure 1.24: PatApr Homologue Alignment. Sequence alignment of the protease domain of PatA 
(PatApr) with its cyanobactin homologues showing a high degree of homology.  
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1.2.3 C-terminal Core Peptide Cleavage and Macrocyclisation 
 
The C-terminal cleavage of the modified core peptide is catalysed by the PatG 
subtilisin-like protease domain (PatGmac). This process occurs after both 
heterocyclisation (PatD) and N-terminal cleavage (PatApr) because the leader 
sequence must be removed to allow the N-terminus of the core peptide to bond 
directly with its C-terminus [64]. PatGmac, like PatApr, contains a classic subtilisin triad 
and the active site is comprised of residues Asp548, His618 and Ser783 [84], [85]. 
However, unlike PatApr, PatGmac has macrocyclase activity. At a molecular level, it has 
been reported that PatGmac recognises the cleavage signal ‘AYD’ in the P1’ – P3’ 
positions (and possibly Gly in the P4’ position), [88] whilst in many related cyanobactin 
pathways the C-terminal cleavage signal is ‘SYD’. There is also the requirement for a 
heterocycle (thiazoline/thiazole, oxazoline/oxazole) or a proline in the final position of 
the modified core peptide, the residue which also constitutes the P1 position of the 
protease substrate [88]. 
 
Macrocyclisation is a common feature in both non-ribosomal and ribosomal peptide 
biosynthetic pathways. For non-ribosomal peptides macrocyclisation is generally 
carried out by thioesterase (TE) domains containing the same Asp-His-Ser catalytic 
triad as PatGmac and PatApr [89]. The substrate initially binds to a peptidyl carrier 
protein (PCP) as a thioester, followed by the transfer to the active site serine of a TE 
domain, forming an acyl-enzyme intermediate [90]. (Figure 1.25 A). The N-terminal 
amine of the peptide then attacks the ester carbonyl, displacing the serine and forming 
the macrocycle.  
 
The molecular detail of how macrocyclisation occurs in ribosomally synthesised 
peptides was unclear. There is no homology between PatGmac and known 
thioesterase domains (< 4 % ). PatGmac is proposed to proceed through cleavage of 
the peptide, leading to the formation of an acyl-enzyme intermediate with the 
catalytic serine, with no requirement for a PCP. Following removal of the ‘AYD(G)’ 
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cleavage recognition residues from the active site, the N-terminal amine of the 
modified core peptide attacks the acyl-enzyme intermediate, displacing the serine and 
yielding the macrocycle in a similar mechanism to the TE domain [63], [88]. (Figure 1.25 
B). The macrocyclisation process has been found to be particularly slow with only one 
reaction per enzyme per day [63]. This may be to allow time for the N-terminal of the 
peptide to orientate itself for the nucleophilic attack of the acyl-enzyme intermediate. 
 
 
 
 
Figure 1.25: Peptide Macrocyclisation. Schematic of (A) peptide macrocyclisation via thioesterase 
intermediate formation and (B) the proposed peptide macrocyclisation by PatGmac 
showing N-terminal attack of the acyl-enzyme intermediate.  
 
PatGmac is one of only a handful of ribosomal macrocyclases to have been isolated to 
date. These other macrocyclases are involved in pathways across the RiPP family 
including PCY1 of the caryophyllaceae cyclic peptide pathway [91], GmPOPB [92] in -
amanitin biosynthesis and butelase-1 in cyclotide production [93]. At present, no 
structural or mechanistic data has been determined on these macrocyclases however 
extensive kinetic analysis shows they have wide variation in their reaction rates. 
Butelase 1 (0.06 - 17 s -1) and GmPOPB (5.6 s-1) turnover at an order of magnitude of 
three to four higher than PCY1 (1 h-1) and PatGmac (1 h-1).  
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1.2.4  Epimerisation 
 
In the patellamides, two of the amino acids, adjacent to the thiazoles, are epimerised 
to D-stereoisomers (Figure 1.26). The process of this epimerisation is likely to occur 
after heterocyclisation and before oxidation of the thiazoline as the -carbon before a 
thiazoline is more liable to epimerisation due to the adjacent imine bond [94] (Figure 
1.27). The pKaof the -carbon when adjacent to a thiazoline will be approximately 30 
however when adjacent to a thiazole it will be higher at approximately 40 (estimated 
using JChem). Epimerisation post-oxidation is possible but disrupting the newly 
formed, highly stable, aromatic heterocycle makes this less likely.  
 
 
 
Figure 1.26: Epimerisation in Patellamides. Chemical structures of A) Patellamide A and B) Patellamide 
B with the epimerised amino acids adjacent to the thiazoles highlighted in magenta.  
 
 
 
 
Figure 1.27: Epimerisation Mechanism. Mechanism schematic of the epimerisation of the amino acid 
adjacent to the thiazoline.  
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There are currently two hypotheses for how the epimerisation occurs; either it is 
controlled enzymatically or it can occur spontaneously [94]. Bioinformatics analysis of 
the patellamide gene cluster however shows no evidence of an epimerase enzyme 
[47]. As there are two epimerisation events, it is possible that these are catalysed 
individually by the related DUF domains of PatA and PatG (51 % homologous to each 
other, Figure 1.28), however as they show no sequence homology to any known 
epimerases, these would represent a novel class.  
 
 
 
Figure 1.28: PatA and PatG DUF Alignment. Sequence alignment of the C-terminal domains of unknown 
function from PatA and PatG.  
 
The structure of the PatG DUF domain (PatG residues 914-1191) has been determined 
by Greg Mann (University of St Andrews) [95] yet has given no further insight into its 
potential role in epimerisation (Figure 1.29) or indeed any other reactions however 
binding studies have ruled out any interaction with the leader peptide [95]. 
Alternatively, the epimerisation reaction could be non-enzymatic as studies have 
shown that lissoclinamide, a related cyanobactin, chemically synthesised in the wrong 
enantiomer can be epimerised by heating to 60 °C in mild base [94]. This may be a 
result of conformation change in the patellamide which influences epimerisation. 
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Although a spontaneous epimerisation remains an option, occurring under these harsh 
conditions would be unlikely in nature. 
 
 
Figure 1.29: PatG DUF Structure. Secondary structure representation of the C-terminal DUF domain 
from PatG (alpha helices – red, beta sheets – yellow) (PDB code: 4UVQ, [95]) 
 
 
1.2.5 Oxidation 
 
 
Heterocyclisation of threonine/serine and cysteine residues results in the formation of 
oxazolines and thiazolines respectively as described previously. In final natural 
products the thiazolines have been further oxidised to form thiazoles (Figure 1.30) 
[49]. Although at present there is no definitive evidence that the N-terminal domain of 
PatG carries out this oxidation, it would appear to be highly likely as sequence analysis 
of this domain shows a high degree of conservation with other oxidases [47], and most 
cyanobactin pathways also contain a homologous oxidase domain either within the 
PatG equivalent or as a stand-alone protein [34]. 
 
 
 
Figure 1.30: Thiazole Structure. Chemical structure of thiazoline and its oxidised analogue thiazole. 
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It is also currently unknown at what stage oxidation occurs, whether before or after 
macrocyclisation of the modified core peptide. An interesting observation is the lack of 
oxazoles within the patellamides [49], suggesting that the PatG oxidase domain is 
specific in oxidising only thiazolines. This is in contrast to other cyanobactins where 
oxazoles and thiazoles occur together (e.g. tenuecyclamides [36], Figure 1.5 A). This 
may be a result of either substrate recognition (only binds thiazolines) or down to 
chemistry (can only oxidise thiazolines). At this stage it is also unclear which co-factors 
are required for oxidase activity, although FMN is required for similar thiazoline 
oxidases such as in the TOMMS, bleomycin and epothilone biosynthetic pathways [96] 
[97]. 
 
 
1.2.6 Prenylation 
 
Another post-translational modification found in many of the cyanobactins is the 
prenylation of specific residues within the core peptide (Figure 1.31). Prenylation, the 
addition of a prenyl group (3-methyl-but-2-en-1-yl) (Figure 1.32 A), can occur in the 
forward or reverse positions commonly on oxygen or carbon atoms in cyanobactins 
(Figure 1.32 B, C) [65]. In proteins, multiple prenyl groups can be linked together to 
from longer chains (e.g. farnesylation, geranylgeranylation [98] [65]) however in 
cyanobactins only prenylation and in rarer cases geranylation occur (e.g. piricyclamides 
[99]). Prenylation is generally associated with membrane targeting and cellular 
localisation or in protein:protein interactions, while they can also make compounds 
more lipophilic aiding in pharmacokinetics [100]. In the cyanobactins, the prenyl group 
is derived from dimethylallyl pyrophosphate (DMAPP) (Figure 1.32 D), an intermediate 
of the mevalonate pathway [65] [101]. 
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Figure 1.31: Cyanobactin Prenylation. Chemical structures of cyanobactins containing prenylated side 
chains (magenta). (A) Prenylagaramide B exhibiting forward O-prenylation on a 
tyrosine residue (B) Trunkamide A containing reverse O-prenylation on both threonine 
and serine residues [65] (C) an Aestuaramide showing forward C-prenylation on a 
tyrosine residue [102]. 
 
 
 
Figure 1.32: Prenylation. Chemical structures of (A) a prenyl group, (B) O-linked forward prenylation (C) 
O-linked reverse prenylation and (D) Dimethylallyl pyrophosphate (DMAPP). 
 
To date the function of PatF has not been confirmed however studies on related 
cyanobactin pathways have shown that the PatF family of enzymes is responsible for 
the prenylation of specific amino acids within the core peptide [65], [103]. TruF1 from 
the trunkamide pathway (41 % homologous to PatF [62]) catalyses the addition of 
prenyl groups to the hydroxyl group of threonine and serine residues in the macrocycle 
[103], while studies on LynF (44 % homologous to PatF) from the Aestuaramide 
pathway (Lyngbya aestuarii) show that it catalyses prenylation on the hydroxyl of  
tyrosine residues which is followed by a Claisen rearrangement to yield forward C-
prenylation ortho to the hydroxyl group on the aromatic ring [65] [104] [102]. 
 
Of the patellamide natural products isolated and studied to date, there is no evidence 
of prenylation [49]. This could be explained by the lack of naturally occurring tyrosine 
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residues within the core peptide or that PatD, unlike TruD, heterocyclises threonine 
and serine residues early in the biosynthesis process and as a result these residues 
would no longer be amenable to prenylation.  
 
Interestingly, although these proteins have some degree of sequence homology 
among themselves, they show no sequence homology to other known prenyl 
transferases. The PatF family of enzymes therefore represent a novel subclass of 
prenyl transferases unique to the cyanobactins.  
 
1.2.7 Non-defined Patellamide Proteins 
 
The PatB and PatC proteins have been determined to be non-essential in the 
production of patellamides [47], [61], yet these proteins are highly conserved across 
cyanobactin pathways (Figures 1.33, 1.34). Nevertheless, their protein sequences do 
not offer any insights into their potential function [34].  There can be several 
hypotheses for the function in which they may be involved from offering the host a 
form of resistance against the patellamide or to regulators of the pathway. 
 
 
Figure 1.33: PatB Homologue Alignment. Sequence alignment of PatB with its cyanobactin homologues 
showing a high degree of homology. 
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Figure 1.34: PatC Homologue Alignment. Sequence alignment of PatC with its cyanobactin homologues 
showing a highly conserved region. LynC and TenC however have significant additions to 
their N-terminus in comparison to PatC, ArtC and MicD. 
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1.3 Aims 
 
 
This thesis is concerned with the ribosomal biosynthesis of the cyanobactin cyclic 
peptide superfamily, with particularly emphasis on the patellamides.  
 
The study of the prenylase family of enzymes from cyanobactins (PatF family) will be 
explored through structural and biochemical methods to obtain an understanding of 
prenylation on the final macrocyclic peptides.  
 
The PatG macrocyclase domain will be explored in structural and biochemical studies 
to determine substrate binding and rationalise the mechanism of macrocyclisation. 
 
The oxidation step in patellamide biosynthesis has not been characterised to date, but 
is believed to be catalysed by the N-terminal oxidoreductase domain of PatG. This 
protein and its homologues will be explored both structurally and biochemically to 
confirm this hypothesis and determine its associated mechanism. 
 
Through isolation of the proteins (or their individual domains) from the patellamide (or 
related) biosynthetic pathway(s) the reconstitution of patellamide production in vitro 
will be pursued the process used to create a diverse range of compounds including 
known and unknown amino acid sequences, and also in varying peptide length. 
 
Once the pathway is established in vitro, identification of the flexibility of the process 
by using unnatural amino acids in the precursor peptide to incorporate them in the 
final patellamide product will be studied. These precursor peptides can be derived 
from cell growth on media containing unnatural amino acids or by semi-synthesis with 
techniques such as intein technology. 
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2. Structural and Biochemical Studies of PatF and 
Homologues 
 
2.1 Introduction 
 
PatF has previously been reported as essential in the production of patellamides on 
the basis of studies knocking out the gene encoding for it which results in no 
detectable patellamide products [47]. The biochemical role of PatF in patellamide 
production has yet to be confirmed; however related pathways have revealed the PatF 
family to be prenyl transferases. LynF, from Lyngbya aestuarii [65], [104] and PagF 
from Planktothrix agardhii (unpublished, Nair et al.) have both been shown to 
prenylate tyrosine residues, while TruF1 from the trunkamide pathway (Prochloron sp.) 
prenylates serine and threonine residues [103] (Figure 2.1 A). At present no 
patellamide natural products have been discovered where prenylation is evident so it 
is unknown which residue(s) PatF acts on (if any).  
 
 
Figure 2.1:  PatF Family Prenylation. (A) Products of cyanobactin prenylation, PagF – forward O-
prenylation of tyrosine, LynF – Forward C-prenylation of tyrosine, TruF1 – reverse O-
prenylation of Ser/Thr (R=Me or H) and PatF – unknown.  (B) Mechanism for LynF 
catalysed prenylation; initial reverse-O prenylation on tyrosine followed by a spontaneous 
Claisen rearrangement to give forward C-prenylation. Figure adapted from McIntosh et al. 
(2011)
 
[65] 
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It is clear that there are significant differences in the mechanisms associated with the 
closely related prenylases. LynF catalyses the reverse O-prenylation of tyrosine 
residues which is followed by spontaneous Claisen rearrangement resulting in forward 
C-prenylation of the tyrosine aromatic ring ortho to the hydroxyl group (Figure 2.1 B) 
[65] [102] [104]. PagF carries out forward prenylation directly on the hydroxyl group 
with no rearrangement (unpublished, personal communication, S. Nair - University of 
Illinois). Finally, TruF1 also reverse prenylates on oxygen, this time in threonine and 
serine residues. 
 
The X-ray crystal structure of PatF was sought in order to explore its potential function 
and give insight into its catalytic mechanisms. Biochemical characterisation of both 
PatF and its homologues using in vitro assays with a range of different amino acid 
substrates was also pursued. 
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2.2  Materials and Methods 
 
 
2.2.1 DNA Cloning 
 
The gene encoding full length PatF was synthesised in the pJexpress 411 plasmid using 
optimised codons for E. coli (DNA 2.0) [105]. The plasmid consists of full length PatF 
with an N-terminal His6-tag and additional Arg and Ser residues at the C-terminus (a 
cloning artefact) (Figure 2.2 A).  
 
A Tobacco Etch Virus (TEV) protease recognition site was subsequently introduced 
between the His6-tag and the PatF protein (Figure 2.2 B) using the site-directed 
mutagenesis (SDM) technique of Liu & Naismith [106] (Figure 2.3). Polymerase chain 
reactions (PCR) were carried out on the original plasmid using KOD polymerase 
(Novagen) with specifically designed mutagenesis primers (Life technologies, Table 2.1) 
to insert the nucleotide sequence for TEV recognition site. The template DNA 
(methylated) was digested using DPN-1 enzyme (20 units) leaving only the newly 
synthesised (mutated) plasmid. This plasmid was used to transform DH5 E. coli cells. 
Single colonies were picked and grown in 10 ml Luria-Bertani (LB) media at 37 °C, 200 
rpm overnight. The cultures were harvested (4,000 x g) and the plasmid DNA was 
extracted using the Qiagen mini-prep kit. Purified plasmid DNA was sequenced (GATC 
Biotech) to confirm the presence of the desired mutation(s). 
 
 
Figure 2.2:  Schematic for PatF Constructs. (A) Original PatF construct with N-terminal His6-tag and C-
terminal RS residues. (B) Construct modified from original with the addition of a TEV 
protease recognition site between the His6-tag and the protein. 
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Figure 2.3: Schematic for Primer Design for Site-directed Mutagenesis. Primer design using non-
overlapping and overlapping regions for (A) insertion and (B) point mutations. INS 
indicates the location of insertions, and triangles indicate the locations of mutations in the 
primer sequences. Figure adapted from Liu & Naismith (2008) [106]. 
 
Point mutations of the active site (M136K and H125D/G127R/M136K) were created 
using the mutagenesis technique using primers shown in Table 2.1. (Note: The triple 
mutant was made from a single PCR experiment using the single mutant, M136K, as 
the template.) 
 
5’ PatFTEV gaaaacctgtattttcaggacttgatcgaccgtctgcag 
3’ PatFTEV gtcctgaaaatacaggttttcgtggtgatggtgatgatgcat 
5' PatF H125DG127R attggtgtggatctgcgtagcaagttggaggacagcagcgtc 
3' PatF H125DG127R caacttgctacgcagatccacaccaatggtgttattgataat 
5' PatF M136K agcagcgtcaaactgtacattcacatcaaaccggaa 
3' PatF M136K aatgtacagtttgacgctgctgtcctccaacttgct 
 
Table 2.1: PatF Primer Sequences. Mutagenesis oligonucleotide sequences for PatF mutagenesis 
experiments.  
 
Full length LynF was synthetically cloned into the pJexpress 411 plasmid using 
optimised codons for E. coli (DNA 2.0) [105]. The plasmid consists of full length LynF 
with an N-terminal His6-tag and TEV protease site (Figure 2.4 A). 
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The LynF gene was subsequently PCR amplified using specifically designed primers to 
yield NcoI and XhoI restriction sites on the 5’ and 3’ ends respectively (Table 2.2). The 
amplified DNA was then digested with NcoI and XhoI restriction enzymes and ligated 
into the pSUMO plasmid (a gift from C.D. Owen, University of St Andrews) consisting of 
an N-terminal His6-tag, SUMO (Small Ubiquitin-like Modifier) protein to aid solubility 
and TEV protease site (Figure 2.4 B).  
 
 
 
Figure 2.4:  Schematic for LynF Constructs. (A) LynF construct with N-terminal His6-tag and TEV protease 
recognition site. (B) LynF SUMO construct with N-terminal His6-tag, SUMO domain and 
TEV protease recognition site. 
 
5’ LynFNcoI ggcgccatggcgattgcaaaccgtgtaccgtac 
3’ LynFXhoI tttctcgagttagccgaagctacgacggta 
 
Table 2.2: LynF Primer Sequences. Oligonucleotide sequences for LynF cloning experiments.  
 
 
2.2.2  PatF Expression and Purification 
 
PatF was expressed from the pJexpress 411 plasmid using BL21 (DE3) E. coli cells 
grown on auto-induction medium using the Studier method [107] (see Appendix A.1 
for media and buffer composition). The cultures were grown at 20 °C, 250 rpm for 48 
hours before harvesting by centrifugation.  
(L)-Selenomethionine-labelled PatF was expressed in BL21 (DE3) E. coli cells, cultures of 
which were grown in a minimal medium supplemented with glucose-free nutrient mix 
(Molecular Dimensions) and 5 % glycerol. The medium was inoculated with overnight 
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culture grown in LB medium which was subsequently washed three times with minimal 
medium. After 15 min growth at 37 °C, 60 mg L-1 (L)-selenomethionine was added to 
the cultures. An amino acid mix (100 mg L-1 lysine, phenylalanine and threonine, 50 mg 
L-1 isoleucine and valine) was added to the cultures at an optical density at 600nm 
(OD6oonm) of 0.6. After 15 min further growth at 37 °C the cultures were induced with 1 
mM isopropyl -D-1-thiogalactopyranoside (IPTG) and grown for 30 hours at 20 °C 
before harvesting by centrifugation. 
Cell pellets of PatF were re-suspended in lysis buffer plus EDTA-free protease inhibitor 
tablets (Roche) and DNAse at 0.4 mg g-1 wet cell pellet. The re-suspension was lysed by 
passage through a cell disruptor at 30 kPsi (Constant Systems). The lysate was cleared 
by centrifugation (40,000 x g, 4 °C, 20 min) and then loaded onto a Ni-Sepharose 6 FF 
column (GE Healthcare) equilibrated in lysis buffer. The column was washed with lysis 
buffer and then PatF eluted with elution buffer. The protein was then passed over a 
desalt column (Desalt 16/10, GE Healthcare) in desalting buffer. TEV protease was 
added at a mass-to-mass ratio of 1:5 TEV protease : protein and incubated for two 
hours at 20 °C to remove the His6-tag. The sample was then loaded on to a second Ni-
column, in desalt buffer supplemented with 20 mM imidazole. PatF was collected in 
the flow through. The protein was concentrated to 7.5 ml (Vivaspin concentrators, 10 
kDa MWCO) and applied to a Superdex 75 gel filtration column (GE Healthcare) 
equilibrated in gel filtration buffer. The protein was concentrated to 8 mg ml-1 for 
crystallography. The purity of the protein was confirmed by SDS-PAGE analysis and its 
identity confirmed by mass spectrometry (MS). All MS experiments in this thesis were 
carried out by the University of St Andrews BSRC Mass Spectrometry team. 
 
2.2.3 LynF Expression and Purification 
 
LynF was expressed from the pJexpress 411 and pSUMO plasmids using BL21 (DE3) E. 
coli cells, grown on auto-induction medium using the Studier method [107]. The 
cultures were grown at 20 °C, 250 rpm for 48 hours before harvesting by 
centrifugation.  
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Cell pellets of LynF from pJexpress 411 were re-suspended in lysis buffer (Appendix 
A.2) and sonicated at 10 microns (SoniPrep 150, MSE) and centrifuged at 30,000 x g 
with the soluble fraction then applied to a His-tag pull down assay (Qiagen BioSprint). 
The elution and flow-through samples were analysed by SDS-PAGE to determine any 
soluble expression. 
Cell pellets of LynF from pSUMO were processed using the same method as PatF 
(Section 2.2.2) with the SUMO-tag removed at the same time as the His6-tag. The only 
exception to this was that TEV protease was added at a mass to mass ratio of 1:10 and 
a slight variation of buffers (Appendix A.2). The purity of the protein was confirmed by 
SDS-PAGE analysis and its identity confirmed by mass spectrometry (MS) 
 
2.2.4  PatF Crystallography 
 
Initial crystallisation trials were set up using the sitting drop vapour diffusion method 
by means of the Honeybee 963 crystallisation robot (Genomic Solutions). The protein 
was screened against sparse matrix screens prepared in-house, composed from a 
range of known crystallisation conditions [108] (Appendix E). 150 nl and 300 nl protein 
was mixed in sitting drop wells with 150 nl precipitant and equilibrated over a well of 
70 µl reservoir solution. Plates were set up and incubated at 20 °C. Optimisation trials 
were carried out manually using the hanging drop method with drops of 1:1 µl or 1:0.5 
µl protein to precipitant ratios equilibrated over a well of 500 µl. Optimisation trials 
were set up and incubated at 20 °C. Optimal crystals of size 100 x 30 x 30 µm were 
grown in five days by varying the buffer pH, chemical concentration and altering the 
chemical composition of the precipitant. 
Crystals were cryo-protected in solutions of mother liquor containing up to 30 % 
glycerol before being flash frozen in liquid nitrogen. Crystals were screened in-house at 
100 K using a Rigaku 007HFM rotating anode X-ray generator and a Saturn 944 CCD 
detector. Datasets were collected in-house or at the I04 beamline at the Diamond 
Light Source. 
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2.2.5  PatF Additive Screen 
 
Attempts to improve the quality of optimised crystals were carried out using the 
Additive Screen [109] (Hampton Research). Crystal trials were set up manually as 
previously described (Section 2.2.4) with the addition of 0.3 µl additive to the protein-
precipitant drop. The precipitant in both drop and reservoir consisted of 0.1 M sodium 
/ potassium tartrate, 26 % PEG 2K MME. 
 
2.2.6  PatF Seeding 
 
For seeded crystallisation trials a single native crystal was transferred initially into 10 μl 
of fresh mother liquor (0.1 M sodium / potassium tartrate, 26 % PEG 2K MME) and 
crushed with a microtool (Hampton Research). The entire slurry was then transferred 
to a tube containing 290 μl mother liquor and briefly vortexed to yield a microcrystal 
stock. Manual crystallisation trials were set up in hanging drop trays with 2 μl of 4 mg 
ml-1 PatF mixed with 0.5 μl microcrystal stock solution and 1 μl reservoir solution and 
equilibrated against a 500 μl reservoir of precipitant. 
 
2.2.7 PatF Data Collection and Structure Solution 
 
The crystal of SeMet PatF was cryo-protected in a solution of mother liquor 
supplemented with 30 % glycerol and flash frozen in liquid nitrogen. A single 
wavelength anomalous dispersion (SAD) dataset was collected at the Se-K absorption 
edge at 100 K on beamline IO4 (Diamond Light Source). The data were processed and 
scaled using the xia2 [110] package incorporating XDS for integration [111] and Scala 
for scaling [112]. Initial analysis of the processed data was carried out with SHELX C, D 
and E [113] [114]. The structure was solved using AutoSol as part of the PHENIX suite 
[115]. Automated model building of the chains was carried out using PHENIX AutoBuild 
[115]. The model was then refined by iterative cycles of manual rebuilding in Coot 
[116] and refinement using REFMACv5 [117] as part of the CCP4 suite [118]. PISA [119], 
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[120] was used to assess the oligomeric state of the protein. TLS restraints were 
calculated using the TLSMD server [121], [122] and used in refinement [123]. The 
structure was validated using MolProbity [124]. Structural coordinates were deposited 
in the Protein Data Bank - PDB code: 4BG2. 
 
 
2.2.8  Homology Model Building 
 
Homology models of LynF and TruF1 were created using the “one to one threading” 
module of Phyre2 [125] by inputting the respective protein sequence along with PDB 
coordinates for the determined PatF structure.  
 
 
2.2.9  Structural Alignments 
 
Structural alignments of PatF and related proteins were performed in Coot [116] using 
the Secondary Structure Matching (SSM) Superpose tool. Structural coordinates of 
related proteins were downloaded from the Protein Data Bank (PDB) [126] or received 
directly from their authors.  
 
 
2.2.10  Biochemical Studies of PatF and LynF 
 
Biochemical reactions of both PatF and LynF were set up on the 100 µl reaction scale 
with 10 µM enzyme, 1 mM amino acid derivative, 1 mM DMAPP, 1 M NaCl, 12 mM 
MgCl2, 10 mM HEPES pH 7.4 and 3 mM TCEP incubated at 37 °C either overnight or for 
72 hours. 50 mM amino acid derivative stocks of Boc-Tyr, Boc-Ser and Boc-Trp were 
made up in a 50 % DMSO solution due to solubility. DMAPP was purchased from 
Cayman chemical and solubilised in water to 10 mM. All reactions were analysed by 
LC-ESI MS (Micromass LCT) using a Phenomenex C18 column run in H2O / 0.1 % formic 
acid vs methanol / 0.1 % formic acid gradient.    
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2.3 Results 
 
2.3.1  PatF Expression, Purification and Crystallisation 
 
PatF was overexpressed with an N-terminal His6-tag in BL21 (DE3) E. coli cells using the 
Studier auto-induction method [107]. Initial purifications were carried out using a 
construct lacking a TEV protease site, with the protein applied directly to gel filtration 
following desalting. The protein yield was 8 mg L-1 culture. Initial crystallisation trials of 
PatF (with tag remaining) against sparse matrix screens were carried out at 8 mg ml-1 
[108].  Crystal hits were evident in several drops, however the visual morphology was 
poor and subsequent attempts to optimise these proved difficult. In one experiment a 
single crystal grown from a precipitant composition of 24 % PEG 5000 MME, 0.15 M 
sodium / potassium phosphate pH 6.6 was achieved (Figure 2.5). This crystal diffracted 
to 2.08 Å and a dataset was collected (Table 2.3).  
Subsequent attempts to reproduce this result proved difficult with the growth of only 
fine needles which showed poor diffraction by X-ray. 
In order to assess if the His6-tag was hindering crystallisation, site directed 
mutagenesis was carried out on the protein to introduce the TEV protease cleavage 
signal ‘ENLYFQ’ between the His6-tag and the protein [127]. The tag was removed 
during the purification process using TEV protease with approximately 80 % efficiency 
and the final purified protein placed into crystallisation trials at 8 mg ml -1. A final yield 
of 4 mg L-1 culture was achieved (Figure 2.6). 
Purified PatF following tag removal gave several hits in crystallisation trials but like the 
PatF with tag remaining, visual morphology was poor. Single needles (100 x 5 x 5 µm) 
of poor diffraction quality were evident and optimisation in both nanolitre and 
microlitre drops yielded no improvement in these crystals.  
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Figure 2.5: Crystallography of PatF. (A) Initial screening of PatF (with tag) in PEG-based screens gave 
needle-like crystals. These were grown in a condition of 26% PEG 5000 MME, 0.21 M 
sodium / potassium phosphate pH 7.0. (B) Optimisation of these crystals resulted in the 
formation of a single 3-dimensional crystal. This crystal was grown in a condition of 24 % 
PEG 5000 MME, 0.15 M sodium / potassium Phosphate pH 6.6 (C) Single crystal diffraction 
to 2.08 Å in house.  (D) Zoom view of diffraction spots 
 
PatF Native dataset  
Wavelength (Å) 1.54 
Space group P 21 21 21  
a, b, c (Å) 46.1, 51.5, 144.1 
α, β, γ (°) 90, 90, 90 
Resolution (Å) 2.08 (2.19-2.08) 
I/σI 16.9 (7.98)  
Rmerge (%) 9.6 (32.5) 
Completeness (%) 99.5 (94.4) 
Multiplicity 5.9 (4.0) 
 
Table 2.3:  Data Collection Statistics for a Native Dataset. The statistics provided are averages with 
values for the highest resolution shell provided in parentheses. The dataset was collected 
in house (Rigaku 007-HFM, Saturn 944 CCD).  
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Figure 2.6:  Purification of PatF. (A) SDS-PAGE analysis of Ni-sepharose column fractions showing PatF 
isolated from the soluble lysate. (B) SDS-PAGE analysis of second Ni-sepharose column 
flow through and elute fraction of PatF treated with TEV protease indicating 
approximately 80 % cleaved PatF (C) SDS-PAGE analysis of final gel filtration fractions 
showing the sample to be > 98 % pure. (D) Gel filtration chromatograph of PatF with a 
single elution peak corresponding to a monomer. 
 
 
 
2.3.2  PatF Additive Screening 
 
Additive screens consist of small molecules including detergents, alcohols, salts and 
metal ions. These additives can aid protein solubility, increase stability between 
protein molecules and therefore improve crystallisation. PatF was screened against the 
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Hampton Additive screen (Hampton Research). The additives were added directly to 
the protein-precipitant drop with precipitant lacking additive in the reservoir. The 
precipitant was that of the best quality native crystals (0.1 M sodium / potassium 
tartrate, 26 % PEG 2K MME) 
Several conditions improved the visual quality of the crystals with the addition of 
barium chloride, strontium chloride, taurine or sucrose giving single three-dimensional 
crystals, however when screened by X-ray these crystals showed no improvement in 
diffraction quality and in most cases had detrimental effects when compared to native 
crystals.  
 
 
2.3.3  PatF Seeding 
 
Multiple iterations of optimisation resulted in no significant improvement in PatF 
crystals with only thin needles, which diffracted poorly, being produced (Figure 2.8 A). 
In order to progress to well diffracting three-dimensional crystals, seeding experiments 
were carried out. 
 
Vapour diffusion crystallisation occurs through the removal of water from the protein-
precipitant drop into the precipitant solution in the reservoir. This causes the protein 
concentration to increase and shift to a supersaturated state, either in the form of 
precipitation or ideally into the labile zone where nucleation and crystal growth can 
occur (Figure 2.7).  Upon nucleation, the protein concentration in solution will reduce 
and under the ideal condition will move into the metastable zone resulting in 
continued growth with no further nucleation [128]. 
Seeding can be used to bypass the need for a nucleation event and we can place the 
crystallisation experiment directly into the metastable zone with seeds as the nucleant 
to achieve sustained crystal growth. Seed crystals can be any crystals of the target 
protein (no matter how poor) and are normally crushed, vortexed and diluted prior to 
addition to new crystallisation experiments.  
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Figure 2.7: Phase Diagram for Crystal Growth. Vapour diffusion crystallisation occurs through the 
removal of water from protein-precipitant drop. Upon crystal trials the protein will be 
soluble (undersaturated) however as water is removed it will become supersaturated. If 
this occurs under the optimum conditions, the protein will move to the labile zone where 
nucleation can occur. This nucleation will cause a decrease in solution protein 
concentration and move it to the metastable zone where continued crystal growth but no 
further nucleation will occur. Too high a precipitant or protein concentration will push the 
protein to the irreversible precipitation zone. – (Figure adapted from Chayen N. (2004) 
[128]). 
 
 
Seeding was successfully utilised for PatF crystallisation. The first round of seeding into 
new vapour diffusion drops resulted in a decrease in crystal numbers and an increase 
in crystal volume, however the crystals were still of poor, non-singular quality (Figure 
2.8 B). A second round of seeding, using new crystals from the first round as the seed 
stock, was carried out with the protein concentration lowered to 4 mg ml-1. Single 
three-dimensional crystals formed which diffracted to 3.0 Å in-house (Figure 2.8 C).  
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Figure 2.8:  Crystals of PatF from Seeding Experiments. (A) Initial needle like crystals of PatF grown 
from a condition of 0.1 M sodium / potassium tartrate, 26 % PEG 2K MME and used in 
seeding trials. (B) First round of seeding experiments with crystals of more volume but 
still not singular. (C) Second round of seeding experiments using crystals from first round 
and reducing protein concentration to 4 mg ml
-1
. These single crystals diffract to ~3.0 Å 
resolution in house.  
 
 
 
2.3.4  Selenomethionine-labelled PatF 
 
PatF has no sequence homology greater than 20 % to any other structures currently in 
the Protein Data Bank (PDB) [126]. The PatF family has been identified as prenyl 
transferases however attempts to determine the structure by molecular replacement 
(MR) against known prenyl transferase structures were not successful. It therefore was 
necessary to determine the phases experimentally [129].   
In order to determine phases, heavy atoms are typically incorporated into the protein. 
Heavy atoms absorb X-rays and then re-emit them at a different phase and 
wavelength, a process called anomalous dispersion. Friedel’s Law states that the 
intensity of the reflection hkl is equal to that of the reflection –h-k-l.  (Figure 2.9 A) 
[129] [130] [131]. Under anomalous dispersion, Friedel’s law is broken and the 
difference in intensities between the Friedel pairs can be used to locate the heavy 
2. Structural and Biochemical Studies of PatF and homologues   
 52 
atom within the asymmetric unit (Figure 2.9 B). The phases from the heavy atoms can 
then be used to determine the structure of the protein. 
 
 
 
Figure 2.9: Friedel’s Law. Schematic diagrams of (A) Structure factors obeying Friedel’s law (B) Structure 
factors when a heavy atom is present in under both scattering and non-scattering 
wavelengths (Adapted from notes taken directly from Birkbeck University course).  
 
The most efficient and reproducible method of incorporating heavy atoms into the 
protein is to replace methionine residues with selenomethionines, a derivative 
containing selenium in place of the sulfur. To achieve this, (L)-methionine is replaced 
by (L)-selenomethionine in the E. coli growth medium resulting in selenomethionine 
being directly incorporated into the protein during expression [132].  
PatF contains four methionine residues, one of which is the first residue that is cleaved 
off during reaction with TEV protease.   
An alternative approach to incorporating heavy atoms is to soak native crystals in 
solutions of heavy metals [133], however attempts at achieving this with samarium 
acetate, potassium osmium oxide, and mercury acetate soaks resulted in the 
deterioration of the crystals. 
 
Purification of SeMet PatF occurs as with the native protein. A final yield of 2 mg L-1 
cell culture with final purity greater than 98 % was achieved (Figure 2.10 A, B). MS 
2. Structural and Biochemical Studies of PatF and homologues   
 53 
analysis confirmed that the final purified protein was fully labelled with three 
selenomethionine residues as expected (Figure 2.10 C).  
 
 
 
Figure 2.10:  Purification of SeMet PatF. (A) SDS-PAGE of final SeMet PatF sample indicating a purity of 
> 98 % (Minor dimer band due to reducing agent boiling off during sample preparation.) 
(B) Gel filtration chromatograph for SeMet PatF showing protein eluted a single 
monomer peak. (C) MS analysis of native and SeMet PatF gives masses of 37000 and 
37144 respectively. This corresponds to the incorporation of the expected three 
selenomethionine residues (100 % Se incorporation).  
 
 
SeMet PatF was applied to crystallisation trials under the same conditions as for the 
native protein following tag removal using the micro-seeding method. A single crystal 
diffracted to 3.2 Å in-house, which was improved to 2.13 Å under synchrotron 
radiation (Figure 2.11).  To achieve anomalous scattering, the crystal was scanned by 
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fluorescence to assess the optimum wavelength (Figure 2.12) [129]. A dataset was 
then collected at the selenium absorption edge (wavelength of 0.9790 Å).  
 
 
Figure 2.11:  Crystallisation of SeMet PatF. (A) The best quality crystals of SeMet PatF were grown in a 
condition of 0.1 M sodium / potassium tartrate, 26 % PEG 2K MME following seeding. (B) 
In-house diffraction pattern of SeMet PatF to 3.2 Å. (C) Synchrotron diffraction pattern 
of SeMet PatF to 2.1 Å (D) Zoom view of synchrotron diffraction 
 
 
Figure 2.12: SeMet PatF Fluorescence Scan. Fluorescence scan of SeMet PatF crystal collected at 
beamline I04 (Diamond Light Source) showing the inflection and peak wavelengths.  
 
The data was processed to 2.13 Å in the space group P21. Matthew’s analysis [134] 
suggested that the asymmetric unit contained two molecules. The processed dataset 
was analysed first with SHELXC showing a relatively weak anomalous signal overall but 
with a reasonable signal to approximately 6.5 Å (Figure 2.13 A). The SHELXC output 
was then processed by SHELXD to a resolution of 6.5 Å which suggested that four 
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heavy atom sites were present in the asymmetric unit (Figure 2.13 B). The correlation 
histogram of SHELXD shows a single peak at 39 suggested a solution had been found 
(Figure 2.13 C). The output of SHELXD was finally carried into SHELXE, however SHELXE 
failed to find a reasonable solution, i.e. the native and heavy atom do not diverge as 
would be expected (Figure 2.13 D).  
 
 
Figure 2.13: SHELX Output Statistics. A) Anomalous signal against resolution for SHELXC with signal 
strong to ~ 6.5 Å. B) Site occupancy against peak number for SHELXD location of the 4 Se 
atoms from SAD data C) CC histogram for the selenium-SAD phasing with single peak at 
39 and D) Variation of the contrast during SHELXE density modification with a lack of 
divergence indicating no defined solution (Figures created using HKL2MAP [135]). 
 
As the SHELXC and SHELXD outputs strongly proposed that a solution would be 
possible, it was decided to attempt to find a solution using PHENIX AutoSol. In 
agreement with SHELXD, the heavy atom search function of PHENIX AutoSol found 
four atoms of good occupancy > 0.88. However, unlike SHELXE, a structure solution 
was found from the heavy atom phasing giving a figure of merit of 0.262 and overall 
score 24.22 +/- 14.6. As there are three selenomethionines present in the protein, and 
Matthew’s analysis suggests two monomers in the AU, it was predicted that one 
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selenomethionine in each monomer lies on a disordered part of the structure and 
could be discarded from the structure solution. 
A round of density modification gave an R-work of 0.2827 and visual analysis of the 
map indicated that the correct solution had been found with secondary structure 
elements clearly visible in the density (Figure 2.14). 
 
 
 
Figure 2.14:  Density Modification Map. Density modification output for PatF from PHENIX AutoSol 
showing clear crystal packing with each macromolecule having elements of secondary 
structure strongly suggesting a solution had been found for PatF structure. Figure 
created using Coot [116].   
 
The solution was then processed by PHENIX AutoBuild in order to assign the structure 
to the electron density. Eight peptide fragments incorporating a total of 531 residues 
were built into the density across the two chains. A final R-work of 0.2305 and R-free 
of 0.2813 were observed following automated chain building. 
The PHENIX AutoBuild output was manually rebuilt in Coot with significant rebuilding 
required in the loop regions and the termini of each chain. Each round of rebuilding 
was refined using Refmac. TLS restraints were calculated using the TLSMD server and 
used in refinement. All angles were checked by Ramachandran plots in Coot, and poor 
rotamers analysed on the MolProbity server. These outliers were manually corrected.  
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The final data collection and refinement statistics are presented in Table 2.4. The final 
structure was analysed using the MolProbity server [124] with the output statistics 
presented in Table 2.5.  
 
PatF SAD dataset  
Wavelength (Å) 0.9790 
Space group P 1 21 1  
a, b, c (Å) 47.1, 135.8, 48.7 
α, β, γ (°) 90, 118.5, 90 
Resolution (Å) 35.32 - 2.13 (2.19-2.13) 
I/σI 14.0 (3.5) 
Rmerge (%) 10.1 (69.3) 
Completeness (%) 97.9 (97.5) 
Multiplicity 9.5 (9.8) 
Anomalous completeness 97.9 (97.6) 
Anomalous multiplicity 4.8 (4.9) 
 
Refinement 
 
R-factor  0.1899 
Rfree  0.2210 
R.m.s.d   
           Bond Lengths (Å) 0.009 
           Angles (°) 1.314 
B-factors  
           All  
           Protein 
           Water 
41.7 
41.6 
40.0 
 
Table 2.4: Data Collection and Refinement Statistics for SeMet PatF. An anomalous data set was 
collected using a single crystal on beamline I04 (Diamond Light Source). Statistics are 
presented as averages with values for the highest resolution shell included in parentheses. 
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Table 2.5: MolProbity Statistical Output for PatF Structure. The final coordinate file was processed in 
the MolProbity server and confirmed as a structure in the 100
th
 percentile in terms of 
quality when compared to structures of similar resolution
 
[124]. 
 
2.3.5  Crystal Structure of PatF 
 
The structure of PatF has been determined by single-wavelength anomalous dispersion 
(SAD) to 2.13 Å. The structure contains two molecules in the asymmetric unit. PatF is 
formed of a twelve-stranded beta barrel pore surrounded on the outside by twelve 
alpha helices in a similar but not identical conformation as the TIM barrel motif [136] 
(Figure 2.15 A,B). The refined model contains residues 3-196 and 205-307 in chain A, 
and 3-197 and 205-307 in chain B. The missing residues are the connecting loop 
between beta strand 8 and alpha helix 8 and the N- and C- termini, all of which are 
presumed to be disordered. A single disulfide bridge is present at the C-terminus 
linking residues Cys276 and Cys307. PatF is a globular protein of dimensions 45 x 43 x 
53 Å. 
 
The electrostatic potential of PatF (Figure 2.15 C) shows that the pore region, where 
the putative binding site is located, is strongly electronegative indicating that accepting 
the proposed DMAPP substrate, which itself is negatively charged due to the 
phosphate group, will be challenging.   
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The native dataset of PatF with His6-tag remaining was determined by molecular 
replacement (MR) using PHASER [137] with the SeMet PatF structure as the model. 
The native structure contains one monomer in the asymmetric unit. The resolution 
difference of 2.13 Å (SeMet) to 2.08 Å (native) is negligible and indeed the native 
structure has more disordered residues (ordered residues 3-195, 204-305). In addition, 
there was no evidence of the His6-tag in the electron density. 
Crystals of native PatF with the tag removed diffract to 2.5 Å at best and as a result, 
the SeMet PatF structure was used in subsequent homology modelling and structural 
alignments. 
 
 
2.3.6  Homology Models 
 
Homology models of LynF and TruF1 have been built using Phyre2 [126] by inputting 
their respective amino acid sequences along with coordinates of the PatF structure. 
The models appear to show similar overall structure in the form of a beta barrel 
surrounded by alpha helices (Figure 2.16 A). The significant difference when comparing 
these models to PatF is in the electrostatic potential. PatF shows large patches of 
electronegativity through the pore of the structure (Figure 2.15 C), the presumed 
active site, which makes the likelihood of the negatively charged DMAPP binding 
particularly low. LynF and TruF1 however do not show large numbers of acidic residues 
in the pore (Figure 2.16 B, C).  
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Figure 2.15: The Crystal Structure of PatF. (A) Asymmetric unit of PatF featuring two monomers. (B) 
Secondary structure analysis of PatF. The monomer consists of twelve β-strands 
arranged into a β-barrel (yellow) and surrounded on the outside by twelve -helices 
(red). (C) Electrostatic surface map representation of PatF rotated around 180°. (Red-
negative, blue-positive). Electrostatic surface figures which were produced using 
CCP4MG [138] [139]. 
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Figure 2.16: Homology Models of LynF and TruF1. (A) Homology models of (i) LynF and (ii) TruF1 both 
showing a beta barrel (yellow) surrounded by alpha helices (red). (B) Electrostatic 
potential model of LynF rotated around 180°. (C) Electrostatic potential model of TruF1 
rotated around 180°. 
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2.3.7  Structural Alignments 
 
To further characterise the PatF structure, structural alignments with related proteins 
were carried out. PatF is presumed to be a prenyl transferase so the structure of 
dimethylallyl tryptophan synthase (DMATS) from Aspergillus fumigatus in complex 
with an inactive DMAPP mimic and tryptophan [140] was downloaded from the 
Protein Data Bank (PDB code: 3I4X, Figure 2.17 A). In addition, the structure of PagF 
(currently unpublished), a member of the PatF family from Planktothrix agardhii, 
which is known to prenylate tyrosine residues was kindly provided by Prof. S. Nair 
(University of Illinois) (Figure 2.17 B). 
 
 
 
Figure 2.17: Structures of Prenyl Transferases – Secondary structure representations of (A) 
Dimethylallyl tryptophan synthase from Aspergillus fumigatus in complex with 
tryptophan and a DMAPP derivative (B) PagF, a cyanobactin prenyl transferase from 
Planktothrix agardhii known to prenylate tyrosine residues. 
 
DMATS is considerably different from PatF and PagF in terms of sequence homology (< 
5 %) however all three contain the characteristic beta barrel pore with surrounding 
alpha helices. The presence of the DMAPP mimic in the pore of DMATS allows this 
structure to be used as a starting model for structural alignments to identify the 
potential residues involved in PatF/PagF DMAPP binding. 
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The structures of PatF, PagF and the DMATS complex were aligned in Coot [116] using 
the SSM superpose tool.  
 
Two key interactions in DMAPP mimic binding which appear conserved in PagF and 
DMATS are significantly different in PatF. Met136 of PatF is found to be lysine residues 
in both PagF and DMATS which forms a strong salt bridge with one of the phosphate 
oxygens of the DMAPP mimic (Figure 2.18). His125 of PatF is an aspartic acid residue in 
the other structures. The Asp residue forms two salt bridges, one to the lysine 
mentioned previously and one to an arginine (Arg66 in PatF) stabilising them to form 
two further salt bridge interactions with the DMAPP mimic (Figure 2.19)  
 
 
 
 
Figure 2.18: Structural Alignment of PatF Met136. The structural alignment of PatF (magenta), PagF 
(cyan) and DMATS (green) showing the difference of Met136 to Lys in both PagF and 
DMATS. The salt bridge interaction of the Lys in DMATS to the DMAPP mimic is shown 
by dashed line. 
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Figure 2.19: Structural Alignment of PatF His125. The structural alignment of PatF (magenta), PagF 
(cyan) and DMATS (green) highlighting the difference of His125 to Asp in both PagF and 
DMATS. The stabilising salt bridge interactions in the DMATS structure (dashed lines) are 
shown to the Arg66 equivalent and the Lys (Met136 in PatF), which in turn form salt 
bridges with the DMAPP mimic. 
 
 
2.3.8  LynF Expression and Purification 
 
LynF in pJexpress 411 plasmid was overexpressed with an N-terminal His6-tag in BL21 
(DE3) E. coli cells using the Studier auto-induction method [107]. The soluble protein 
was isolated on a Ni-sepharose column. TEV protease was added to the protein to 
cleave the His6-tag and the tag was removed by passage over a second Ni-sepharose 
column (Figure 2.20). At this stage protein levels were less than 0.2 mg L-1 of original 
cell culture and the protein was precipitating significantly. As a result of these issues, 
this LynF construct was discontinued.  
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Figure 2.20: LynF Purification (pJexpress 411). (A) SDS-PAGE analysis of LynF purification with Ni-
sepharose isolation and TEV protease cleavage steps.  
 
To improve solubility, LynF was re-cloned into the pSUMO plasmid for co-expression 
with a SUMO domain as a solubility tag. The His6/SUMO tag was removed with TEV 
protease with ~95% efficiency. Two significant peaks eluted off the gel filtration 
column, a highly aggregated peak and a soluble monomer peak. SDS-PAGE analysis 
confirmed the soluble monomer peak to be pure LynF with the aggregation peak 
containing a small amount of LynF and significant contaminant proteins (Figure 2.21). 
The LynF protein was confirmed by MS and a final purified yield of 1.5 mg L-1 culture 
was achieved. 
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Figure 2.21: LynF Purification (pSUMO). (A) SDS-PAGE analysis of LynF purification from initial Ni-
sepharose isolation, TEV protease cleavage to remove His6/SUMO tag and final gel 
filtration step. Fractions of peak two contain >98% pure LynF.  (B) Gel filtration 
chromatograph for LynF showing protein eluted as a monomer peak (Peak2) with the 
contaminants eluting in the void volume (Peak 1). 
 
 
2.3.9  Biochemical Studies on PatF and LynF 
 
Biochemical reactions of PatF were set up with a range of amino acid derivatives and 
DMAPP. The reactions were analysed by LC-ESI MS. For the three amino acid 
derivatives assessed, Boc-Tyr, Boc-Ser and Boc-Trp, no evidence of prenylation was 
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found when incubated overnight or for 72 hours. All MS spectra showed starting 
material only.  
 
As a control, a reaction of LynF with Boc-Tyr and DMAPP was set up, repeating the 
experiment detailed in McIntosh et al. (2011) [65]. A peak with m/z = 372.08 
corresponding to mass plus sodium of prenylated Boc-Tyr was observed. Examination 
of the LC peak would suggest that overnight incubation with 10µM LynF prenylated 
greater than 50 % of the Boc-Tyr. This can be observed by the shift in elution time due 
to the large hydrophobic group added to the molecule (Figure 2.22)  
 
 
 
 
Figure 2.22:  LC-ESI MS Spectrum for BocTyr Reactions. (A) Boc-Tyr in reaction conditions without 
enzyme present. Elution at 8.58 min with [M+Na]
+
 peak for Boc-Tyr present. (B) Reaction 
of Boc-Tyr + LynF showing two peaks at 8.62 min and 11.35 min with [M+Na]
+
 peak for 
Boc-Tyr and [M+Na]
+
 peak for prenylated Boc-Tyr respectively. 
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2.3.10 Active Site Mutants of PatF 
 
PatF mutants M136K and H125D/G127R/M136K were created in order to attempt the 
introduction of an active site based on the structural and sequence data obtained. 
Unfortunately, these constructs resulted only in the expression of insoluble protein. 
This was confirmed by running both the insoluble and soluble fractions of the lysed 
cells on SDS-PAGE (Figure 2.23).  
 
 
Figure 2.23: SDS-PAGE of PatF Mutants. SDS PAGE analysis of the soluble and insoluble fractions of PatF 
mutants M136K and H125D/G127R/M136K. The largest bands in the insoluble fraction 
correspond to the mutated PatF. There are no or minor bands corresponding to soluble 
protein for both mutants. (Note: The insoluble fraction was suspended in 8M urea to 
enable SDS-PAGE run). 
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2.4 Discussion 
 
The PatF crystal structure has been determined to 2.1 Å and confirms it to possess a 
central beta barrel surrounded by alpha helices in a TIM barrel-like conformation.  
 
Electrostatic potential maps of the PatF structure reveal that the central pore, where 
the putative binding site is located, is highly electronegative. This suggests that binding 
of the electronegative DMAPP substrate is unlikely given the potential repulsion 
interactions which would occur. 
 
Structural alignments of PatF with two other known prenyl transferases, DMATS a 
tryptophan prenyl transferase in complex with a DMAPP mimic from an unrelated 
pathway and PagF, a related cyanobactin tyrosine prenyl transferase, has provided us 
with information on the key interactions involved in DMAPP binding. It appears that 
two interactions involved in DMATS and PagF are not conserved in PatF and their 
subsequent equivalents would have a detrimental effect on binding. His125 and 
Met136 of PatF are conserved as Asp and Lys residues, respectively, in both DMATS 
and PagF and both residues are involved in DMAPP binding. Interestingly, sequence 
alignments of the PatF family (Figure 2.24, Appendix B) show that both His125 and 
Met136 are fully conserved as aspartic acid and lysine/arginine residues respectively in 
all other PatF family members. Additionally, residue Gly127 is fully conserved as an 
arginine in all PatF related proteins; however this residue is not located at the binding 
site but is found at the pore opening. It is possible that this could have an effect on 
DMAPP entry into the protein although this has not been confirmed. 
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Figure 2.24: Partial Sequence Alignment of PatF. Sequence alignment of PatF with related family 
members from residues 98 to 146. The key residue changes, H125D and M136K are 
starred. Secondary structure elements of PatF are also shown above (alpha helices in 
red, beta sheet in yellow). The full sequence alignment can be found in Appendix B.  
 
 
Biochemical studies of PatF to date have yielded no prenylated product when 
substrates of DMAPP and amino acid derivatives Boc-Tyr, Boc-Ser and Boc-Trp have 
been used. This is most likely due to a lack of binding as discussed previously. The 
demonstration of activity when using a known active cyanobactin prenyl transferase, 
LynF, further supports this hypothesis.  
 
Mutation of the PatF active site to align with all other PatF family members  resulted in 
only insoluble protein suggesting that these mutations cause disruptive interactions 
within the protein. 
 
These studies on PatF have given a strong indication that the protein has become 
evolutionary inactive with respect to prenyl transferase activity, however this is always 
difficult to prove conclusively. One final question remains, if PatF is indeed an inactive 
prenyl transferase, why do PatF gene knockouts result in no patellamide products? 
Perhaps it has an unknown function which still needs to be investigated.  
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2.5 Conclusions and Future Work 
 
The crystal structure of PatF has been determined to 2.1 Å resolution. PatF is formed 
of a twelve strand beta barrel motif surrounded by twelve alpha helices. The function 
of PatF is still not clear and indeed whether it still retains function despite the protein 
containing structural characteristics of a prenyl transferase. The structure has shown 
that the lack of conservation of two and possibly three amino acids with respect to 
other members of the PatF family could significantly inhibit DMAPP binding. This 
appears to be confirmed by a lack of activity in biochemical assays. The mutation of 
PatF to attempt to reintroduce DMAPP binding results in only insoluble protein. PatF 
has been designated as essential in previous studies, therefore further study will be 
required to assess what this role may be. LynF has been purified and shown to be 
active in biochemical assays. Future work will look to examine LynF (and potentially 
other homologues) in crystallisation trials in the presence of DMAPP (or its mimic) and 
tyrosine analogues to determine their crystal structures and give an insight into the 
mechanism of cyanobactin prenyl transferases. 
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3.  Structural and Biochemical Studies of PatGmac 
 
The work in this chapter was a collaboration between Dr Jesko Koehnke (University of 
St Andrews) and myself. The apo protein structure was determined by Dr Koehnke 
whilst the protein-peptide complex structure and the mutant activity assays were 
performed by myself. Conclusions on the enzyme mechanism were a joint contribution 
from us both.   
 
3.1 Introduction 
 
PatG consists of three domains; an N-terminal oxidase domain, protease / 
macrocyclase domain and a C-terminal domain of unknown function. The 
macrocyclase domain (PatGmac) catalyses one of the final steps in patellamide 
biosynthesis, the C-terminal cleavage and macrocyclisation of the eight amino acid 
core peptide into the final cyclic product. Structural and biochemical studies of this 
enzyme should give a greater insight into the mechanism of macrocyclisation and also 
identify the substrate tolerance of the enzyme. 
 
Bioinformatic analysis of PatGmac identifies it to be a member of the subtilisin-like 
serine proteases [84], [85] containing the typical active site catalytic triad – Asp, His 
and Ser. Subtilisin-like proteases accept peptide substrates and the notation P4-P2’ is 
used to donate the substrate residues, with peptide cleavage occurring between 
residues P1 and P1’.  
 
The native PatGmac structure was determined to a resolution of 2.19 Å by Dr Jesko 
Koehnke and the structure has given an understanding into how its variation from 
other subtilisin-like proteases may result in macrocyclisation [141] (PDB code: 4AKS). 
Sequence alignments of the PatGmac family when compared to other subtilisin-like 
proteases show a significant insertion of between 35 and 50 amino acids (37 amino 
acids for PatGmac, Figure 3.1, Appendix C). This insertion in the PatGmac structure has 
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been defined as the “macrocyclisation insertion” and consists of a helix-turn-helix 
motif which sits directly over the active site (Figure 3.2 A, B). The removal of this 
insertion abolishes macrocyclisation activity resulting only in linear proteolysis [141]. In 
addition, compared to standard subtilisin-like proteases e.g. Bacillus Ak.1 protease 
[142], the ability of the substrate to form an extended conformation upon binding is 
hindered by conformational changes in the protein which results in three residues, 
Met660, Arg686 and Phe684, blocking the traditional P3 and P4 sites. (Figure 3.2 C).  
 
 
Figure 3.1: Sequence Alignment of PatGmac and Ak1. Sequence alignment of the macrocyclase domain 
of PatG (PatGmac) and the subtilisin-like protease Ak1. Corresponding residues are 
group in black. The large “macrocyclisation insertion” is coloured in cyan. 
 
 
To further enable the understanding of macrocyclase activity and to identify the key 
interactions required, a crystal structure of PatGmac in complex with a substrate 
peptide followed by site specific mutations and subsequent activity assays were 
targeted.  
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Figure 3.2: The Structure of PatGmac.  (A) The crystal structure of PatGmac with the active site residues 
Asp548, His618 and Ser783 highlighted as sticks and the macrocyclisation insertion 
coloured in red.  (B) The structure of PatGmac (green/red) overlaid with the structure of 
Ak1, a subtilisin-like protease (magenta) clearly showing the macrocyclisation insertion 
in PatGmac. (PDB codes: PatGmac: 4AKS Ak1: 1DBI) (C) View of the active site of 
PatGmac showing the three residues which block the extended conformation, Met660, 
Arg686 and Phe684 (spheres) and the catalytic triad (sticks). 
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3.2 Materials and Methods 
 
3.2.1  DNA Cloning 
 
Full length PatG was originally cloned from genomic DNA (Prochloron sp.) into the 
pHISTEV vector by Dr Wael Houssen (University of Aberdeen). The macrocyclase 
domain ‘PatGmac’ (PatG residues 492-851) along with its mutants PatGmac H618A, 
PatGmac K594D, PatGmac K598D, and PatGmac R589D,K594D,K598D were sub-cloned 
by Dr Houssen and Dr Jesko Koehnke. 
 
3.2.2  Expression and Purification 
 
The inactive mutant PatGmac H618A (PatG residues 492-851) was expressed from the 
pHISTEV plasmid (Liu et al. [143]) with an N-terminal His6-tag and Tobacco Etch Virus 
(TEV) protease recognition site using BL21 (DE3) E. coli cells grown on auto-induction 
medium using the Studier method [107] (see Appendix A.3 for media and buffer 
compositions). The cultures were grown at 20 °C, 250 rpm for 48 hours before 
harvesting by centrifugation.  
 
Cell pellets of PatGmac H618A were re-suspended in lysis buffer supplemented with 
DNAse at 0.4 mg g-1 wet cell pellet. The re-suspension was lysed by passage through a 
cell disruptor at 30 kPsi (Constant Systems). The lysate was cleared by centrifugation 
(40,000 x g, 4 °C, 20 min) and then loaded onto a Ni-Sepharose 6 FF column (GE 
Healthcare) equilibrated in lysis buffer. The column was washed with lysis buffer and 
PatGmac H618A eluted with elution buffer. The protein solution was then passed over 
a desalt column (Desalt 16/10, GE Healthcare) in desalting buffer. TEV protease was 
added at a mass-to-mass ratio of 1:10 TEV protease : protein and incubated for one 
hour at 20 °C to remove the His6-tag. The sample was then loaded on to a second Ni-
column, in desalt buffer. PatGmac H618A was collected in the flow through and loaded 
onto a monoQ column (GE healthcare) equilibrated in Q buffer A. The protein was 
eluted through a NaCl gradient (Q buffer B) eluting at 350 mM NaCl. The protein was 
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concentrated to 7.5 ml (Vivaspin concentrators, 10 kDa MWCO) and applied to a 
Superdex 75 gel filtration column (GE Healthcare) equilibrated in sizing buffer and 
concentrated to 30 mg ml-1 for crystallography. The purity of the protein was assessed 
by SDS-PAGE analysis and its identity confirmed by mass spectrometry (MS). 
 
Native PatGmac and active site mutants PatGmac K594D, PatGmac K598D and 
PatGmac R589D K594D K598D were expressed and purified using the same methods as 
PatGmac H618A. 
 
3.2.3  Crystallography 
 
To obtain a complex structure, the inactive PatGmac H618A was used in crystallisation 
trials to ensure the substrate peptide wasn’t processed. PatGmac H618A was 
subjected to stochastic crystallisation screening [108] at both 20 °C and 4°C followed 
by manual optimisation at 4 °C using the same methods as for PatF (see section 2.4.2). 
Soaking trials with the substrate mimic were set up by incubating several apo crystals 
in mother liquor supplemented with 7.5 mM peptide VPAPIPFPAYDG (provided by Dr. 
Laurent Trembleau, University of Aberdeen) at 4 °C for 72 hours.   
For co-crystallisation with the substrate mimic, PatGmac H618A was mixed with a 10 
fold excess of peptide VPAPIPFPAYDG at 4 °C overnight prior to being used in crystal 
trials. The putative complex was then subjected to stochastic crystallisation screening 
and optimisation as above [108]. 
 
3.2.4  Data Collection and Structure Solution 
 
The crystal of PatGmac H618A in complex with VPAPIPFPAYDG peptide was cryo-
protected in a solution of mother liquor supplemented with 30 % glycerol and flash 
frozen in liquid nitrogen. A dataset on a single crystal was collected in-house at 100K 
on a Rigaku 007HFM rotating anode X-ray generator with a Saturn 944 CCD detector. 
The data were processed using xia2 [110] and the structure determined by molecular 
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replacement with PHASER [137] using the structure of PatGmac as a model (PDB: 
4AKS). Manual rebuilding was performed with Coot [116] and refinement was carried 
out using REFMAC5 [117] as part of the CCP4 suite [118]. TLS restraints were 
calculated using the TLSMD [121], [122] server and used in refinement [123]. The 
structure was validated using MolProbity [124] and the coordinates deposited in the 
Protein Data Bank [126] (PDB Deposition ID: 4AKT). 
 
3.2.5  Biochemical Studies 
 
Macrocyclisation reactions of a substrate mimic with both native and active site 
mutants of PatGmac were used to assess ratios of non-cleaved, linearly cleaved and 
macrocyclised product.  
100 µM peptide VGAGIGFPAYDG (provided by Dr. Laurent Trembleau, University of 
Aberdeen) , was incubated with 50 µM enzyme in 150 mM NaCl, 10 mM HEPES pH 8.0, 
1 mM TCEP for 120 hours at 37 °C. All reactions were carried out at 100 µl scale with 
samples analysed by LC-ESI MS (Micromass LCT) using a Phenomenex C18 column run 
in H2O/0.1% formic acid vs methanol/0.1% formic acid gradient. 
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3.3 Results 
 
3.3.1  Expression and Purification 
 
PatGmac H618A was overexpressed with an N-terminal His6-tag and TEV protease 
recognition site in BL21 (DE3) E. coli cells using the Studier auto-induction method 
[107]. The protein was isolated using the His6-tag on nickel resin and the tag cleaved at 
close to 100 % efficiency by the addition of TEV protease. The tag was removed by 
passage over a second nickel column. The protein was further purified on an ion-
exchange mono-Q column with the protein eluting at 350 mM of a NaCl gradient. The 
sample was subjected to size-exclusion chromatography where PatGmac H618A eluted 
as primarily a monomer peak with a slight dimer shoulder (Figure 3.3). The addition of 
the small dimer contaminant has no effect on crystallisation. Final protein yields were 
200 mg L-1 cell culture.  
 
 
 
Figure 3.3: Purification of PatGmac H618A. (A) Gel filtration chromatograph of PatGmac H618A 
showing primarily a monomer peak, with a slight dimer shoulder. (B) SDS-PAGE analysis of 
PatGmac H618A gel filtration fractions showing > 98% purity. 
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3.3.2  Crystallography 
 
Stochastic screening [108] of apo PatGmac H618A yielded several crystal hits with the 
best visually grown at 4 °C in a condition of 22 % PEG 3350, 50 mM calcium acetate. 
These crystals diffracted to 2.5 Å and belonged to the space group C2, the same as the 
native PatGmac (PDB: 4AKS). The crystal structure was determined by molecular 
replacement (MR) using Phaser with the native PatGmac structure as the search 
model. Apo crystals of PatGmac H618A were then subjected to soaking trials with 7.5 
mM peptide VPAPIPFPAYDG at 4 °C both overnight and for three days. Datasets were 
collected on these crystals and the structure determined by MR, however no density 
for the peptide was evident.  
 
Stochastic screening of PatGmac H618A in putative complex with 7.5 mM peptide 
VPAPIPFPAYDG yielded several crystal hits with 1.2 M sodium citrate, 0.1 M sodium 
cacodylate pH 7.0 giving the best crystals by visual analysis (Figure 3.4 A). Datasets 
were collected on these crystals again to 2.5 Å and the structure was determined by 
MR. The structure was analysed in Coot and there appeared to be density in the active 
site for one of two molecules in the asymmetric unit (AU). The density however was 
poor and therefore not conclusive suggesting that the peptide may be present but in 
low occupancy (Figure 3.5 A). In order to improve the occupancy, the co-crystals were 
subsequently soaked with a further 7.5 mM peptide overnight at 4 °C prior to data 
collection.  
 
A dataset was collected on the soaked co-crystal to a resolution of 2.6 Å and the 
structure was again determined by MR (Figure 3.4 B, C). This time there was clear 
density in the active site of one of the two molecules in the AU which corresponding to 
residues PIPFPAYDG of the peptide (Figure 3.5 B). The peptide chain was fitted into the 
structure, and minor conformational changes were manually rebuilt in Coot. The 
structure was refined using REFMAC [117] and the structure checked by MolProbity 
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[124]. Final data collection and refinement statistics can be found in Table 3.2. Final 
MolProbity statistics can be found in Table 3.3 
 
 
 
Figure 3.4: Crystallisation of PatGmac H618A in Complex with VPAPIPFPAYDG. (A) Single crystals of 
PatGmac H618A co-crystallised with VPAPIPFPAYDG peptide grown in a condition of 1.2 
M sodium citrate, 0.1 M sodium cacodylate pH 7.0. (B) In-house diffraction pattern from 
a single crystal co-crystallised with VPAPIPFPAYDG peptide then soaked overnight with 
additional peptide. (C) Zoom view of diffraction spots 
 
 
Figure 3.5: PatGmac Electron Density Representations. Electron density of PatGmac crystal structure 
zoomed in to the active site when (A) co-crystallised with peptide VPAPIPFPAYDG and 
(B) co-crystallised followed by additional soaking of peptide VPAPIPFPAYDG. Minor 
density for the peptide can be seen for the co-crystal however not conclusive for chain 
building. Unambiguous density for the peptide can be seen in the co-crystal plus soaking 
experiment and could be used for chain building. Both maps are contoured at 1 σ. 
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PatGmac H618A + Peptide Dataset  
Wavelength (Å) 1.54 
Space group C 1 2 1  
a, b, c (Å) 135.6, 67.3, 137.9 
α, β, γ (°) 90.0, 116.8, 90.0 
Resolution (Å) 2.63 (2.77-2.63) 
I/σI 10.1 (2.3) 
Rmerge (%)  10.1 (52.2) 
Completeness (%) 99.3 (96.4) 
Redundancy 3.7 (3.1) 
Refinement  
R-factor 0.191 
Rfree 0.218 
R.m.s.d   
           Bond Lengths (Å) 0.009 
           Angles (°) 1.253 
B-factors  
           All  
           Protein 
           Peptide 
           Water 
60.56 
60.70 
77.98 
47.19 
 
Table 3.1:  Data Collection and Refinement Statistics of PatGmac H618A Complex with VPAPIPFPAYDG 
Peptide. Values for the highest resolution shell are provided in parentheses. The dataset 
was collected in house (Rigaku 007-HFM, Saturn 944 CCD).  
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Table 3.2: MolProbity Statistical Output for PatGmac Structure in Complex with VPAPIPFPAYDG 
Peptide. The final coordinate file was processed in the MolProbity server and confirmed 
as a structure in the 100
th
 percentile in terms of quality when compared to structures of 
similar resolution
 
[124]. 
 
3.3.3  Crystal Structure of PatGmac H618A in Complex with VPAPIPFPAYDG Peptide 
 
The structure of PatGmac H618A, the inactive form of PatGmac, in complex with the 
substrate mimic VPAPIPFPAYDG peptide has been determined by molecular 
replacement to 2.63 Å (Figure 3.7 A, B). The VPAPIPFPAYDG peptide was chosen as it 
includes the eight residue core peptide and four residue macrocyclisation signal with 
proline residues mimicking the heterocycles of a normal substrate. This peptide is 
however a poor substrate and only achieves approximately 30 % turnover [141]. 
 
The difference electron density for the peptide in the active site of one of the 
molecules in the asymmetric unit was unambiguous for residues PIPFPAYDG (P5 to P4’) 
(Figure 3.7 C). The second molecule in the asymmetric unit contains a hint of density 
for the peptide but is not strong enough to confirm. The refined model contains 
residues 514-686, 694-719, 727-747, 754-823, and 833-851 in chain A, and 515-651, 
657-688, and 692-851 in chain B.  
 
Residues P5 (Pro) and P4 (Ile) of the peptide make no contact with the protein while P3 
(Pro) has some weak van der Waals interactions with the main chain. P2 (Phe) also 
makes some limited van der Waals contacts and the side chain sits in a shallow pocket. 
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The Pro of P1 adopts a cis peptide conformation and the side-chain makes van der 
Waals contacts with His618Ala and Val622. The carbonyl of the P1–P1’ peptide is 
oriented for nucleophilic attack by the hydroxyl of Ser783 with the side-chain of 
Met784 sitting on this face of the carbonyl. The tetrahedral intermediate is stabilised 
by the side-chain of Asn717 pointing towards the opposite face of the carbonyl. The 
P1’ Ala makes only a few hydrophobic interactions, including contacts with Met784 
and the protein backbone. The P2’ (Tyr) residue makes extensive contacts with the 
protein: A π stacking interaction with Phe747, a hydrogen bond to His746 and 
hydrogen bonds between the main-chain oxygen and the nitrogen of Thr780. The side-
chain of P3’ (Asp) is oriented towards a large electropositive patch created by Arg589, 
Lys594, and Lys598. It makes a salt bridge with Lys598 and possibly Lys594, though the 
side chain of Lys594 is not well ordered. The P4’ Gly residue appears to make no direct 
contact with the protein, although larger residues in this position may be disfavoured 
by the proximity to Lys594. (Figure 3.6, 3.7 B) 
 
 
Figure 3.6: PatGmac Binding to VPAPIPFPAYDG Peptide. LigPlot
+
 representation of the residues 
involved in PatGmac binding of the substrate peptide VPAPIPFPAYDG (only residues 
‘PIPFAPAYDG’ are ordered). Figure was created in LigPlot
+
 [144] 
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Figure 3.7: The Crystal Structure of PatGmac H618A in Complex with Peptide ‘VPAPIPFPAYDG’. (A) 
Asymmetric unit of PatGmac H618A in complex with peptide ‘VPAPIPFPAYDG’ featuring 
two monomers, one with substrate present (yellow sticks), one without. Macrocyclisation 
insertion residues are shown in red. (B) Two representations of the active site of PatGmac 
H618A with substrate peptide bound (yellow). (C) Difference electron density (Fo-Fc map) 
fit for residues ‘PIPFPAYDG’ in chain A of PatGmac H618A contoured at 2.5σ.  
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3.3.4  Biochemical Studies on PatGmac 
 
To examine substrate specificity, a range of mutant PatGmac proteins were expressed 
and purified for use in biochemical reactions with the substrate mimic peptide 
‘VGAGIGFPAYDG’. The mutants K598D, K594D, R589D/K594D/K598D were made based 
upon the key interactions in the active site involved in the binding of the AYDG leaving 
group. The reactions were analysed by LC-MS for unprocessed substrate and linear and 
cyclic products (Table 3.3). (The data accumulated from this method has some 
limitations as it is appreciated that certain peptides may ionize better in the MS than 
others however it should give a good comparison of the products. Additionally, due to 
the lack of charged N- and C- termini it more likely that the cyclic peptides will not 
ionize as well as linear peptides.) 
 
 
Table 3.3:  Relative Ion Counts of Linear Cleaved and Macrocyclised Peptide Substrate. 
 
Native PatGmac accepts the peptide VGAGIGFPAYDG and macrocyclises it with 100 % 
efficiency when reacted 100 µM peptide : 50 µM PatGmac at 37 °C for 120 hours. 
PatGmac K598D accepts the peptide however results in only linear product being 
formed with the complete absence of any macrocyclised peptide. PatGmac K594D 
gives a 7:3 ratio of linear to macrocyclised product. Finally, PatGmac 
R589D/K594D/K598D mutant results in mostly unprocessed starting material with a 
small (6 %) amount of linear product. (Figure 3.8) 
 
Unprocessed  
ion count (%) 
(M + H = 1123) 
Linear  
ion count (%) 
(M + H = 717) 
Cyclic  
ion count (%) 
(M + H = 699) 
PatGmac 0 0 100 
PatGmacK598D 0 100 0 
PatGmacK594D 0 71 29 
PatGmac 
R589D/K594D/K598D 
94 6 0 
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Figure 3.8: Mass Spectrometry Analysis of Peptide VGAGIGFPAYDG after Reaction with Native and 
Mutant PatGmac. LC-MS analysis showing chromatogram and spectra of 
VAGAGIGFPAYDG peptide following reaction with (A) native PatGmac resulting in 
complete macrocyclisation (octagon) (B) PatGmac K598D showing 100 % linear product 
(waved line). (C) PatGmac K594D gives a mixture of linear and macrocycle products (D) 
PatGmac R589D/K594D/K598D showing only linear product. 
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3.4 Discussion 
 
The crystal structure of PatGmac in complex with substrate mimic peptide, 
VPAPIPFPAYDG, has provided extensive information on the protein-peptide 
interactions involved in the macrocyclisation process and has also given us some 
insight into the mechanism of reaction. 
 
The complex structure shows that the P1-P1’ bond of the substrate is in the correct 
position for nucleophilic attack by Ser783 with Asn717 stabilising the tetrahedral 
intermediate, which would subsequently collapse to the classical acyl-enzyme 
intermediate. 
 
It is known that there is a requirement for macrocyclisation to have a proline or a 
heterocycle at the C-terminal end of the modified core peptide (P1) [88]. The complex 
structure identifies that a proline in this position adopts a cis conformation, enabling 
the peptide to bend back on itself which in turn promotes macrocyclisation. A non-
cyclic residue in this position would not be able to adopt a similar conformation 
without a significant energy penalty [145] [146] 
 
The side chain of P2 (Phe) points into a non-specific shallow pocket while P3 – P5 point 
away from the protein surface. The non-specific cavity that binds P2 and the lack of 
any further contacts between PatGmac and the patellamide core peptide is consistent 
with the known lack of enzyme specificity for the core peptide sequence with the 
exception of the P1 residue [64] and explains why the core peptide region is 
hypervariable. 
The Ala (P1’) and Gly (P4’) of the macrocyclisation signature, ‘AYDG’, appear to make 
no significant interactions with the protein, while the aromatic ring of Tyr (P2’) makes 
extensive interactions. The Asp (P3’) forms salt bridges with one, possibly two, lysine 
residue(s) (Lys598 and possibly Lys594).  
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In order to favour the nucleophilic attack of the acyl-enzyme intermediate by the N-
terminus of the patellamide modified core peptide over hydrolysis it is essential for 
PatGmac to protect the acyl-enzyme-intermediate from water which is at 55.5 M. We 
propose that this is achieved through the requirement of the macrocyclisation 
signature ‘AYDG’ remaining bound post-cleavage and working together with the 
macrocyclisation insertion shield the acyl-enzyme intermediate from water (Figure 
3.9). 
 
 
 
Figure 3.9: PatGmac in Complex with Peptide VPAPIPFPAYDG. Structure of PatGmac with peptide 
showing how the AYDG leaving group (yellow - spheres) along with the macrocyclisation 
insertion (red) combine to shield the active site from water, giving the core peptide 
residues (yellow - sticks) time to orientate for nucleophilic attack of the acyl-enzyme 
intermediate. 
 
It was shown that removal of the macrocyclisation insertion removes macrocycle-
forming activity whilst retaining protease activity [141]. Point-mutations in the 
macrocyclisation insertion designed to disrupt the interactions it has with the 
macrocyclisation signature of the peptide have also been found to either reduce 
(K594D) or abolish (K598D) macrocyclase activity. 
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The accumulation of both structural and biochemical data has now allowed a 
mechanism for the macrocyclisation of peptides by PatGmac to be proposed (Figure 
3.9) 
 
 
 
 
 
Figure 3.10: Proposed PatGmac Mechanism. The macrocyclase cleaves the P1-P1’ bond by means of the 
catalytic triad (green) forming the classical acyl enzyme intermediate. The AYDG 
recognition portion of the peptide (blue) is held in place by protein: peptide interactions 
from the macrocyclisation insert (red) and not released until the N-terminal of the core 
peptide is in place for the nucleophilic attack of the acyl enzyme intermediate. Following 
macrocyclisation the enzyme collapses back to its native state releasing the macrocycle. 
Amino acid Y, which must be either a proline or heterocycle (thiazol(in)e or oxazol(in)e), 
adopts a cis peptide conformation (magenta). Figure adapted from Koehnke et al. (2014) 
[147] 
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3.5 Conclusions and Future Work 
 
The crystal structure of PatGmac in complex with substrate mimic peptide, 
VPAPIPFPAYDG, has been determined by molecular replacement to 2.63 Å resolution. 
This structure has allowed the identification of the key interactions involved in 
substrate binding and the rationalisation of its macrocyclisation mechanism. The 
amino acid insertion represents a head group which sits over the active site. The AYDG 
leaving group of the substrate forms extensive interactions holding it in place within 
the binding site. Together these two features, shield the active site from water until 
the N-terminus of the core peptide can orientate itself to attack the acyl-enzyme 
intermediate to form the cyclic peptide. The presence of a heterocycle or proline in the 
P1 position is required as these can adopt the cis conformation which is needed to 
allow the peptide to bend back on itself promoting macrocyclisation. 
 
The rate-limiting step involved in macrocyclisation was still to be determined; is it the 
rate of proteolysis or the time taken for the N-terminus of the peptide to orientate for 
nucleophilic attack or perhaps given the structural insights it could possibly be the 
dissociation rate of AYDG? Following our publication of this work [141], Agarwal et al. 
(2012) subsequently published their own structure of PatGmac which independently 
validated our structure [66]. Their study further explored the rate of proteolysis by 
mutating the active site serine (Ser783) to a cysteine and a proline (Pro225) to an 
alanine to form a subtiligase type enzyme as described previously [148] [149] [150]. 
The change of the oxygen to a sulfur atom should result in a better nucleophile and as 
a result the attack of the acyl-enzyme intermediate occurs at an increased rate. The 
changes were implemented and assessed for activity and as expected increased levels 
of macrocyclisation were observed over the wild type enzyme. 
 
Further work will be carried out to assess if PatGmac can be re-engineered to increase 
rates, accept alternate peptide motifs and accept longer core peptides and thus 
produce larger macrocycles. Alternatively, homologues of PatGmac will also be studied 
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as there are known macrocyclases which can process up to 20 residues in the core 
peptide [34]. 
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4. In Vitro Biosynthesis of Patellamides 
 
4.1 Introduction 
 
 
Cyclic peptides are common entities in a wide variety of drugs and biotechnology tools 
[151]. Their synthesis however can be particularly challenging and expensive. Many 
cyclic peptide natural products have been discovered in a wide range of species and 
there is much interest in exploiting the biosynthetic pathways for their production to 
produce novel chemically interesting cyclic peptides. 
 
The patellamides, a member of the cyanobactin superfamily, are cyclic peptides of six 
to eight amino acids in length and contain D-stereo centres and heterocyclised amino 
acids in the form of oxazolines (from serine, denoted SOxn or from threonine, denoted 
TOxn) and thiazolines (from cysteine, denoted CThn), the latter of which can be further 
oxidised to thiazoles (denoted CThz) [40]. 
 
Patellamide biosynthesis has been examined in some detail, as previously described in 
Chapter 1, and its products have a range of bioactivities including reversing drug efflux 
pumps and showing cytotoxicity against leukaemia cells [40], [55]. These compounds 
have however had very limited development since their initial isolation and this is 
most likely due to the lack of ability to obtain them in significant quantities. Natural 
sources are difficult to access and yields from these are low whilst the bacterial strain 
responsible for production, Prochloron spp. can’t be cultured, as it requires its 
symbiont, the sea squirt Lissoclinum patella, for sustained growth [152]. Chemical 
synthesis of the patellamides is possible, but is a complex multi-step process with no 
fast route to diversity (Chapter 1, [59] , [60]). A recent study has been carried out 
showing that the patellamide pathway can be utilised in vivo using Escherichia coli cells 
to generate patellamides, and patellamide-derived cyclic peptides containing 
unnatural amino acids [103]. Despite the success in producing these, yields in the 
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range of µg L-1 culture continues to make generating enough material for further 
studies challenging. 
   
We aimed to explore the in vitro biosynthesis of cyclic peptides utilising isolated 
enzymes from the patellamide pathway (and related pathways) and to re-engineer the 
pathway where appropriate to improve reaction rates and overall yields.  
 
The work on the nine residue compound ‘IITACIMAC’ was carried out in collaboration 
with Rachael Graham (University of St. Andrews, B.Sc project student). 
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4.2 Material and Methods 
 
4.2.1 DNA Cloning 
 
To explore in vitro cyclic peptide production, a PatE precursor peptide (PatE2) was 
engineered by Dr Jesko Koehnke (University of St Andrews) consisting of a 37-residue 
N-terminal leader sequence and N- and C- terminal cleavage recognition sites flanking 
a single core peptide (ITACITFC) corresponding to the natural product Patellamide D. In 
addition, a C-terminal His6-tag was added to aid in the purification process (Figure 4.1 
A). The construct was cloned into the pBMS23CHis plasmid (gift from Dr Huanting Liu, 
St Andrews). 
 
Following initial experiments with PatA and discussion with colleagues, it was decided 
to introduce alternatives to the PatA recognition site for N-terminal cleavage. PatE2 
was subsequently mutated by Dr. Wael Houssen (University of Aberdeen) to introduce 
a lysine between the final residue of the PatApr cleavage site, ‘GLEAS’, and the first 
residue of the core peptide to allow for cleavage by trypsin (PatE2K, Figure 4.1 B). A 
further construct to introduce the TEV protease site ‘ENLYFQ’ immediately after the 
‘GLEAS’ motif of PatE2 was created using site directed mutagenesis protocols 
described in section 2.2.1 with primers shown in Table 4.1. (PatE2TEV, Figure 4.1 C). 
 
Figure 4.1: PatE Protein Sequences. Schematics of (A) PatE2, (B) PatE2K and (C) PatE2TEV precursor 
peptide sequences identifying leader sequences, cleavage sites, core peptide residues 
and the C-terminal His6-tag. 
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Finally, a range of PatEs based on the PatE2K sequence were created with variations in 
the core peptide sequence. These were all created by PCR using a standard 5’ primer 
with Nco1 restriction site, while varying the 3’ primer to introduce the new desired 
core peptide sequence and an Xho1 restriction site (Table 4.1). These new PatE inserts 
were separated on an agarose gel and extracted using the Qiagen Gel Extraction Kit. 
The purified DNA moleule was cleaved using restriction enzymes Nco1 and Xho1 and 
ligated into the pBMS23CHis plasmid (pre-cut with the same enzymes and then 
alkaline phosphatase treated). The ligated plasmid was used to transform E. coli DH5 
cells and the single colonies obtained were grown in 10 ml LB culture, mini-prepped 
(Qiagen MiniPrep Kit) and their sequences confirmed by sequencing (GATC Biotech). 
 
Full length PatD, full length TruD and PatApr (PatA residues 10-289) were synthesised 
into the pJexpress 411 plasmid using optimised codons for E. coli (DNA 2.0) [105]. Each 
plasmid contained an N-terminal His6-tag, and TruD and PatApr additionally contained 
a TEV protease recognition site between the His6-tag and the protein. PatGmac was 
cloned as described in section 3.2.1. 
 
 
4.2.2  PatE Expression and Purification 
 
PatE2 was expressed from the pBMS23CHIS vector in E. coli BL21 (DE3) cells grown on 
auto-induction medium [107] (see Appendix A.4 for media and buffer compositions) 
for 24 hours at 30 °C, driving the protein to inclusion bodies. Cells were harvested by 
centrifugation at 4,000 x g for 15 min at 20 °C, re-suspended in urea lysis buffer and 
lysed by sonication at 15 microns (SoniPrep 150, MSE). The lysate was cleared by 
centrifugation at 40,000 x g, 20 °C, 20 min followed by passage through a 0.45 µm 
filter. The cleared lysate was applied to a Ni-Sepharose 6 FF column (GE Healthcare) 
equilibrated with urea lysis buffer and protein was eluted with urea elution buffer. The 
protein was then supplemented with 10 mM dithiothreitol (DTT) to induce refolding 
and subjected to size-exclusion chromatography (Superdex 75, GE Healthcare) in gel 
4. In Vitro Biosynthesis of Patellamides   
 97 
filtration buffer. The protein was visualised by SDS-PAGE and its identity confirmed by 
MS. 
 
5’ PatE cttccatggacaaaaaaaacattcta  
 
5’ PatETEV gctggtttggaagcatctgaaaacctgtattttcagataactgcttgcat
cactttttgcgct 
3’ PatETEV ctgaaaatacaggttttcagatgcttccaaaccagcatcgccgagagc 
 
3' core pep     
   ‘VTVCVTVC’ 
cttctcgagttcaccatcataagcgcacacggtcacgcacacggtcactt
tagatgcttccaaaccagc 
3' core pep 
   ‘ITACITYC’ 
cttctcgagttcaccatcataagcgcaataagtgatgcaagcagttattt
tagatgcttccaaaccagc 
3' core pep 
   ‘IMACIMAC’ 
cttctcgagttcaccatcataagcgcacgccatgatgcacgccatgattt
tagatgcttccaaaccagc 
3' core pep 
   ‘IDACIDFC’ 
cttctcgagttcaccatcataagcgcaaaaatctatgcacgcatctattt
tagatgcttccaaaccagc 
3' core pep 
   ‘ITACITAC’ 
cttctcgagttcaccatcataagcgcacgcagtgatgcaagcagttattt
tagatgcttccaaaccagc 
3' core pep 
   ‘ATACITFC’ 
cttctcgagttcaccatcataagcgcaaaaagtgatgcaagcagtcgctt
tagatgcttccaaaccagc 
3' core pep 
   ‘ITACISFC’ 
cttctcgagttcaccatcataagcgcaaaagctgatgcaagcagttattt
tagatgcttccaaaccagc 
3' core pep 
   ‘ICACITFC’ 
cttctcgagttcaccatcataagcgcaaaaagtgatgcaagcgcatattt
tagatgcttccaaaccagc   
3' core pep 
   ‘IAACITFC’ 
cttctcgagttcaccatcataagcgcaaaaagtgatgcaagccgctattt
tagatgcttccaaaccagc   
3' core pep 
   ‘ITAAITFC’ 
cttctcgagttcaccatcataagcgcaaaaagtgatcgcagcagttattt
tagatgcttccaaaccagc   
3’ core pep 
   ‘IITACIMAC’  
cttctcgagttcaccatcataagcgcacgccatgatgcacgcggtaataa
ttttagatgcttccaaaccagc 
3' core pep 
   ‘ITVCISVC’ 
cttctcgagttcaccatcataagcgcacacgctaatgcacacggttattt
tagatgcttccaaaccagc 
3' core pep 
   ‘ICFPTIC’ 
cttctcgagttcaccatcataagcgcaaatggtcggaaagcaaattttag
atgcttccaaaccagc 
 
Table 4.1: PatE Primer Sequences. PCR primer sequences used to generate PatE variants. 
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Both PatE2K, PatE2TEV and all PatE2K core residue variants were expressed and 
purified using the same methods as PatE2. 
 
4.2.3  Enzyme Expression and Purification 
 
For in vitro processing, each enzyme was individually expressed and purified with the 
exception of Bovine Trypsin which was sourced from Sigma-Aldrich. PatGmac was 
expressed and purified as previously described (Section 3.2.2). PatD, TruD and PatApr 
were expressed from the pJexpress 411 vector. All three were expressed using BL21 
(DE3) E. coli grown on auto-induction medium using the Studier method [107] (see 
Appendix A.5 – A.7 for media and buffer compositions). The cultures were grown at 20 
°C, 250 rpm for 48 hours before harvesting by centrifugation.  
 
PatApr and TruD were both purified by re-suspending the cell pellets in lysis buffer 
plus DNAse (0.4 mg g-1 wet cell pellet). TruD was additionally supplemented with 
EDTA-free protease inhibitor tablets (Roche). The re-suspended cells were passed 
through a cell disruptor (Constant Systems) at 30 kpsi. The lysate was cleared by 
centrifugation (40,000 x g, 4 °C, 20 min) and then loaded onto a Ni-Sepharose 6 FF 
column (GE Healthcare) equilibrated in lysis buffer. The column was washed with lysis 
buffer and the protein eluted with elution buffer. The protein was then passed through 
a desalting column (Desalt 16/10, GE Healthcare) in desalting buffer. Tobacco Etch 
Virus (TEV) protease was added at a ratio of 1 mg TEV protease per 10 mg protein and 
incubated for 1 hour at 20 °C to remove the His6-tag. The sample was then loaded on 
to a second Ni-column, in desalt buffer. The protein was collected in the flow through, 
concentrated to 7.5 ml (Vivaspin concentrators) and subjected to size exclusion 
chromatography. PatApr was applied to a Superdex 75 gel filtration column (GE 
Healthcare), while TruD was applied to a Superdex 200 gel filtration column (GE 
Healthcare), both equilibrated in sizing buffer.  
PatD was purified by re-suspending the cell pellets in lysis buffer plus DNAse (0.4 mg g-
1 wet cell pellet) and EDTA-free protease inhibitor tablets (Roche). The re-suspended 
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cells were passed through a cell disruptor (Constant Systems) at 30 kpsi. The lysate 
was cleared by centrifugation (40,000 x g, 4 °C, 20 min) and then loaded onto a Ni-
Sepharose 6 FF column (GE Healthcare) equilibrated in lysis buffer. The column was 
washed with lysis buffer and the protein eluted with elution buffer. PatD was 
concentrated to 7.5 ml and applied to a Superdex 200 gel filtration column (GE 
Healthcare) equilibrated in gel filtration buffer. 
 
The purity of all proteins was confirmed by SDS-PAGE analysis and their identity 
confirmed by mass spectrometry (MS). 
 
 
4.2.4  Heterocyclisation 
 
Purified PatE2 and PatE2K precursor peptides were subjected to in vitro processing. 
The incubation of 100 µM PatE2/PatE2K with 5 µM PatD or TruD in 150 mM NaCl, 10 
mM HEPES pH 7.4, 5 mM ATP, 5 mM MgCl2 at 37 °C for two hours was carried out for 
heterocyclisation. Alternatively, to reduce heterocyclase enzyme usage, 100 µM 
PatE2/PatE2K was incubated with 1 µM PatD or 0.5 µM TruD in 150 mM NaCl, 10 mM 
HEPES pH 7.4, 5 mM ATP, 5 mM MgCl2 at 37 °C for 16 hours to drive heterocyclisation 
to completion. Heterocyclised peptides were purified from the PatD / TruD on an S75 
gel filtration column (GE Healthcare) and the heterocyclisation state of the peptide 
was confirmed by MS.  
 
 
4.2.5  N-terminal Core Peptide Cleavage 
 
Heterocyclised (by either TruD or PatD) PatE2 pro-peptide was incubated with 20 µM 
PatApr at 37 °C for 200 hours to drive N-terminal cleavage to completion. The cleaved 
peptide was separated from the leader sequence and PatApr by passage through a 
Superdex S30 column (GE Healthcare) pre-equilibrated in 150 mM NaCl, 20 mM Bicine 
pH 8.1. PatE2K (after reaction with PatD or TruD) was N-terminally cleaved by 
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incubation with 1:250 bovine trypsin (Sigma) at 37 °C for two hours and the cleaved 
peptide purified as for PatE2. 
 
 
4.2.6  C-terminal Core Peptide and Macrocyclisation 
 
100 µM heterocyclised and N-terminally cleaved PatE2/PatE2K was incubated with 20 
µM PatGmac for 72 hours at 37 °C in 20 mM Bicine pH 8.1, 500 mM NaCl, 5 % DMSO to 
drive the completion of macrocyclisation as determined by MALDI TOF MS. 
 
 
4.2.7  Cyclic Peptide Purification 
 
The final macrocycles derived from PatE2/PatE2K were purified by reverse-phase HPLC 
by passage over a Jupiter C4 column (Phenomenex) then subsequent passage of 
macrocycle peaks over an Eclipse C18 column (Agilent). The sample was applied to both 
columns and eluted with a 5 - 95 % MeOH/water gradient. Peak fractions were 
identified by MALDI TOF MS. 
 
 
4.2.8   Mass Fragmentation 
 
Mass fragmentation of both HPLC purified macrocycles was carried out by Dr. Matt 
Fuszard and Dr. Sally Shirran. The samples were applied to LC/MS/MS on an AB SCIEX 
Triple TOF 5600 system. Peaks were assigned based on the expected chemical 
structures.  
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4.2.9  NMR Spectroscopy 
 
1H Nuclear Magnetic Resonance (NMR) spectroscopy was carried out on the 
macrocycle resulting from PatE2K treatment with TruD, trypsin and PatGmac 
(cyclo[ITACThnITFCThn]) following HPLC purification. The sample was analysed on a 500 
MHz NMR spectrometer (Bruker) in 20 mM sodium potassium phosphate pH 6.8. 1H 
NMR spectroscopy was also carried out on cyclo[IMACThnIMACThn] with the sample 
analysed on a 500 MHz NMR spectrometer (Bruker) in 100 % deuterated methanol. 
NMR experiments were carried out and the data processed by Dr. Uli Schwarz-Linek 
(University of St Andrews). 
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4.3 Results 
 
 
4.3.1 DNA Cloning 
 
PatE2 and PatE2K constructs were supplied by collaborators. PatE2TEV and all core 
peptide variants were cloned by PCR using the PatE2K DNA as a template. The newly 
synthesised DNA inserts were analysed by argarose gel electrophoresis to confirm they 
were of correct size (Figure 4.2) and then DNA sequenced (GATC Biotech) to ensure 
correct sequence.  
 
 
 
Figure 4.2: PatE DNA Cloning. Representative examples of PatE inserts (200 bp) run on agarose gel 
electrophoresis. Lane 1) 100bp plus DNA markers (Life Technologies), Lane 2) PatE2K-
‘VTVCVTVC’ and Lane 3) PatE2K-‘ITACITYC’. 
 
4.3.2  PatE Expression and Purification 
 
PatE2 and PatE2K were overexpressed with a C-terminal His6-tag in BL21 (DE3) E. coli 
cells using the Studier auto-induction method [107]. The peptide was solubilised from 
inclusion bodies in urea lysis buffer, isolated by Ni-NTA chromatograpy and refolded 
using DTT. The peptide elutes off a gel filtration column as a single peak at 
approximately 75 ml (Figure 4.3). The final protein yield was between 200 and 250 mg 
L -1 culture. 
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Figure 4.3: Purification of PatE2 Precursor Peptide. A) SDS-PAGE analysis of PatE2 showing > 98% 
purity. B) Gel filtration UV chromatograph of PatE2 showing protein elutes as a single 
peak. Due to the unfolded nature of PatE2 it runs aberrantly on SDS-PAGE ~5 KDa and 
elutes at 75 ml on gel filtration. 
 
 
 
4.3.3  Enzyme Expression and Purification 
 
PatGmac, PatApr and TruD were all overexpressed with an N-terminal His6-tag and TEV 
protease recognition site in BL21 (DE3) E. coli using the Studier auto-induction method. 
The proteins were isolated using the His6-tag on nickel resin and the tag removed by 
addition of TEV protease with cleavage efficiency close to 100 %. PatGmac was further 
purified on an ion-exchange mono-Q column with the protein eluting at 350 mM of a 
NaCl gradient. PatGmac and PatApr were finally subjected to size exclusion on an S75 
gel filtration column (GE Healthcare) while TruD was subjected to size exclusion on an 
S200 gel filtration column (GE Healthcare). 
 
PatD was overexpressed with an N-terminal His6-tag in BL21 (DE3) E. coli cells using the 
Studier auto-induction method. The protein was isolated using the His6-tag on nickel 
resin and then subjected to size exclusion on an S200 gel filtration column (GE 
Healthcare). 
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PatApr, PatGmac and TruD all eluted from gel filtration as monomers, with PatGmac 
and TruD showing slight dimer contaminants which have no detrimental effects on 
subsequent biochemical reactions. PatD eluted from gel filtration as a dimer (Figure 
4.4 A). All proteins were analysed by SDS-PAGE (Figure 4.4 B) and their identities were 
confirmed by MS. Final protein yields are summarised in Table 4.2 
 
Protein Yield (mg protein L-1 cell culture) 
PatE2 / PatE2K 200-250 
PatApr 200-250 
PatGmac 200-250 
TruD 40-60 
PatD 20-30 
 
Table 4.2: Protein Purification Yields. Final purified protein yields per litre of cell culture for all proteins 
involved in cyclic peptide in vitro biosynthesis. 
 
 
 
 
Figure 4.4: Enzyme Purification. (A) Gel filtration chromatographs of each enzyme showing primarily 
monomer elutes for TruD, PatApr and PatGmac and dimer elute for PatD  (B) SDS-PAGE 
analysis of the final purified protein for enzymes TruD, PatD, PatApr and PatGmac showing 
> 98 % purity for all but PatD which shows > 95 % purity. 
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4.3.4  Heterocyclisation 
 
 
Incubation of PatE2/PatE2K with TruD results in a loss of 36 Da by MS corresponding to 
the expected two water losses resulting from cysteine heterocyclisation (two 
heterocycles). The incubation of PatE2/PatE2K with PatD results in the loss of 72 Da 
corresponding to both threonine and cysteine heterocyclisation (total of four 
heterocycles) (Figure 4.5). 
 
 
 
Figure 4.5: MS Analysis of Heterocyclisation. MALDI TOF MS spectra of peptide products from the 
reactions of A) PatE2 + TruD - [M+H]
+ 
of 6826, B) PatE2 + PatD - [M+H]
+ 
of 6790 C) 
PatE2K + TruD - [M+H]
+ 
of 6954 and D) PatE2K + PatD - [M+H]
+ 
of 6919 (Note: E2K + PatD 
shows a secondary [M+H]
+ 
peak of 6937 corresponding to the formation of only 3 
heterocycles). 
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The heterocyclised peptide was purified from the heterocyclases by gel filtration 
(Figure 4.6). The heterocyclases can be recycled at a yield of up to 80 % recovery and 
remain active. The enzyme still achieves the same level of heterocyclisation as when 
freshly purified and has no adverse effect on the reaction rates. 
 
 
 
Figure 4.6: Purification of PatE2 from TruD. S75 gel filtration UV chromatogram of the reaction 
between PatE2 and TruD showing three distinct elution peaks corresponding to TruD, 
heterocyclised PatE2 and ATP/AMP. 
 
 
4.3.5  N-terminal Core Peptide Cleavage 
 
 
PatApr mediated cleavage of heterocyclised PatE2 is a slow process and takes at least 
200 hours at 37 °C to achieve completion. The protease cleaves between the ‘GLEAS’ 
recognition site and the first residue of the core peptide. The cleaved peptide was 
purified from the leader sequence and PatApr by separation on a Superdex S30 column 
(GE Healthcare). MS analysis was used to confirm N-terminal cleavage of both TruD 
and PatD treated peptides (Figure 4.7). 
 
The slow processing by PatApr led us to re-engineer PatE2 to contain a lysine residue 
after the ‘GLEAS’ PatApr recognition sequence (PatE2K). PatE2K was treated with both 
heterocyclases and the additional residue was found to have no detrimental effect on 
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heterocyclisation. Incubation of the peptide with 1:250 trypsin resulted in complete N-
terminal cleavage after just two hours at 37 °C. 
 
Additionally, as an alternative to trypsin which would still allow for the use of lysine 
and arginine residues in the core peptide, we introduced a TEV protease site ‘ENLYFQ’ 
immediately after the GLEAS sequence of PatE2 (PatE2TEV). Tests of the peptide with 
heterocyclase TruD revealed no detrimental effects on heterocyclisation with two 
heterocycles formed. The N-terminal leader was removed by addition of 1 mg TEV 
protease per 10 mg PatE and purified as for PatE2/PatE2K. 
 
 
 
Figure 4.7: MS Analysis of N-terminal Cleavage. MALDI TOF MS spectra of the purified PatE2K peptide 
following leader sequence removal with trypsin after initial treatment with either A) 
TruD - [M+H]
+ 
of 2435 and [M+Na]
+
 of 2457 or B) PatD - [M+H]
+ 
of 2399. 
 
 
4.3.6  C-terminal Core Peptide Cleavage and Macrocyclisation 
 
Heterocyclised (with either TruD or PatD) and N-terminally cleaved PatE2/E2K were 
macrocyclised by incubation with PatGmac at 37 °C. Initial reactions were carried out 
in 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP and found to be slow (> 200 hours 
for completion). Switching the reaction to published buffer conditions of 500 mM 
NaCl, 20 mM bicine pH 8.1 and 5 % DMSO resulted in complete macrocyclisation in 
under 48 hours [141]. The formation of the macrocycles cyclo[ITACThnITFCThn] and 
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cyclo[ITOxnACThnITOxnFCThn], derived from TruD and PatD treatment respectively, were 
confirmed by MALDI TOF MS (Figure 4.8).  
 
 
 
Figure 4.8: MS Analysis of Macrocyclisation. MALDI TOF MS spectrum and associated chemical 
structures of the macrocyclised peptides A) cyclo[ITAC
Thn
ITFC
Thn
] ([M+H]
+
 = 817 Da) and 
B) cyclo[IT
Oxn
AC
Thn
IT
Oxn
FC
Thn
] ([M+H]
+
 = 781). 
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4.3.7  Cyclic Peptide Purification 
 
 
The macrocycles were purified by HPLC by passage over a C4 column then subsequent 
passage of macrocycle peaks over a C18 column. The sample eluted off both columns at 
between 70 and 90 % methanol (Figure 4.9). Peak fractions were identified by MALDI-
MS. 
 
 
 
 
Figure 4.9: HPLC Purification of Macrocycle. HPLC chromatogram of the macrocycle 
cyclo[ITAC
Thn
ITFC
Thn
] when run over (A) an initial C4 column followed by (B) a subsequent 
C18 column.   
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4.3.8  Mass Fragmentation 
 
 
Mass fragmentation of both the TruD and PatD treated PatE2K derived macrocycles 
(cyclo[ITACThnITFCThn] and cyclo[ITOxnACThnITOxnFCThn]  respectively) was carried out by 
Dr Matt Fuszard (Figure 4.10 and 4.11 respectively). The fragments were assigned 
based on the hypothesised structures and were confirmed to correspond to the 
expected macrocycles.  
 
 
 
Figure 4.10: Mass Fragmentation of cyclo[ITAC
Thn
ITFC
Thn
]. LC/MS/MS fragmentation of 
cyclo[ITAC
Thn
ITFC
Thn
], a macrocycle derived from TruD-treated PatE2K, confirming the 
presence of two heterocycles, one in Pos1 and the other in Pos5. 
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Figure 4.11: Mass Fragmentation of cyclo[IT
Oxn
AC
Thn
IT
Oxn
FC
Thn
]. LC/MS/MS fragmentation of 
cyclo[IT
Oxn
AC
Thn
IT
Oxn
FC
Thn
], a macrocycle derived from PatD-treated PatE2K, 
confirming the presence of four heterocycles in positions 1, 3, 5 and 7. 
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4.3.9  NMR Spectroscopy 
 
 
Preliminary 1H NMR spectroscopic analysis was carried out on the TruD-treated PatE2K 
macrocycle cyclo[ITACThnITFCThn] by Dr. Uli Schwarz-Linek. The sample was run in 20 
mM sodium phosphate pH 6.8. Analysis of the spectra and assigning of peaks appears 
to confirm the structure of the expected macrocycle (Figure 4.12). Water peak 
suppression was applied to the spectra (4.5-5ppm). 
 
 
 
 
Figure 4.12: 
1
H NMR Spectrum of cyclo[ITAC
Thn
ITFC
Thn
]. 
1
H NMR spectrum of cyclo[ITAC
Thn
ITFC
Thn
], a 
macrocycle derived from TruD-treated PatE2K. Peaks have been assigned which 
correspond to the hydrogens as displayed on chemical structure. Small molecule peaks 
have been discarded by double strikethrough. Water suppression has been implemented 
between 4.5 and 5.0 ppm.  
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4.3.10 Further Compounds 
 
In order to further explore the diversity and the flexibility of the in vitro process, 
several variants of PatE2K were cloned, expressed, purified and taken through the 
process. These samples varied only in the core peptide sequence which, along with 
their subsequent macrocyclic compounds, are summarised in Table 4.3.  
 
The PatE2K variants were expressed and purified in the same way as PatE2K. Each was 
taken through the in vitro process with either PatD or TruD used for heterocyclisation, 
the N-terminal cleavage carried out by trypsin and finally macrocyclisation with 
PatGmac. The final compounds were HPLC-purified.  
 
MALDI-TOF-MS was used to confirm the correct mass of each compound and mass 
fragmentation was carried out on a representative selection of the compounds to 
confirm the in vitro pathway was accurate. All MS and fragmentation data can be 
found in Appendix D. 
 
Core Peptide 
Sequence 
Heterocyclisation 
Treatment 
Expected Chemical Structure Appendix Data 
VTVCVTVC + PatD 
 
cyclo[VTOxnVCThnVTOxnVCThn] 
MS, 
MSMS 
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VTVCVTVC  + TruD 
 
cyclo[VTVCThnVTVCThn] 
MS, 
MSMS 
ITACITYC  + PatD 
 
cyclo[ITOxnACThnITOxnYCThn] 
MS, 
MSMS 
ITACITYC  + TruD 
 
cyclo[ITACThnITYCThn] 
MSMS 
4. In Vitro Biosynthesis of Patellamides   
 115 
IMACIMAC + TruD 
 
cyclo[IMACThnIMACThn] 
MS, 
MSMS 
IDACIDFC + TruD 
 
cyclo[IDACThnIDFCThn] 
MSMS 
ITACITAC + TruD 
 
cyclo[ITACThnITACThn] 
MS, 
MSMS 
N
H
O
N
S
HN
O
NH
NH
O
S
N HN
O
H
N
O
O
S
S
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ATACITFC + TruD 
 
cyclo[ATACThnITFCThn] 
MS, 
MSMS 
ITACISFC + TruD 
 
cyclo[ITACThnISFCThn] 
MS, 
MSMS 
ICACITFC + TruD (3het) 
 
cyclo[ICThnACThnITFCThn] 
MS 
N
H
O
N
S
HN
O
NH
NH
O
S
N HN
OH
N
O
O
Ph
OH
OH
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IAACITFC + TruD 
 
cyclo[IAACThnITFCThn] 
MS 
ITAAITFC + TruD 
 
cyclo[ITAAITFCThn] 
MS 
IITACIMAC + TruD 
 
cyclo[IITACThnIMACThn] 
MS, 
MSMS 
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ITVCISVC + PatD 
 
cyclo[ITOxnVCThnISOxnVCThn] 
MS 
ICFPTIC + PatD 
 
cyclo[ICThnFPTOxnICThn] 
MS 
 
 
Table 4.3: In vitro Biosynthesis Derived Cyclic Peptides. Core peptide sequence, heterocyclisation 
treatment and final chemical structure of fifteen cyclic peptides derived from the 
reconstituted patellamide pathway. Additional data listed can be found in Appendix D.  
 
  
S
N H
N
O
SN
HN
O
O
N
NO
NH
O
Ph
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1H Nuclear Magnetic Resonance (NMR) spectroscopic analysis was carried out on the 
cyclo[IMACThnIMACThn] macrocycle in 100 % deuterated methanol by Dr. Uli Schwarz-
Linek (Figure 4.13). Proton peaks were assigned and are annotated in the chemical 
structure. The use of deuterated methanol produces a sharper NMR spectrum than 
that of the PatE2K macrocyclic product run in 20 mM sodium phosphate pH 6.0 (Figure 
4.12). 
 
 
 
Figure 4.13: 
1
H NMR Spectrum of cyclo[IMAC
Thn
IMAC
Thn
]. 
1
H NMR spectrum of the cyclic peptide 
cyclo[IMAC
Thn
IMAC
Thn
] derived from TruD treated PatE(IMACIMAC). Peaks have been 
assigned which correspond to the hydrogens as displayed on chemical structure. Small 
molecule peaks have been discarded by double strikethrough.  
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4.4 Discussion 
 
Using isolated enzymes from the patellamide and related pathways, cyclic peptides 
have been produced by an in vitro biosynthesis on a milligram scale. 
 
The heterocyclisation step is a fast process and can be completed in less than two 
hours with the ability to recycle the heterocyclase enzyme for future reactions. 
Recycling of the heterocyclases is an important feature as they show the lowest 
expression levels (< 40 mg L-1 culture) but also that enzyme recycling is a cost efficient 
method in any bio-industrial process. 
 
The N-terminal cleavage of the precursor peptide by PatApr is particularly slow with a 
minimum of 200 hour incubation required for full cleavage. This is most likely due to 
the requirement of the leader to remain bound in order for the heterocyclase to work. 
In vivo both of these enzymes will be present at the same time, but in vitro this can be 
controlled by the timing of enzyme addition. In order to overcome the slow 
processing, the PatE2 precursor peptide was re-engineered to introduce either a lysine 
residue or the TEV protease recognition signal ‘ENLYFQ’ between the PatA recognition 
sequence ‘GLEAS’ and the core peptide. Treatment of PatE2K and PatE2TEV with both 
TruD and PatD confirmed that the additional residue(s) had no effect on heterocyclase 
activity. N-terminal cleavage of the core peptide can now be efficiently carried out 
using trypsin or TEV protease in approximately two hours. This represents a 100 fold 
increase in reaction rates. 
 
The final macrocyclisation by PatGmac under our initial conditions was slow (> 200 
hours), however optimisation of the conditions with an increase in both salt 
concentration and buffer pH plus the addition of 5 % DMSO increased the reaction rate 
allowing completion in under 48 hours.  
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Overall, the steps from precursor peptide to macrocycle have been reduced from 
approximately 400 hours down to 50 hours. It is possible that with further optimisation 
we can reduce this further.  
  
The diversity of the pathway has been demonstrated by processing in vitro a range of 
PatE precursor peptides containing broad diversity in the core peptide sequence and 
thus generating multiple cyclic peptides.   
 
Using this process, 1 to 5 mg macrocycle from 100 mg precursor peptide has been 
achieved, which equates to around 5 to 10 mg macrocycle L-1 total cell culture. These 
yields are based on dried solid following HPLC purification which we appreciate has 
limitations (salts, etc). A more accurate quantification method is currently being 
investigated by Greg Mann, University of St Andrews and initial experiments suggest 
our dried solid contains 40 - 60 % macrocycle. This confirms that our process is still on 
the mg scale. In contrast, in vivo studies by Tianero et al. were only able to generate 5 
to 174 µg macrocycle L-1 cell culture [103]. This therefore indicates that the in vitro 
process is able to generate larger quantities of macrocycle for use in further studies, 
e.g. mode of action studies and toxicology screening.  
 
The benefits of this in vitro biosynthesis over in vivo include that all enzymes can be 
produced in large quantities and stored at -80 °C with no detrimental effects, allowing 
multiple reactions to be carried out per enzyme batch, as well as enzyme recycling (as 
demonstrated for the heterocyclases). Also, the ability to take one precursor peptide 
and process it in different ways by enzyme switching (TruD/PatD, oxidised/unoxidised 
(see Chapter 6)) could lead to multiple final products from a solitary starting material. 
Finally, cyanobactins are known to be toxic to certain types of cells and therefore in 
vivo there is the possibility that they will cause host cell death; the in vitro biosynthesis 
eliminates this risk as only the non-toxic precursor protein is produced in vivo.  
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On the final macrocyclic compounds the oxidation of thiazolines to thiazoles, which 
appear in the majority of patellamide natural products, was not carried out. It is widely 
believed that this oxidation is catalysed by the N-terminal domain of PatG which 
bioinformatic analysis has identified as an oxidase domain and this is studied further in 
Chapter 6. It has however been discovered that in a macrocycle sample derived from 
PatE2K (PatD treated) stored at room temperature for four weeks and re-analysed by 
MALDI-MS, that there is the presence of a minor peak of 777 Da equivalent to a loss of 
4 Da. This may correspond to the oxidation of the two thiazolines and may suggest 
that this process occurs slowly (Figure 4.14).  
 
 
 
Figure 4.14: Potential Oxidation of Thiazolines. MALDI TOF MS spectrum of cyclo[IT
Oxn
AC
Thn
IT
Oxn
AC
Thn
] 
stored at room temperature for 4 weeks showing two peaks; 781 corresponding to the 
macrocycle [M+H]
+
 and 777 which may represent an oxidised derivative [M+H]
+
. 
 
 
Finally, natural patellamides contain two D-stereoisomers, however at present we have 
been unable to ascertain the epimeric state of our macrocycles. The process to which 
epimerisation occurs in natural patellamides is not yet known and may be either an 
enzymatic reaction or may be spontaneous.  
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4.5 Conclusions and Future Work 
 
A library of cyclic peptides containing thiazolines and oxazolines have been produced 
in vitro on the mg scale utilising isolated enzymes from the Patellamide (and related) 
biosynthetic pathway(s). These compounds have been confirmed by mass 
spectrometry and NMR and their production represents a ten to one hundred fold 
yield increase over previous in vivo studies of the same pathway.  The modification of 
our PatE to accommodate cleavage by the more efficient trypsin protease has reduced 
processing times by almost 200 hours over the natural protease PatApr. This 
represents the first stage in our pathway engineering to improve both the speed and 
yield of cyclic peptide production and we will explore further improvements.  
 
At the time of this work a cyanobactin oxidase had not yet been isolated and 
confirmed active for use in the pathway. However progress has since being made on 
this and is described in detail in Chapter 6. Once established fully, the oxidation step 
can be implemented into the in vitro biosynthesis pathway. 
 
Prenylation has been determined to not occur in the patellamide biosynthetic pathway 
(Chapter 2), yet it should be possible to introduce a level of diversity through the use 
of related prenyl transferases. The prenylation of tyrosine residues by LynF has already 
been demonstrated (Section 2.3.9) and as such we aim to implement a prenylation 
step into our in vitro biosynthesis. Obtaining other prenyl transferases which act on 
different amino acids could also increase diversity. 
 
Epimerisation has still not been confirmed to be either enzymatic or spontaneous but 
is likely a key component of the patellamide which results in inhibition of target 
proteins. Studies on epimerisation are being carried out by Greg Mann (University of St 
Andrews) and if reaction conditions can be identified it could be included in our 
compound production. 
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Finally, once a significant library of cyclic peptides has been established, with mg 
quantities of each, biological assays allowing the generation of structure-activity 
relationships (SAR) could be undertaken. Logically, the first target would be p-
glycoprotein (p-GP) as previous studies have identified that the natural product 
Patellamide D inhibits p-GP [55].  
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5. Selenazoline Incorporation into Macrocyclic Peptides 
 
5.1 Introduction 
 
Selenazolines, an alternative to thiazolines where the sulfur is replaced by selenium, 
pose an intriguing motif for medicinal chemistry, where they can act as thiazoline 
substitutes whilst retaining similar activities. Kim et al. [153] have shown that the 
introduction of selenazolines in place of thiazolines in O-GlcNAcase inhibitors does not 
significantly alter activity in human cells. Remarkably, this is despite a 70 fold decrease 
in activity in protein assays, where the thiazoline form is more potent. This is believed 
to be a result of selenazoline containing compounds been internalised by cells more 
efficiently than their thiazoline containing counterparts [153].  
 
Compounds containing selenazolines and their oxidised derivatives 1,3-selenazoles are 
chemically difficult to synthesise and also require the use of toxic precursors such as 
selenocyanide [154] or seleno-urea [155]. 
 
 
Figure 5.1: Selenium Containing Heterocycles. Chemical structures of A) thiazoline B) selenazoline and 
C) selenazole. 
 
Tao et al. (2011) have chemically synthesised patellamide-like macrocycles containing 
selenazoles [156] which target the p-glycoprotein as has been demonstrated for 
Patellamide D [55] (Figure 5.2). The process of making these compounds does however 
lead to significant risks in addition to the toxic precursors, with H2Se being produced, 
which can decompose to H2 gas
 [156]. The ability to produce these macrocycles using a 
biological process with significantly reduced risks would be of high interest.  
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Figure 5.2: Chemical Structures of Selenazole Macrocycles. Structures of macrocyclic compounds 
containing selenazoles chemically synthesised by Tao et al. A) QZ60Se-SSSS B) QZ59Se-SSS [156]. 
 
Cyanobactin heterocyclases PatD and TruD process cysteine residues into thiazolines 
and it is possible that they may accept selenocysteine as a substrate to generate 
selenazolines. If successful, the resultant peptides could be used to make macrocycles 
using additional cyanobactin biosynthetic enzymes. 
 
Salgado et al. (2011) [157] have highlighted a method of incorporating the 
selenocysteine amino acid into proteins expressed in E. coli cells by growing the cells 
on medium containing the selenocysteine precursor seleno-L-cystine.  
 
We proposed to utilise the Salgado method to generate a PatE precursor peptide 
containing selenocysteine in the core peptide sequence. We would then use this SeCys 
PatE to assess the substrate tolerance of the heterocyclase enzyme TruD, i.e. can it 
heterocyclise SeCys to form selenazolines, and if successful, subject the SeCys PatE to 
the full in vitro process described in Chapter 4 to generate selenazoline containing 
cyclic peptides.   
 
The work in this chapter was carried out in collaboration with Falk Morawitz 
(University of St. Andrews, M. Chem project student) 
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5.2 Materials and Methods 
 
5.2.1 Expression and Purification 
 
Selenocysteine-labelled PatE2K was expressed in BL21 (DE3) E. coli cells, cultures of 
which were grown in a minimal medium supplemented with glucose-free nutrient mix 
(Molecular Dimensions) and 5 % glycerol (see Appendix A.8 for media and buffer 
compositions). The medium was inoculated with overnight culture grown in Luria-
Bertani (LB) medium which was subsequently washed three times with minimal 
medium. The cultures were grown to an optical density (OD) at 600 nm wavelength of 
0.6 then an amino acid mix was added. Fifteen minutes after amino acid mix addition, 
0.1 g L-1 seleno-L-cystine and 1 mM isopropylthio-β-D-galactoside (IPTG) were added. 
The cultures were then grown at 37 °C overnight driving the protein to inclusion bodies 
before harvesting by centrifugation. SeCys PatE2K was purified using the same 
protocols as outlined for native PatE2K in section 4.2.1. Enzymes used in the reactions 
were purified as stated in section 4.2.2 
 
5.2.2 Heterocyclisation 
 
100 µM PatE2K-SeCys was incubated with 0.5 µM TruD in 150 mM NaCl, 10 mM HEPES 
pH 7.4, 5 mM ATP, 5 mM MgCl2 at 37 °C for 16 hours to drive heterocyclisation to 
completion. The heterocyclised PatE2K-SeCys was purified from TruD on an S75 gel 
filtration column (GE Healthcare). The heterocyclisation state of the peptide was 
analysed by MS.  
 
5.2.3 N-terminal Cleavage 
  
PatE2K-SeCys, post treatment with TruD, was N-terminally cleaved by incubation with 
1:500 mass to mass ratio of PatE to bovine trypsin (Sigma) at 37 °C for four hours. The 
cleaved peptide was separated from the leader sequence and trypsin by passage over 
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a Superdex S30 column (GE Healthcare) pre-equilibrated in 150 mM NaCl, 20 mM 
Bicine pH 8.1 
 
5.2.4 Macrocyclisation, Purification and Characterisation 
 
100 µM heterocyclised and N-terminally cleaved PatE2K-SeCys was incubated with 20 
µM PatGmac for 48 hours at 37 °C in 20 mM bicine pH 8.1, 500 mM NaCl, 5% DMSO to 
drive the completion of macrocyclisation. The final SeCys macrocycle was purified from 
PatGmac by reverse-phase HPLC using the same methods as for native peptides 
(Section 4.2.6). The SeCys macrocycle was analysed by mass fragmentation as for the 
native peptides (Section 4.2.7). 
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5.3 Results 
 
5.3.1 Expression and Purification 
 
PatE2K-SeCys precursor peptide was overexpressed with a C-terminal His6-tag in BL21 
(DE3) E. coli using a minimal medium containing seleno-L-cystine. An indicator of 
selenium incorporation was the distinct presence of a red colour in the culture. The 
peptide was solubilised from inclusion bodies in urea buffer, isolated by His6-tag and 
refolded using DTT. The peptide elutes off gel filtration as a single peak. The final 
protein yield was 22 mg L-1 culture (Figure 5.3). Mass spectrometry analysis of the 
purified protein confirmed its identity and indicated that the major species contains a 
single selenium atom while minor species contain no or two seleniums. 
 
 
 
Figure 5.3: Purification of PatE2K-SeCys. (A) SDS-PAGE analysis of final PatE2K-SeCys purified sample 
showing >98% purity. (B) Gel filtration chromatograph for PatE2K-SeCys (Note as with 
PatE2K, due to the unfolded nature of the peptide, the protein travels further on SDS-
PAGE and elutes earlier on gel filtration).  
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5.3.2 Heterocyclisation 
 
Incubation of PatE2K-SeCys with TruD results in a loss of 36 Da by mass spec (Figure 
5.4). This corresponds to the loss of two water molecules as a consequence of two 
heterocycles forming. As the majority of the starting substrate contains one 
selenocysteine, it can be confirmed that with the formation of two heterocycles, one 
will be a thiazoline while the other will be a selenazoline.  
 
 
Fig 5.4: Heterocyclisation of PatE2K-SeCys. MALDI-TOF-MS analysis of the peptide product from 
reaction of PatE2K-SeCys with TruD showing a primary mass of 6997 [M+H]
+
 corresponding 
to two water losses for the majority one selenium species. The minor peaks correspond to 
two water losses for both no (6953 [M+H]
+
) and two (7048 [M+H]
+
) selenium species.  
 
 
5.3.3 N-terminal Cleavage 
 
Initially, trials of SeCys derived PatE2 (with no Lys) were hampered by the fact that the 
slow rate for PatApr to N-terminally cleave (200 hours for native PatE2) resulted in 
precipitation of the peptide. PatE2K-SeCys however could be cleaved efficiently in just 
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over four hours with only a small amount (< 5 %) of precipitation. The cleaved peptide 
was purified and confirmed by MS (Figure 5.5).  
 
 
 
Figure 5.5: N-terminal Cleavage of PatE2K-SeCys. MALDI-MS analysis of the peptide product from 
reaction of TruD treated PatE2K-SeCys with trypsin showing a primary mass of 2483 
[M+H]
+
 corresponding to N-terminally cleaved peptide containing one selenium. The 
minor peaks correspond to cleaved peptide containing no ([M+H]
+
 of 2435) and two 
([M+H]
+
 of 2531) seleniums.  
 
 
5.3.4 Macrocyclisation 
 
The TruD and trypsin treated PatE2K-SeCys sample was finally macrocyclised by 
incubation with PatGmac. MS analysis confirms the removal of 18 Da corresponding to 
the water loss which occurs upon macrocyclisation (Figure 5.6). The majority of the 
sample contains a single selenium atom and it is likely that two different macrocycles 
have formed, with Se at either position 1 or 5 (Figure 5.7). There are also low levels of 
macrocycles containing 0 and 2 selenium atoms. 
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Figure 5.6: Macrocyclisation of PatE2K-SeCys. MALDI-MS analysis of PatE2K-SeCys following treatment 
with TruD, Trypsin and PatGmac. The primary peak represents a macrocycle containing 
a single selenium ([M+H]
+
 of 866 and [M+Na]
+ 
of 888). Minor peaks also exist for no 
selenium ([M+H]
+ 
of
 
818, [M+Na]
+
 of 840) and two selenium ([M+H]
+
 of 914, [M+Na]
+
 
of 936) containing macrocycles 
 
 
 
Figure 5.7: Chemical Structures of Selenazoline Containing Cyclic Peptides. Structures hypothesised 
based on MS data for the PatE2K modified core peptide when grown in SeCys media. 
Macrocycles (A) cyclo[ITAC
Thn
ITF(SeCys)
Sen
] (B cyclo[ITA(SeCys)
Sen
ITFC
Thn
]) and (C) 
cyclo[ITA(SeCys)
Sen
 ITF(SeCys)
Sen
]. 
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5.3.5  Cyclic Peptide Purification 
 
Selenazoline containing macrocycles were purified by reverse-phase HPLC in 100 % 
methanol (Figure 5.8). Macrocycles containing no, one and two seleniums eluted off 
the C18 column as separate peaks and their identity confirmed by MS.  
 
 
Figure 5.8: SeCys Macrocycle Purification. Reverse-phase HPLC chromatogram of the purification of 
SeCys macrocycles on a C18 column. 
 
 
 5.3.6  Mass Fragmentation 
 
LC/MS/MS spectra were recorded for both one and two selenium containing 
macrocycles by Dr. Matt Fuszard (University of St Andrews). The single selenium 
containing macrocycles fragment in a manner which confirms the presence of two 
species; one containing a selenazoline in the P1 position with a thiazoline in P5, 
cyclo[ITACThnITF(SeCys)Sen], while the second species has the selenazoline and 
thiazoline switched around, cyclo[ITA(SeCys)SenITFCThn] (Figure 5.9). The macrocycles 
containing two selenium atoms fragments as would be expected for two selenazolines 
per macrocycle, cyclo[ITA(SeCys)SenITF(SeCys)Sen] (Figure 5.10). 
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Figure 5.9: Mass Fragmentation of Single Selenazoline Containing Macrocycle. LC/MS/MS spectrum of 
mixed species of single selenazoline containing macrocycles showing fragments 
which confirm the identity of two species; Form A:  cyclo[ITAC
Thn
ITF(SeCys)
Sen
] and 
Form B: cyclo[ITA(SeCys)
Sen
ITFC
Thn
]. 
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Figure 5.10: Mass Fragmentation of cyclo[ITA(SeCys)
Sen
ITF(SeCys)
Sen
]. LC/MS/MS spectrum of mixed 
species of single selenazoline containing macrocycles showing fragments confirming 
the presence of cyclo[ITA(SeCys)
Sen
ITF(SeCys)
Sen
]. 
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5.4 Discussion 
 
 
Incorporation of selenium into the PatE2K precursor peptide has been achieved by 
expressing it in E. coli BL21 (DE3) cells grown on a minimal medium supplemented with 
selenocysteine. Mass spectrometry analysis shows the incorporation of primarily a 
single selenium per peptide, with small levels of peptide containing no incorporation 
or the incorporation of two seleniums. The single selenium species was presumed to 
result in two different precursor peptides forming, one with core peptide sequence 
ITACITF(SeCys) and the other ITA(SeCys)ITFC. In future experiments it will be possible 
to re-engineer the core peptide region of the PatE precursor peptide to include only a 
single cysteine residue which we would expect to result in a greater selenium 
incorporation. The PatE2K-SeCys was taken through the in vitro process optimised for 
native peptides in Section 4. The loss of two water molecules during treatment with 
TruD confirms selenazoline formation. The heterocyclised peptides were then cleaved 
and macrocyclised to yield selenazoline containing cyclic peptides. 
 
Reverse-phase HPLC was used to separate the 0, 1 and 2 selenium containing 
macrocycles and LC/MS/MS analysis was carried out to confirm their structures. The 
single selenium containing macrocycle fragmentation pattern clearly showed the 
presence of two species corresponding to the expected sequences 
cyclo[ITACThnITF(SeCys)Sen] and cyclo[ITA(SeCys)SenITFCThn]. LC/MS/MS of the two 
selenium containing macrocycles confirmed the presence of two selenazolines; 
cyclo[ITA(SeCys)SenITF(SeCys)Sen]. 
 
This study represents an enzymatic route to selenazoline containing natural products 
and allows scope for a library of diverse selenazoline containing macrocycles to be 
produced. To date, no natural products containing selenazoline or selenazoles have 
been isolated directly from living organisms and the only known compounds have 
been created by chemical synthesis. 
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5.5 Conclusions and Future Work 
 
We have shown that we can introduce unnatural amino acids into a macrocycle 
through the direct incorporation of seleno-cysteine into the precursor peptide during 
expression. LC/MS/MS analysis confirms the presence of selenium and strongly 
support the macrocyclic structure. Seleno-cysteine is considerably less toxic than other 
selenium containing molecules and so offers a safer and greener method of 
selenazoline production.   
 
Future work will be to oxidise selenazoline containing macrocycles to contain 
selenazoles and also further explore in vitro synthesis to incorporate other unnatural 
entities into cyclic peptides. 
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6. Structural and Biochemical Studies on Cyanobactin 
Oxidases 
 
6.1 Introduction 
 
The oxidation of heterocyclised residues is an important step in the majority of 
cyanobactin pathways with thiazolines and in some pathways also oxazolines being 
oxidised to form thiazoles and oxazoles respectively (Figure 6.1) [22].  
 
 
 
Figure 6.1: Cyanobactin Oxidation: Chemical structures of a range of cyanobactins with oxidised 
heterocycles. The oxidation of thiazoline rings forming a thiazole is highlighted in cyan 
whilst the oxidation of an oxazoline ring forming an oxazole is highlighted in magenta. A) 
Tenuecyclamide C
 
[36], B) Patellamide D
 
[42] and C) Ulithiacyclamide A
 
[39]. 
 
In the patellamide biosynthetic pathway only thiazolines are oxidised to form thiazoles 
while the oxazolines are left in their reduced state [40]. To date it has not been 
confirmed how the oxidation process is carried out, although bioinformatic analysis of 
the patellamide gene cluster highlights a putative oxidoreductase domain in the N-
terminal portion of PatG [47]. In most other cyanobactin pathways an oxidase domain 
is also present; either contained in the PatG equivalent or as an isolated protein [34], 
and there is a high level of homology between them (Figure 6.2). This would strongly 
suggest that these domains are indeed responsible for the oxidation of the thiazolines 
and/or oxazolines.  
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Figure 6.2: PatGox Homologue Sequence Alignment: Sequence alignment of the N-terminal domains 
(including oxidase) of PatG and its homologous domains from ArtG (Arthrospira 
platensis), CyaG (Cyanothece sp. PCC 7425 and PC7822), LynG (Lyngbya sp.), MicG 
(Microcystis aeruginosa NIES-298) and TriG (Trichodesmum erythraeum IMS101)  
 
 
The activities of cyanobactins can vary greatly dependent on the oxidation states of 
their heterocycles. Studies on the lissoclinamides have shown that the oxidation of one 
thiazoline heterocycle (lissoclinamide 5 over lissoclinamide 4) can result in a 100-fold 
decrease in cytotoxicity in T24 bladder carcinoma cells (Figure 6.3) [42] [54]. 
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Figure 6.3: Lissoclinamide Oxidation: Chemical structures of A) lissoclinamide 4 and B) lissoclinamide 
highlighting the single oxidation state difference between the two which results in a 
100 fold difference in cytotoxicity against T24 bladder carcinoma cells [42]
 
[54]. 
 
 
As discussed, to date little is known of the oxidation of cyanobactins and of the oxidase 
domains found in the gene cluster. BcerB, an oxidoreductase enzyme from Bacillus 
cereus has been studied previously by Melby et al. (2012) through its use as a 
substitute for the native enzyme in the TOMM’s pathway described previously 
(Chapter 1). The study showed that BcerB can oxidise both thiazolines and oxazolines 
to form thiazoles and oxazoles respectively [96] (Figure 6.4). Unlike the patellamide 
pathway, the TOMMS pathway generates linear peptides so BcerB must function on a 
linear substrate as well. In order to generate substrate processing, the enzyme had to 
be purified with the co-factor flavin mononucleotide (FMN) bound confirming its 
requirement in the oxidation process.  
 
 
 
Figure 6.4 –BcerB Utilisation in TOMMs pathway – The oxidation of heterocyclic residues by BcerB 
protein with the FMN co-factor reduced to FMNH2. X = O or S.  
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PatGox and BcerB catalyse similar reactions, the oxidation of heterocyclic amino acids, 
although BcerB has a wider substrate tolerance (Figure 6.5). The two proteins have 
homology of approximately 40 % suggesting that they will have a similar structure. It is 
also likely that PatGox will require FMN for activity as in addition to BcerB it is also 
required in the epothilone and bleomycin biosynthesis pathways as means to oxidise 
thiazolines [97]. One interesting observation between the protein sequences of PatGox 
and BcerB is that the former has a 197 amino acid addition at the N-terminus (Figure 
6.6). This small N-terminal domain of unknown function is also conserved within 
cyanobactin homologues (Figure 6.2) 
 
 
 
 
Figure 6.5: BcerB and PatGox Oxidation Reactions. Schematic of oxidation by enzymes BcerB and PatG 
oxidase domain highlighting the differences between the two. BcerB oxidises both 
thiazolines and oxazolines to thiazoles and oxazoles respectively. PatGox catalyses only 
the oxidation of thiazolines to thiazoles. 
 
 
The study of the oxidase domain of PatG (PatGox) would assist in determining the 
mechanism and upon which substrate it acts; linear or macrocyclic peptide. Oxidation 
must occur after heterocyclisation and is most likely to occur after epimerisation as the 
extraction of the hydrogen from an aromatic ring is less energetically favourable than 
that of a azoline. Additionally, it would be intriguing to elucidate why PatGox only 
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oxidises thiazolines. It may be due to the enzyme only binding thiazolines or because 
of the chemistry of the reaction.  
 
 
 
Figure 6.6 – PatGox and BcerB Sequence Alignment – Sequence alignment of the N-terminal domain of 
PatG (PatGox) from Prochloron sp. and BcerB from Bacillus cereus. 
 
 
This study set out to determine the structure of the N-terminal domain (oxidase) of 
PatG or related enzymes and to determine biochemically their substrates and potential 
position within the biosynthetic pathway.  
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6.2 Materials and Methods 
 
6.2.1 DNA Cloning 
 
The 5’-region of patG, encompassing the oxidase domain (residues 1-517, PatGox) was 
synthesised using optimised codons for E. coli into the pJexpress 411 vector (DNA 2.0) 
with an N-terminal His6-tag and TEV protease site [105]. 
 
PatGox was sub-cloned by PCR to create two shorter constructs of residues 250-478 
(PatGox2) and 271-481 (PatGox3) using the primers outlined in Table 6.1 giving NcoI 
and EcoRI/SalI restriction sites at the 5’ and 3’ ends respectively. The PCR products 
were digested with the appropriate restriction enzymes and ligated into the pHisTEV 
and pHisMBPTEV vectors. PatGox3 was additionally cloned into the pSUMO plasmid.  
 
 
5’PatGox2NcoI cttgccatgggcgatcgtattgtgccg 
3’PatGox2EcoRI cttgagctcttagcccaggatgaattcaccaac 
5’PatGox3NcoI ggcgccatgggcacgctgacggaagcgattgaa 
3’PatGox3XhoI tttctcgagttacagggagcccaggatgaattc 
 
Table 6.1: PatGox Primer Sequences: Oligonucleotide sequences for PatGox2 and PatGox3 cloning 
experiments.  
 
The 5’-regions of a selection of patG homologues were synthesised using optimised 
codons for E. coli into the pJexpress 401 vector (DNA 2.0) with an N-terminal His6-tag 
and TEV protease site (Figure 6.7) as outlined in Table 6.2. The CyaGox PCC7425 was 
supplied by Dr Houssen (University of Aberdeen). 
 
 
 
Figure 6.7:  Schematic for Oxidase Protein Constructs:  Oxidase constructs with N-terminal His6-tag 
followed by a TEV protease site and the protein of interest. 
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Protein Organism Construct Name Protein Residues 
ArtG Arthrospira platensis ArtGox 2-481 
CyaG Cyanothece sp. PCC 7425 CyaGox PCC 7425 1-473 
CyaG Cyanothece sp. PCC 7822 CyaGox PCC 7822 2-458 
MicG Microcystis aeruginosa NIES-298 MicGox 2-517 
TriG Trichodesmum erythraeum IMS101 TriGox 2-475 
 
Table 6.2: PatGox Homologues: Cyanobactin oxidase proteins, source organisms and construct lengths.  
 
6.2.2 PatGox Expression and Purification 
 
PatGox was expressed from the pJexpress 411, pHisTEV and pHisMBPTEV plasmids in a 
range of E. coli cell lines [BL21 DE3, BL21 Star, BL21 gold, Rosetta, C43, Origami, Tuner] 
on a small scale (10 ml cultures). The cells were grown in LB media to an optical 
density at 600 nm (OD600nm) of 0.6 and then induced with 0.01, 0.05, 0.1 and 0.25 mM 
IPTG concentrations and expressed at either 37 °C for 3 hours, 30 °C for 5 hours, or 25 
°C or 20 °C overnight.  
 
Each culture was harvested by centrifugation (4,000 x g) with the cell pellet re-
suspended in lysis buffer (Appendix A.9), sonicated at 10 microns (SoniPrep 150, MSE) 
and centrifuged at 30,000 x g with the soluble fraction then applied to a His-tag pull 
down assay (Qiagen BioSprint). The elution and flow-through samples were analysed 
by SDS-PAGE to determine any soluble expression. 
 
PatGox2 and PatGox3 were expressed from the pHisTEV and pHisMBPTEV or pSUMO 
plasmids in BL21 (DE3) E. coli cells by growing in LB medium at 37 °C to an OD600nm of 
0.6 and inducing with 1 mM IPTG and growing overnight at 20 °C. The cultures were 
treated as for PatGox and applied to His-tag pull down assay. Samples were analysed 
by SDS-PAGE. 
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6.2.3 Homologue Expression Trials 
 
Homologues of PatGox (ArtGox, CyaGox PCC 7425, CyaGox PCC 7822, MicGox and 
TriGox) were expressed separately from the pJexpress 401 plasmid using BL21 (DE3) E. 
coli cells grown on auto-induction medium using the Studier method [107] with the 
addition of 50 µM riboflavin (see Appendix A.10). The cultures were grown at 20 °C, 
250 rpm for 48 hours before harvesting by centrifugation.  
 
Each culture was harvested by centrifugation (4,000 x g) with the cell pellet re-
suspended in lysis buffer, sonicated at 10 microns (SoniPrep 150, MSE) and centrifuged 
at 30,000 x g with the soluble fraction then applied to a His-tag pull down assay 
(Qiagen BioSprint). The elution and flow-through samples were analysed by SDS-PAGE 
to determine any soluble expression. 
 
 
6.2.4 ArtGox Expression, Purification and Crystallisation 
 
ArtGox was expressed from the pJexpress 401 plasmid as described in section 6.2.3.  
 
Cell pellets of ArtGox were re-suspended in lysis buffer plus EDTA-free protease 
inhibitor tablets (Roche) and DNAse at 0.4 mg g-1 wet cell pellet. The re-suspension 
was lysed by passage through a cell disruptor at 30 kPsi (Constant Systems). The lysate 
was cleared by centrifugation (40,000 x g, 4 °C, 20 min) and then loaded onto a Ni-
Sepharose 6 FF column (GE Healthcare) equilibrated in lysis buffer. The column was 
washed with lysis buffer and then ArtGox eluted with elution buffer. The protein was 
then passed over a desalting column (Desalt 16/10, GE Healthcare) in desalting buffer. 
TEV protease was added at a mass-to-mass ratio of 1:10 and the protein was digested 
for two hours at 20 °C to remove the His6-tag. The sample was then loaded on to a 
second Ni-column, in desalting buffer. ArtGox was collected in the flow through. The 
protein was concentrated to 7.5 ml (Vivaspin concentrators, 30 kDa MWCO) and 
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applied to a Superdex 200 gel filtration column (GE Healthcare) equilibrated in gel 
filtration buffer. FMN was included in all stages of the purification with the exception 
of the final gel filtration step. The protein was concentrated to 7.5 mg ml-1 for 
crystallography. The purity of the protein was confirmed by SDS-PAGE analysis and its 
identity confirmed by mass spectrometry (MS).  
Crystallisation trials were set up at varying concentrations from 5 - 10 mg ml-1 using the 
Gryphon crystallisation robot against a range of stochastic screens. 
 
 
6.2.5 CyaGox (PCC 7425) Expression, Purification and Crystallisation 
 
CyaGox (PCC 7425) was expressed from the pJexpress 401 plasmid as described 
previous in section 6.2.3. The protein was purified using the same methods used for 
ArtGox (section 6.2.4).  
 
(L)-Selenomethionine-labelled CyaGox was expressed in BL21 (DE3) E. coli cells, 
cultures of which were grown in a minimal medium supplemented with glucose-free 
nutrient mix (Molecular Dimensions), 5 % glycerol and 50 µM riboflavin. The medium 
was inoculated with overnight culture grown in LB medium which was subsequently 
washed three times with minimal medium. After 15 min growth at 37 °C, 60 mg L-1 (L)-
selenomethionine was added to the cultures. An amino acid mix (100 mg L-1 lysine, 
phenylalanine and threonine, 50 mg L-1 isoleucine and valine) was added to the 
cultures at an optical density at 600nm (OD6oonm) of 0.6. After 15 min further growth at 
37 °C the cultures were induced with 1 mM isopropyl -D-1-thiogalactopyranoside 
(IPTG) and grown for 30 hours at 20 °C before harvesting by centrifugation. SeMet 
CyaGox was purified using the same protocols as native CyaGox and ArtGox. 
 
Crystallisation trials were set up at 5 - 12 mg ml-1 using the Gryphon crystallisation 
robot against a range of stochastic screens. Additionally, the protein was incubated 
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with 1 mM FMN and 1:1.1 equivalents of either PatE2-C50P or the peptide 
‘NILPQQGQPVIR’ and set up in crystallisation trials as for the apo protein. 
 
 
6.2.6 Phasing Trials 
 
Native crystals were soaked in a drop of 10 - 100 mM heavy atom solutions made up in 
mother liquor and suspended over a fresh well of mother liquor at 20 °C for various 
time periods ranging from five minutes to 48 hours.  
 
 
6.2.7 Oxidase Activity Assays 
 
The activity of ArtGox was determined by incubation of the enzyme with either full 
length Cys-heterocyclised PatE-IMACIMAC or with a selection of macrocycles 
containing thiazolines (created in Section 4). 200 µM PatE / macrocycle was incubated 
with 20 µM ArtGox and 1 mM FMN at 37 °C overnight in the dark. (The reaction was 
carried out in the absence of light due to the potential for FMN to oxygenate His 
residues on light activation). The reactions were analysed by MALDI-MS or by LC-MS. 
 
 
6.2.8 Structural Predictions 
 
 
Structural predictions of PatGox, ArtGox and CyaGox (PCC 7425) were carried out using 
the Phyre2 server by inputting the amino acid sequence and searching against the PDB 
database of protein structures. 
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6.3 Results 
 
 
6.3.1  PatGox Expression and Purification 
  
PatGox was expressed from pJexpress 411 plasmid in various E. coli cell lines with a 
range of induction concentrations and induction temperatures. Each expression trial 
was analysed by applying the soluble fraction to a His-tag pull-down assay (Qiagen 
BioSprint) and running the appropriate eluted fraction on SDS-PAGE (Figure 6.8). No 
significant PatGox protein was found under any of the conditions/cell lines. A screen of 
the lysis buffer (Appendix A.11) also led to no isolated protein from nickel elution.  
 
 
 
Figure 6.8: SDS-PAGE Analysis of PatGox Expression Trials: Representative SDS-PAGE analysis of PatGox 
expression trials under varying cell lines, induction concentrations and temperatures. 
There was no evidence of PatGox expression under any conditions. Gel bands in the 
size region of PatGox (57 kDa) were confirmed by peptide mass fingerprinting to be E. 
coli proteins. 
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Analysis of the His-tag pull-down flow-through (non-bound material) showed 
significant quantities of PatGox (Figure 6.9). Two feasible explanations for this are 
possible; firstly, the His-tag is somehow occluded in the PatGox structure or secondly, 
the protein is highly aggregated resulting in no tag being free to bind the nickel resin. 
 
 
 
Figure 6.9: SDS-PAGE Analysis of PatGox Non-Bound Material: SDS PAGE analysis of the flowthrough 
(non-bound) sample of a His-tag pull-down experiment showing a significantly sized band 
corresponding to PatGox. 
 
 In order to assess this further, a large scale expression was applied first to a His-trap 
affinity column with the flow-through then passed over a Capto-Q column with the aim 
to separate proteins based on their charge. An elution gradient of 0.1 to 1 M NaCl was 
applied to the column after loading. However, multiple broad peaks were observed 
with PatGox present in all peaks, each with significant contaminants. The most 
abundant PatGox containing peak was pooled and applied to gel filtration (Superdex 
S200). However, the PatGox eluted in the void volume confirming that the protein is 
highly aggregated (Figure 6.10). 
 
As a wide range of expression trials (differing cell lines, buffers, induction 
concentrations, temperatures) were trialled, but led to no improvement in expression 
or reduction in aggregation the full length PatGox construct was abandoned. 
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Figure 6.10: Gel Filtration of PatGox: UV spectrum from gel filtration of PatGox pooled from Capto-Q 
column. The PatGox is the predominant protein and elutes in the void volume (40 - 55 
ml) indicating that the protein is highly aggregated. 
 
PatGox2 and PatGox3 were expressed from the pHisMBPTEV and/or pSUMO plasmids 
in BL21 (DE3) E. coli cells however both constructs showed no level of soluble 
expression when applied to His-tag pull down assays. Minimal levels were found in the 
flow through and insoluble fractions. 
 
 
6.3.2 Homologue Expression Trials 
 
Five cyanobactin oxidase proteins were expressed from the pJexpress 401 plasmid in 
BL21 DE3 E. coli cells and analysed by His pull-down using the Qiagen Biosprint robot. 
The flow through and elution fractions were analysed by SDS-PAGE to assess soluble 
expression (Figure 6.11) 
 
ArtGox and CyaGox PCC7425 showed significant levels of soluble protein in the elution 
fractions, while TriGox showed a minor level of soluble protein in the elution fraction. 
All three proteins were confirmed by MS. At this stage ArtGox and CyaGox PCC7425 
were carried forward for large scale expression and purification trials. 
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Figure 6.11: SDS-PAGE Analysis of Oxidase Homologues: SDS-PAGE analysis of six cyanobactin oxidase 
proteins (ArtGox, CyaGox PCC7822, MicGox, TriGox and CyaGox PCC7425) when 
analysed by His pull-down. Flow-through and elution fractions for each protein are 
shown. ArtGox and CyaGox PCC 7425 show significant levels of expression in the 
elution fraction. TriGox shows minor expression in the elution (gel band is not clear so 
has been circled).  
 
 
6.3.3 ArtGox Expression and Purification 
 
ArtGox was expressed from the pJexpress 401 plasmid in BL21 DE3 E. coli cells using 
the Studier method [158]. The protein was isolated by nickel chromatography using 
the His6-tag. The tag was removed by treatment with TEV protease at > 95 % 
efficiency. The protein eluted off gel filtration as a monomer and with a distinct yellow 
colour indicating that FMN was bound (No FMN was included in the final gel filtration 
buffer). A final yield of 25 mg L-1 culture was achieved. SDS-PAGE analysis shows the 
protein to be > 95 % pure but with a shadow band directly under the main band 
(Figure 6.12). MSMS analysis of both gel bands confirmed that both contained ArtGox 
peptides suggesting that the lower band has been slightly cleaved. The protein was 
concentrated to 7.5 mg ml -1 and applied to crystallisation trials.  
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Figure 6.12: Purification of ArtGox: (A) SDS-PAGE analysis of ArtGox gel filtration fractions (B) Gel 
filtration UV spectra of ArtGox showing a single peak corresponding to a monomer (C) 
Concentrated ArtGox post gel-filtration showing a deep yellow colour indicating the 
presence of FMN.  
 
 
6.3.4 CyaGox (PCC 7425) Expression and Purification 
 
CyaGox (PCC 7425) was expressed from the pJexpress 401 plasmid in BL21 DE3 E. coli 
cells using the Studier method [158]. The protein was isolated by nickel 
chromatography using the His6-tag. The tag was removed by treatment with TEV 
protease at > 90 % efficiency. The protein eluted off gel filtration as a monomer and 
with a distinct yellow colour indicating that FMN was bound (No FMN was included in 
the final gel filtration buffer) (Figure 6.13). A final yield of 5 mg L-1 culture was 
achieved. SDS-PAGE analysis shows the protein to be > 95 % pure. The protein was 
concentrated to 12 mg ml -1 and applied to crystallisation trials.  
 
Purification of SeMet CyaGox occurs as with the native protein however with much 
reduced yields. A final yield of 5 mg L-1 cell culture with purity greater than 98 % was 
achieved and the protein confirmed by SDS-PAGE and MS.  
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Figure 6.13: Purification of CyaGox: (A) SDS-PAGE analysis of CyaGox purification steps with CyaGox the 
primary band (B) Gel filtration UV of CyaGox showing a single peak corresponding to a 
monomer.  
 
 
6.3.5 ArtGox Crystallisation 
 
Crystallisation trials of ArtGox were carried out against stochastic screens (Appendix E) 
using the Gryphon nanolitre crystallisation robot. In the majority of cases, only clear or 
precipitated drops were observed under a range of protein concentrations. However, 
under one condition (Qiagen PEGS I Suite, condition 64 – 0.2 M potassium thiocyanate, 
20 % PEG 3350) small, non-single crystals were observed. These were confirmed as 
protein due to their yellow colour (as result of bound FMN) and their high absorbance 
under ultraviolet light (Figure 6.14). 
 
 
 
Figure 6.14: Crystallisation of ArtGox: (A) Crystals of ArtGox grown in 0.2 M potassium thiocyanate, 20 
% PEG 3350 (B) The same crystals under ultraviolet light.  
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Several attempts were made to repeat and optimise these into X-ray diffraction quality 
crystals but to date this has been unsuccessful. 
 
6.3.6 CyaGox (PCC 7425) Crystallisation 
 
Crystallisation trials of CyaGox PCC 7425 resulted in no crystal hits, however a single 
crystal hit was observed when the protein was setup in complex with 1 : 1.1 
equivalents of PatE2-ITACITFP and 1 mM FMN. The preliminary crystals were found in 
the Wizard Screen 2 (Rigaku Reagents) condition 16 (1.0 M sodium citrate, 0.1 M CHES 
pH 9.5). These crystals were analysed by UV light and subsequently soaked in Izit Dye 
(Hampton Research) to confirm that they were protein and not salt crystals (Figure 
6.15).  
 
 
  
Figure 6.15: Crystallisation of CyaGox: Crystals of CyaGox grown in 1.2 M sodium citrate, 0.1 M CHES pH 
8.5 (A) under visible light (B) under UV light and (C) when soaked with Hampton Izit 
dye. 
 
Several rounds of optimisation were carried out with single crystals grown in a 
condition of 0.9 M sodium citrate, 0.1 M CHES pH 8.0 and with a protein concentration 
of 5 mg ml-1. Crystals of size 50 x 50 x 50 µm were observed after three days (Figure 
6.16.A). The crystals were cryo-protected in paraffin oil and analysed by synchrotron 
radiation at the Diamond Light Source, beamline I04-1. A dataset was collected (Figure 
6.16 B, C) and processed to 2.97 Å in the space group P41212 with a cell of 110 x 110 x 
197 Å (Table 6.3). These crystals did not diffract reproducibly and often diffraction 
datasets were limited to 8.0 Å.  
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Figure 6.16: Optimisation and Analysis of CyaGox Crystals: (A) Optimised co-crystals of CyaGox and 
PatE2-ITACITFP grown in 0.9 M sodium citrate, 0.1 M CHES pH 8.0 (B) X-ray diffraction 
pattern of CyaGox complex with PatE2-ITACITFP with spots to 2.97 Å (C) Zoom view of 
diffraction pattern 
 
 
Native CyaGox + PatE2-ITACITFP Dataset  
Wavelength (Å) 0.92 
Space group P 41 21 2 
a, b, c (Å) 109.8, 109.8, 196.9 
α, β, γ (°) 90.0, 90.0, 90.0 
Resolution (Å) 73.30 – 2.97 (3.05-2.97) 
I/σI 27.9 (3.6) 
Rmerge (%) 7.6 (83.9) 
Completeness (%) 100.0 (100.0) 
Redundancy 14.3 (15.2) 
 
Table 6.3: Data Collection Statistics of CyaGox in Complex with PatE-C50P: Values for the highest 
resolution shell are provided in parenthesis. The dataset was collected at the Diamond 
Light Source beamline I03 (Dectris Pilatus 6M detector).  
 
Following the initial CyaGox:PatE-C50P native dataset, a second shorter peptide was 
trialled in co-crystallisation with CyaGox and 1mM FMN. The use of the PatE leader 
sequence fragment ‘NILPQQGQPVIR’ yielded significantly larger (200 x 80 x 80 µm) and 
visually better looking crystals (Figure 6.17 A). These crystals were cryo-protected in 
paraffin oil, analysed by X-ray and found to diffract more routinely in-house (to 
between three and five angstroms) than the previous crystals. Several crystals were 
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tested at the synchrotron with the best dataset being collected to a resolution of 2.65 
Å (Figure 6.17 B, C and Table 6.4). 
 
 
 
Figure 6.17: Co-crystallisation of CyaGox: (A) Optimised co-crystals of CyaGox and NILPQQGQPVIR 
peptide grown in 1.05 M sodium citrate, 0.1 M CHES pH 7.75 (B) Synchrotron X-ray 
diffraction patterns of CyaGox complex with ‘NILPQQGQPVIR’ peptide with spots to 
2.65 Å (C) Zoom view of diffraction pattern.  
 
 
Native CyaGox + NILPQQGQPVIR pep Dataset  
Wavelength (Å) 1.77 
Space group P 41 21 2 
a, b, c (Å) 109.3, 109.3, 195.4 
α, β, γ (°) 90.0, 90.0, 90.0 
Resolution (Å) 72.83 – 2.65 (2.72-2.65) 
I/σI 17.9 (2.7) 
Rmerge (%)  8.3 (83.6) 
Completeness (%) 100.0 (100.0) 
Redundancy 8.1 (8.5) 
 
Table 6.4: Data Collection Statistics of CyaGox in Complex with Peptide NILPQQGQPVIR: Values for the 
highest resolution shell are provided in parenthesis. The dataset was collected at the 
DLS beamline I02 (Dectris Pilatus 6M detector). 
 
In order to confirm fully that the protein crystals were indeed CyaGox and not a 
contaminant, several crystals were washed in four subsequent drops of fresh mother 
liquor (to remove any remaining soluble protein) and then finally dissolved in SDS 
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loading buffer. The sample was then run on SDS-PAGE (Figure 6.18). The gel band at 53 
kDa was excised, subjected to tryptic digest (ProGest robot) and analysed by MALDI 
TOF MS with the resultant peptides further analysed by MSMS. The data was searched 
using the Mascot server (Matrix Science) against the St Andrews and NCBI databases 
with both searches giving strong peptide hits for CyaGox confirming the crystals were 
as expected.  
 
 
 
Figure 6.18: SDS-PAGE of CyaGox Crystals: SDS-PAGE analysis of CyaGox protein crystals dissolved in 
SDS loading buffer with a single band at 53 KDa.  
 
 
6.3.7 CyaGox (PCC 7425) Phasing Trials 
 
Molecular replacement, using Phaser [137] as part of the CCP4 suite [138], was initially 
attempted to determine the crystal structure with several known FMN 
oxidoreductases used as search models, in particular two putative nitroreductases 
from anabena varibilis (PDB code: 3EO7) and ralstonia eutropha (PDB code: 3HJ9) 
which showed the highest sequence homology of any PDB entry. Analysis of the 
Matthews coefficient strongly suggested two molecules in the asymmetric unit and as 
6. Structural and Biochemical Studies on Cyanobactin Oxidases 
 159 
a result two models were searched for in each trial. Unfortunately, no success was 
gained even after trimming side chains and flexible loops from these structures 
(summarised in Table 6.5). In general a minimum Z-score of 8.0 is the cut-off for 
proceeding with molecular replacement and both molecules must pack in the 
asymmetric unit. A model (Figure 6.19) was creating using the Robetta [159] and 
server and subsequently used in MR trials however this too failed to correctly 
determine the phases.   
 
 
Model Protein Residues Notes Top Z-Score Packs? 
PDB: 3EO7 1-510 Full length 6.0 Yes 
PDB: 3E07 274-510 Aligned region 6.1 Yes 
PDB: 3E07 274-510 Side chains removed 5.9 Yes 
PDB: 3E07 274-510 Side chains & loops removed 6.1 Yes 
PDB: 3HJ9 2-216 Full length 6.1 Yes 
PDB: 3HJ9 19-204 Aligned region 6.3 No 
PDB: 3HJ9 19-204 Side chains removed 5.7 No 
PDB: 3HJ9 19-204 Side chains & loops removed 5.6 Yes 
Rosetta Output 1-477 None 6.0 No 
 
Table 6.5: CyaGox Molecular Replacement Trials. Z-scores from Phaser output of CyaGox dataset versus 
various models  
 
The failure of MR led to a focusing of efforts on solving the phases via crystallisation of 
the selenomethionine-containing protein. SeMet CyaGox was placed into co-
crystallisation trials using both the PatE-C50P and NILPQQGQPVIR peptide under the 
same conditions as for native CyaGox. No crystals were observed, however, under 
these conditions or subsequent optimisation around them. Additionally, the SeMet 
protein complexes were subjected to stochastic screening, but again no crystals were 
observed. This result suggests that the one or more of the SeMet residues may be 
causing an interference with the crystal packing.  
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Figure 6.19: Robetta Molecular Model. Molecular model created from the Robetta server upon input of 
the CyaGox protein sequence (alpha helices - red, beta sheets - yellow) [159].  
 
As SeMet crystallisation was not possible with the current protein construct, attempts 
were made to soak various heavy atoms into native crystals. Short, high concentration 
and also longer, lower concentration soaks were carried out with the following heavy 
atom derivatives; K2PtCl4, KAu(CN)2, (CH3)3PbCl, NaBr, NaI, I3C, KBr, KI, SmOAc2, 
K2PtBr4, HgCl2 and Thiomersal (C9H9HgNaO2S). 
Crystals were cryo-protected, frozen in at 100 K and assessed under synchrotron 
radiation at the appropriate wavelength (anomalous edge) to give the strongest 
anomalous signal for the heavy atom used. The crystals diffracted in general between 
3.0 and 5.0 Å and a high redundancy dataset was collected on each. Unfortunately no 
anomalous signal was detected with any of the heavy atoms trialled to date. At the 
time of writing work is still on-going to determine phases for the CyaGox crystals. 
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6.3.8 Oxidase activity assay 
 
Full length PatE (IMACIMAC) was heterocyclised by TruD to give two thiazolines from 
the cysteine residues as determined by a loss of 36 Da. The heterocyclised PatE was 
subsequently incubated with ArtGox and FMN overnight and MALDI-MS confirmed a 
further loss of 4 Da indicating the oxidation of the thiazolines to thiazoles (Figure 6.20)  
 
In order to confirm the oxidation of the thiazoline to thiazole, PatE was N-terminally 
cleaved by trypsin and macrocyclised with PatGmac. The resultant macrocycle was 
confirmed by MS and shown by MSMS fragmentation to be the oxidised variant of 
IMACIMAC (Figure 6.21, 6.22) 
 
 
 
Figure 6.20: Linear Oxidation of PatE by ArtGox. MALDI-TOF-MS spectra of PatE-IMACIMAC (A) 
unprocessed (B) after heterocyclisation by TruD showing loss of 36 Da confirming 
production of two heterocycles (C) after heterocyclisation and subsequent oxidation 
by ArtGox with a further 4 Da loss confirming heterocycle oxidation.  
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Figure 6.21: MS of cyclo[IMAC
Thz
IMAC
Thz
]. MALDI TOF MS spectrum of the cyclo[IMAC
Thz
IMAC
Thz
] 
macrocycle. The sample arose from the oxidation of linear TruD heterocyclised PatE 
(Figure 6.20) and subsequent cleavage by trypsin and macrocyclisation by PatGmac. 
 
 
 
Figure 6.22: LC/MS/MS Analysis of cyclo[IMAC
Thz
IMAC
Thz
]. LC/MS/MS spectrum of 
cyclo[IMAC
Thz
IMAC
Thz
]. Several of the fragment ions have been assigned and correlate 
with the chemical structure. 
 
To explore the diversity of the oxidase enzyme ArtGox, samples of non-oxidised 
cyclo[ATACThnITFCThn] and cyclo[ITAAITFCThn] (generated in Chapter 4) were incubated 
overnight with ArtGox and FMN and re-tested by MS. Losses of 4 and 2 Da were 
observed respectively corresponding to the oxidation of the thiazolines to thiazoles 
(Figures 6.23 and 6.24).  
6. Structural and Biochemical Studies on Cyanobactin Oxidases 
 163 
 
 
Figure 6.23: Oxidation of cyclo[ATAC
Thn
ITFC
Thn
]. MALDI-TOF-MS spectra of cyclo[ATAC
Thn
ITFC
Thn
]prior to 
ArtGox incubation and post ArtGox incubation resulting in a loss of 4 Da, when H
+
/Na
+ 
ions are taken into account, generating cyclo[ATAC
Thz
ITFC
Thz
]. Chemical structures for 
both are shown with oxidation highlighted in magenta. 
 
 
 
Figure 6.24: Oxidation of cyclo[ITAAITFC
Thn
]. MALDI-TOF-MS spectra of cyclo[ITAAITFC
Thn
] prior to 
ArtGox incubation and post ArtGox incubation resulting in a loss of 2 Da, when H
+
/Na
+ 
ions are taken into account, generating cyclo[ITAAITFC
Thz
]. Chemical structures for 
both are shown with oxidation highlighted in magenta. 
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6.3.9 Structure Predictions 
 
Homology models of PatGox, ArtGox and CyaGox (PCC 7425) were created using 
Phyre2 structure prediction software [125] by supplying the protein sequences, with 
similar structural predictions observed for each (Figure 6.25). Predictions were also 
determined by supplying separately the N-terminal DUF and the oxidase portions of 
each protein. The N-terminal DUF portions of PatGox, CyaGox and ArtGox all gave 
moderate structural predictions (confidence 65 - 74 %) based on the peptide-binding 
domain of NisB (PDB: 4WD9, [30]) from the Nisin pathway (a member of the  
lanthipeptide class of RiPPs discussed in Chapter 1), whilst ArtGox and CyaGox 
additionally gave predictions (65 and 83 % confidence respectively) based on the 
peptide-binding domain of TruD (PDB 4BS9, [67]) from the trunkamide pathway 
(Chapter 1). The remaining oxidase portions of the proteins all gave strong predictions 
(confidence > 99 %) based on standard oxidoreductase domains such as those from 
anabena varibilis (PDB code: 3EO7) and ralstonia eutropha (PDB code: 3HJ9) (Table 
6.6). 
 
Protein Domain Residues 
Searched 
Residues 
Aligned 
Model Residues 
Aligned 
Prediction 
Confidence 
PatGox N-term DUF 1 - 197 14 - 101 NisB 140 - 229 67 % 
ArtGox N-term DUF 1 - 196 7 - 101 NisB 141 - 229 65 % 
ArtGox N-term DUF 1 - 196 5 - 95 TruD 3 - 80 65 % 
CyaGox (PCC 7425) N-term DUF 1 - 194 7 - 92 NisB 140 - 229 74 % 
CyaGox (PCC 7425) N-term DUF 1 - 194 7 - 87 TruD 6 - 81 83 % 
PatGox Oxidase 198 - 486 19 - 304 Flavoprotein  
(a. variabilis) 
9 - 258 100 % 
PatGox Oxidase 198 - 486 46 - 285 Oxidoreductase 
(r. eutropha) 
16 - 214 100 % 
ArtGox Oxidase 197 - 481 19 - 285 Flavoprotein 
(a. variabilis) 
9 - 239 100 % 
ArtGox Oxidase 197 - 481 48 - 283 Oxidoreductase 
(r. eutropha) 
16 - 211 100 % 
CyaGox (PCC 7425) Oxidase 195 - 473 19 - 275 Flavoprotein 
(a. variabilis) 
9 - 241 100 % 
CyaGox (PCC 7425) Oxidase 195 - 473 48 - 274 Oxidoreductase 
(r. eutropha) 
16 - 214 100 % 
 
Table 6.6: Phyre2 Structural Predictions.  
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Figure 6.25: Homology Models of Oxidase Proteins: Phyre2 derived homology models of (A) PatGox, (B) 
ArtGox and (C) CyaGox (PCC7425). 
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6.4 Discussion 
 
 
Isolation of the oxidase domain of the PatG protein has not been possible to date as 
difficulties with aggregation or no expression at all has hampered efforts. Attempts to 
improve soluble expression by varying cell lines, induction conditions and also the 
domain boundaries failed.  
 
As a result of the lack of PatGox protein, efforts were shifted to related cyanobactin 
oxidases ArtGox from Arthrospira platensis and CyaGox from Cyanothece sp. PCC 7425 
and both of these have been expressed and purified. Crystals have been obtained for 
both proteins, with optimised crystals and native datasets in complex with two 
substrate peptides for CyaGox. At present, no phases have been calculated to allow 
structure determination however efforts are on-going.  
 
Homology models of PatGox, ArtGox and CyaGox (PCC 7425) have been created using 
Phyre2 prediction software [125]. The proteins predominantly show structural 
homology to known oxidoreductases, however this analysis has determined that the 
N-terminal DUF of the proteins has structural homology to the peptide-clamp domains 
of NisB and TruD proteins. This finding could provide a theory for why the oxidase 
protein can function on both the macrocyclic and linear substrates, because the full 
length linear peptide can be held in place by the clamp domain.  
 
Finally, activity of the ArtGox enzyme on both the final macrocycle and the full length 
PatE has been determined by MS. The MS analysis suggests that ArtGox processes the 
macrocycle faster than the linear peptide which would imply that in nature the enzyme 
works on the macrocycle. However, detailed kinetic experiments will have to be 
carried out to fully ascertain this. The preference for the macrocycle over the linear 
peptide would correlate with the hypothesis that epimerisation (which must occur 
before oxidation) occurs on the macrocycle [94] [95].   
  
6. Structural and Biochemical Studies on Cyanobactin Oxidases 
 167 
6.5 Conclusions and Future Work 
 
The oxidase enzyme, PatGox, from the patellamide pathway could not be expressed in 
a soluble state and therefore cyanobactin homologues ArtGox and CyaGox which are 
soluble have been purified and studied instead.  
 
It has been determined that ArtGox is an active oxidase for thiazolines when 
incorporated in both a full length linear peptide and a macrocycle. Our collaborators 
(University of Aberdeen) reported that CyaGox (PCC 7425) is active on the macrocycle, 
[69] however studies by Greg Mann (Naismith Group, University of St Andrews) have 
since shown activity on the linear peptide too. At present, no kinetic experiments have 
been carried out on the oxidase enzymes and this is work to be undertaken. The ability 
to oxidise thiazolines to thiazoles now allows us to add yet more diversity to our in 
vitro compound library. There are cyanobactins from other pathways which also 
contain oxazoles, oxidised oxazolines (e.g. - Tenuecyclamides [36]), and the oxidase 
enzymes responsible for this reaction will be explored, which could enable us to 
introduce oxazoles to further diversify our macrocycle library. 
 
For both enzymes, crystallisation trials were attempted and small initial crystals were 
created in each case, with the CyaGox optimised with two substrate peptides to give  
native datasets to 2.97 and 2.65 Å.  As yet phases have not been found to allow the 
crystal structure to be determined and work on this is on-going. SeMet protein did not 
crystallise, but we have plans to make SeCys protein for Se-SAD experiments and also 
to send native crystals to the long wavelength beamline I23 at the Diamond Light 
Source to attempt sulfur-SAD. Should neither of these techniques work we will mutate 
the protein to selectively remove each methionine in turn and attempt SeMet crystal 
growth or alternatively mutate in a free cysteine which should improve heavy atom 
phasing with for example mercury derivatives.  
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Finally, the absence of a crystal structure has led us to structure predictions which 
appear to suggest a standard FMN binding domain responsible for oxidation but with 
an additional N-terminal DUF domain. This small N-terminal DUF has some homology 
to the peptide-binding clamp in TruD, which could explain the activity on the linear 
peptide. A future crystal structure should elucidate this further. 
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7. Unnatural Amino Acid Incorporation into Cyclic 
Peptides 
 
7.1 Introduction 
 
It has been demonstrated that patellamide-like cyclic peptides can be derived from the 
reconstitution of the patellamide biosynthetic pathway in vitro (Chapter 4). There are 
strict limitations in the composition of these peptides to amino acids which can be 
incorporated in vivo to the precursor peptide PatE. We have explored the 
incorporation of selenium variants with a some success, but selenium is known to be 
accepted into cells (Chapter 5). Taniero et al. (2012) [103] have exploited the pEVOL 
system pioneered by the group of Peter Schultz (Scripps Research Institute) [160], 
[161] to introduce non-proteinogenic amino acids into E. coli cells expressing the 
patellamide biosynthetic pathway in vivo. This in vivo approach has highlighted the 
potential in adapting enzymatic pathways to yield diversified products however the 
quantities of the target compound isolated in this study remain low (5 – 174 µg 
compound L-1 cell culture).  
We sought to establish a method of producing macrocycles containing unnatural 
amino acids in higher yields (mg quantities or above) and as such we explored two 
different approaches; intein-mediated peptide ligation and the use of the pEVOL 
system to generate substrate for in vitro processing. 
 
7.1.1 Intein Technology 
 
Semi synthetic approaches have been employed in a variety of biotechnologies. 
Examples include large scale drug production from a natural product starting material 
expressed in cells (e.g. Yondelis®, an anti-tumour drug [162] [163] ) or the engineering 
of the protein backbone of HIV protease by ligating two peptides by a thioester bond 
[164].  
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One class of semi-synthetic method is the exploitation of intein proteins. Inteins, first 
identified in 1990 [165], are protein elements which self-excise themselves from a 
longer protein and catalyse the subsequent ligation of their N- and C- terminal flanking 
proteins (Figure 7.1) [166].  This is conceptually similar to the well-known pre-mRNA 
splicing where RNA introns are removed and the exons are ligated together; to make 
the analogy explicit, the protein equivalent is termed ‘protein splicing’ with inteins and 
exteins. [167]. 
 
 
 
Figure 7.1: Intein Protein Splicing. Schematic of intein protein splicing where the central intein protein 
element self excises resulting in the two flanking extein segments ligating together to 
form the mature peptide while releasing the intein. Figure adapted from Elleuche 
and Poggeler (2010) [166]. 
 
Inteins have been exploited in biotechnology for multiple purposes including cleavage 
of affinity tags in protein purifications [168], semi-synthesis of cytotoxic proteins [169], 
semi-synthetic protein ligation [170] and peptide cyclisation [171]. 
 
Of particular interest to this project is the intein-mediated protein ligation (IPL) 
method which uses the intein to chemically ligate two peptides to form a larger single 
peptide with a standard peptide bond linking the two (Figure 7.2) [172]. This occurs by 
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expressing a protein-intein fusion and purifying it using standard protein purification 
techniques. The intein is then removed using a free thiol reagent, the most common 
being sodium 2-sulfanylethanesulfonate (MESNA) or 4-mercaptophenylacetic acid 
(MPAA) (Figure 7.3), which reacts at the carbonyl carbon to form an activated peptide 
while releasing the intein. The activated peptide is then reacted with a C-terminal 
peptide with a cysteine at its N-terminus to form the complete peptide. The C-terminal 
peptide can be expressed heterologously or synthesised by chemical means. 
 
 
 
Figure 7.2: Intein-mediated Protein Ligation (IPL). Schematic of intein-mediated protein ligation where 
the N-terminal peptide-intein fusion undergoes an N-S acyl shift followed by cleavage 
with MESNA resulting in activated N-terminal peptide and removal of intein. A 
secondary peptide (which can be chemically synthesised) with an N-terminal Cys is 
added and reacts with the activated peptide to form a combined peptide. Finally, the 
longer peptide undergoes an S-N acyl shift to yield a new peptide with native peptide 
bond.  (Adapted from Xu and Evans, 2001)
 
[172] 
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Figure 7.3: Intein Cleavage Thiols. Chemical structures of two thiols commonly used in the cleavage 
step of intein-mediated peptide ligation – (A) sodium 2-sulfanylethanesulfonate 
(MESNA) (B) 4-mercaptophenylacetic acid (MPAA) 
 
It was planned to generate an intein-mediated protein ligation system to fuse the PatE 
leader sequence to chemically synthesised core peptides containing unnatural amino 
acids plus the C-terminal recognition site ‘AYDG’ (Figure 7.4). The ligated peptides 
would then be processed in vitro to create macrocyclic peptides containing unnatural 
amino acids.  
 
 
 
Figure 7.4: Semi Synthetic PatE Production. Schematic of the production of a semi-synthetic PatE by 
thiol-mediated cleavage of PatE-Intein fusion protein to generate an activated PatE 
leader sequence. The activated peptide is then ligated by a free cysteine on the N-
terminal of a synthetic PatE core peptide. 
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7.1.2 pEVOL Amber Stop Codon Technology 
 
 
Genetically encoding unnatural amino acids directly into proteins in vivo using 
heterologous systems opens up a wide potential for the use in biochemical 
applications. The ability to reassign codons to achieve this was first recognised by 
Normanly et al (1990) [173], however it was the laboratory of Peter Schultz (The 
Scripps Research Institute) which pioneered this field with the development of 
technology using evolved Methanocaldococcus jannaschii aminoacyl-tRNA synthetase 
(aaRS)/suppressor tRNA pairs to incorporate unnatural amino acids in response to the 
amber stop codon ‘TAG’ [174]. The pairs are constructed in a fashion that means they 
are not recognised by endogenous aaRSs or endogenous tRNAs of the host organism 
respectively, thus are orthogonal. The synthetase specificity is altered so that the tRNA 
is only loaded with the unnatural amino acid of interest [175] [176] (Figure 7.5) 
 
 
  
Figure 7.5: Unnatural Amino Acid Incorporation. Schematic of orthogonal aminoacyl-tRNA synthetase 
(aaRS)/suppressor tRNA pairs incorporating unnatural amino acids in response to the 
amber stop codon during protein synthesis. Figure adapted from Lin and Wang, 2008 
[176] . 
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More than seventy unnatural amino acids have been genetically encoded in bacteria, 
yeast, and mammalian cells using this method and a selection of the various amino 
acids is represented in Figure 7.6 [175] [177]. 
 
 
 
Figure 7.6: Genetically Encoded Unnatural Amino Acids. A small representation of the many unnatural 
amino acids which have been genetically encoded in E. coli, yeast or mammalian 
cells. Figure adapted from Wang et al, 2006 [175]. 
 
The development of this technology has been implemented successfully in many areas 
of biochemistry such as the addition of fluorophores [178], the addition of photo-
cross-linkers [179], site directed spin-labelling for Electron Pulse Resonance (EPR) 
[180], introduction of glycosylated residues in E. coli derived proteins [181] and heavy 
atom phasing for X-ray crystallography [182].  
 
Following on from their initial successes, the Schultz group developed a single E. coli 
vector, pEVOL, containing two copies of the M. jannaschii aaRS gene along with an 
optimised suppressor tRNA [160]. The vector can be simply co-expressed 
heterologously in common E. coli expression cells (e.g. BL21 DE3) with a standard 
vector containing the gene of interest (e.g. pET system [158]) complete with the amber 
stop codon ‘TAG’ in the specified position for the unnatural amino acid [160]. The 
vectors are expressed under the influence of different inducers (L-arabinose vs IPTG) 
with the expression resulting in the protein of interest with the unnatural amino acid 
incorporated. A range of different aaRS pEVOL plasmids that incorporate different 
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unnatural amino acids have been developed with a small selection being made 
available commercially through Addgene [160]. 
 
This study proposed to create a PatE containing the unnatural amino acid p-benzoyl-L-
phenylalanine (pBpa) (Figure 7.7) using the pEVOL system [160] [183] and to process it 
in vitro to form a macrocycle containing an unnatural amino acid. 
 
 
 
Figure 7.7: p-Benzoyl-L-Phenylalanine. Chemical structure of the amino acid p-benzoyl-L-phenylalanine 
(pBpa).  
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7.2 Intein-Mediated Approach 
 
7.2.1 Materials and Methods 
 
7.2.1.1 Construct Design and DNA Cloning 
 
A DNA construct of full length PatE leader sequence, lysine and the first three residues 
of the PatE2 core peptide were combined at the C-terminus with the Mxe GyrA Intein 
(txb1, New England Biosciences, [184] [185]) using fusion PCR with the primers listed in 
Table 7.1  
 
The construct was created by a three step PCR process. Firstly, the PatE leader section 
was amplified by PCR using primers to give an Nco1 site at the 5’ end and the first eight 
amino acids from the cleavable cysteine of the intein on the 3’ end. Next, the Intein 
sequence was amplified by PCR using primers to give the final nine residues of the PatE 
to be included at the 5’ end, and an Xho1 site at the 3’ end. Finally, the two newly 
formed DNA fragments were fused by PCR using the 5’ primer of the first reaction and 
the 3’ primer of the second to give the full length DNA insert to be used. (Figure 7.8) 
 
 
Figure 7.8: PatE Intein Fusion PCR Schematic. 3 Step PCR schematic to produce a fusion of PatE leader 
sequence and intein (1txb). 1) N-terminal PatE leader sequence production 2) C-
terminal Intein (1txb) production 3) PCR to fuse the two sequences together to from 
the final DNA product. 
7. Unnatural Amino Acid Incorporation into Cyclic Peptides 
 177 
 
Table 7.1: PatE - Intein Mutagenesis Primers. Oligonucleotide sequences for PatE – Intein fusion, 
truncation and deletion PCR and for model C-terminal peptide CKITAPITWP. 
 
The new DNA insert was gel purified, extracted and ligated into the pBMS23CHis 
plasmid using the methods described in Section 2.2.1 to give the protein construct 
“PatE-Intein Full Length” (Figure 7.9 A) 
 
 
 
Figure 7.9: PatE-Intein Construct Schematic. Construct diagrams for A) PatE-Intein Full Length, B) PatE-
Intein Small C) PatE-Intein Large and D) PatE-Intein GLEA. 
 
5’PatE cttccatggacaaaaaaaacattcta 
3’PatEInt aactagtgcatctcccgtgatgcaagcagttattttagatgcttccaaacc 
5’PatEint ggtttggaagcatctaaaataactgcttgcatcacgggagatgcactagtt 
3’Int cctctcgagggtagcgtgagatacgaaccc 
5’PatEIntSmall cttccatggatgctggtttggaagcatct 
5’PatEIntLarge cttccatgggcttggctgaactgtctgaggaa 
5’PatEIntGLEA ttggaagcatgcatcacgggagatgcactagttgcccta 
3’PatEIntGLEA cgtgatgcatgcttccaaaccagcatcgccgagagcttc 
3’PatE-CKITAPITWP cttctcgagttcaccatcataagccggccaggtaatcggcgcggtaattttg
cactgaaaatacag 
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Two shorter variants of the full length PatE-Intein fusion were created using standard 
PCR methods (primers - Table 7.1) in which the PatE leader sequence was truncated 
from the N-terminal end. The two new constructs were designated ‘PatE-Intein-Small’ 
(Figure 7.9 B) and ‘PatE-Intein-Large’ (Figure 7.9 C). A final construct based on ‘PatE-
Intein Large’ where the intein section of the DNA starts directly after the ‘GLEA’ of the 
GLEAS motif was created using PCR mutagenesis with the primers listed in Table 7.1, 
‘PatE-Intein-GLEA’ (Figure 7.9 D). 
 
The test peptide ‘CITAPITWPAYDGELEHHHHHH’ was created from a full length PatE 
based on the PatE2TEV construct. The full length PatE sequence was created by 
mutagenesis of PatE2TEV (section 4.2.1) using the primers listed in Table 7.1 and the 
PCR method described previously (Section 2.2.1). 
 
 
7.2.1.2 Expression and Purification 
 
Full length PatE-Intein was expressed from the pBMS23CHis plasmid in BL21 (DE3) E. 
coli cells grown in LB medium at 37 °C to an optical density at 600 nm (OD6oo) of 0.6. 
The cultures were then induced with 1 mM IPTG and grown for 24 hours at 37 °C. PatE-
Intein Small, Large and GLEA were expressed from the pBMS23CHis plasmid in BL21 
(DE3) E. coli cells grown in LB medium at 37 °C to an OD6oo of 0.6. The cultures were 
then induced with 0.5 mM IPTG and grown for three hours at 37 °C. All cells were 
harvested by centrifugation (4000 x g).  
 
Full length PatE-Intein was purified by re-suspending cell pellets in urea lysis buffer 
(Appendix A.12) which were then lysed by sonication at 15 microns (SoniPrep 150, 
MSE), cleared by centrifugation (40,000 x g, 4 °C, 20 min) and loaded onto a Ni-
Sepharose 6 FF column (GE Healthcare) equilibrated in urea lysis buffer. The column 
was washed with lysis buffer and the protein eluted with elution buffer. The protein 
was refolded by step dialysis from 8 M to 6 M, 4 M, 2 M, 1 M and final 0 M Urea Lysis 
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Buffer. Each step was carried out over four hours or overnight at 20 °C with the 
exception of the final step from 1 M to 0 M urea which occurred overnight at 4 °C.  
 
PatE-Intein Small, Large and GLEA were purified by re-suspending whole cells in lysis 
buffer (Appendix A.13). The cells were lysed by passage through a cell disruptor at 30 
kPSI (Constant Systems) and the lysate cleared by centrifugation (40,000 x g, 4 °C, 20 
min) and then loaded onto a Ni-Sepharose 6 FF column (GE Healthcare) equilibrated 
with lysis buffer. The column was washed with lysis buffer and the protein was eluted 
with elution buffer. The eluted fraction was subjected to size-exclusion 
chromatography (Superdex 75, GE Healthcare) in gel filtration buffer where the 
protein eluted as a single monomer peak. The samples were visualised by SDS-PAGE 
and their identity confirmed by MS. 
 
 
7.2.1.3 C-terminal Peptide Production 
 
The precursor PatE of the test peptide ‘CKITAPITWPAYDGELEHHHHHH’ was expressed 
and purified as for PatE2K (Chapter 4.2.2). The mature peptide was created by 
cleavage at the TEV protease recognition site using 1 mg TEV protease per 10 mg of 
PatE and incubated at room temperature for 4 hours. The cleaved protein was purified 
on a Superdex S30 column (GE Healthcare) in gel filtration buffer. The peak fractions 
were confirmed by MS and concentrated to 1 mM. 
 
Two synthetic peptides ‘CIS[Bpa]CAYDGE’ and ‘CKI[Thi]ACI[Hyp]APAYDG’ containing 
the unnatural amino acids Benzophenylalanine (Bpa), Thienylalanine (Thi) and 
Hydroxyproline (Hyp) were synthesised by the laboratory of Tom Muir (Princeton 
University) and purchased from Peptide Protein Research respectively (Figure 7.10). 
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Figure 7.10: Chemical Structures of Synthetic Peptides. Chemical structures of chemically synthesised 
peptides with amino acid sequences A) CIS[Bpa]CAYDGE and B) 
CKI[Thi]ACI[Hyp]APAYDG.  
 
 
7.2.1.4 Thiol-mediated Cleavage 
 
For full length PatE-Intein, PatE-Intein-Small and PatE-Intein-Large (Figure 7.9); thiol-
mediated cleavage was achieved by the addition of 200 mM MESNA (sodium 2-
sulfanylethanesulfonate) or MPAA (4-mercaptophenylacetic acid). The cleavage was 
carried out in the PatE-Intein gel filtration buffer and incubated at room temperature 
for 24 hours. Reactions were purified on a Superdex S30 column (GE Healthcare) and 
the identities of the thiol-activated PatE leader sequences were confirmed by MS. 
 
7.2.1.5 Peptide Ligation 
 
Ligation of PatE-Intein Small was abandoned after we showed that TruD could not 
process fully with such a small leader sequence [67]. It was, however, confirmed that 
TruD would process a leader sequence of the same size as PatE-Intein-Large. PatE-
Intein-Large was therefore prioritised for ligation reactions by incubating 50 µM PatE-
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Large-MESNA/MPAA with 100 µM C-terminal peptide in 10 mM HEPES pH 7.4, 150 mM 
NaCl, 5 mM TCEP for 48 hours at 37 °C 
 
7.2.1.6 One Step Thiol Cleavage/Peptide Ligation 
 
One step thiol cleavage and peptide ligation was carried out using PatE-intein-large 
and PatE-intein-GLEA with the various C-terminal peptides. This was achieved by 
incubating the PatE-Intein and C-terminal peptide each at a concentration of 100 µM 
in a buffer of 150 mM NaCl, 10 mM HEPES pH 7.4, 20 mM TCEP and 200 mM MPAA for 
24 hours at room temperature. The ligated peptide was purified on a Superdex S30 
column (GE Healthcare) in gel filtration buffer and its identity was confirmed by MS. 
 
7.2.1.7 In Vitro Processing 
 
The newly formed ligated peptides were processed by the heterocyclase TruD to 
assess activity. The peptide produced by ligation of PatE-Intein-GLEA and the C-
terminal peptide CKI[Thi]ACI[Hyp]APAYDG was subsequently treated with trypsin and 
the macrocyclase enzyme PatGmac to yield a macrocycle. These steps were achieved 
as per the protocol used for PatE2K outlined in Sections 4.2.4 – 4.2.6 
 
7.2.1.8 Mass Fragmentation 
 
The final macrocycle, containing unnatural amino acids, was subjected to LC-MSMS 
using an AB SCIEX Triple TOF 5600 system with the fragment peaks assigned to confirm 
the structure. This work was carried out by Dr. Sally Shirran (University of St Andrews). 
 
 
 
  
7. Unnatural Amino Acid Incorporation into Cyclic Peptides 
 182 
7.2.2 Results 
 
7.2.2.1 Expression and Purification 
 
Full length PatE-Intein was overexpressed with a C-terminal His6-tag in BL21 (DE3) E. 
coli cells. The protein was solubilised from inclusion bodies in urea lysis buffer, isolated 
by Ni-NTA chromatography and refolded using step dialysis into lysis buffer containing 
no urea. The final protein yield was 30 - 40 mg L -1 culture. 
 
PatE-Intein Small, Large and GLEA were overexpressed with a C-terminal His6-tag in 
BL21 (DE3) E. coli cells. The peptide was purified by Ni-NTA chromatography and elutes 
off gel filtration as a single peak (Figure 7.11 A). The final protein yield is 40 - 60 mg L -1 
culture. The purity of all proteins was determined by SDS-PAGE (Figure 7.11 B) 
 
 
Figure 7.11: Gel Filtration and SDS-PAGE Analysis of PatE-Intein. A) Gel filtration UV traces of PatE-
Intein-Small, PatE-Intein-Large and PatE-Intein-GLEA B) SDS-PAGE of: 1) Molecular 
Markers 2) PatE-Intein Full Length 3) PatE-Intein Small 4) PatE-Intein Large and 5) PatE-
Intein-GLEA. All protein samples are > 95 % pure.  
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7.2.2.2 C-terminal Peptide Production 
 
C-terminal peptides ‘CIS[Bpa]CAYDGE’ and ‘CKI[Thi]ACI[Hyp]APAYDG’ were synthesised 
and HPLC purified by collaborators/suppliers. 
 
The C-terminal peptide ‘CKITAPITWPAYDGELEHHHHHH’ was expressed as a PatE 
precursor overexpressed with a C-terminal His6-tag in BL21 (DE3) E. coli cells using the 
Studier auto-induction method [107]. The peptide was solubilised from inclusion 
bodies in urea lysis buffer, isolated by Ni-NTA chromatography and refolded using DTT. 
The peptide elutes off gel filtration as a single peak (Figure 7.12 A, B). The final protein 
yield is 50 mg L -1 culture. The mature peptide was isolated by cleavage with TEV 
protease and purified on a Superdex S30 with a single main peak corresponding to the 
cleaved peptide (Figure 7.12 C). A final mature peptide yield of 10 mg L -1 original 
culture was achieved and confirmed by MS (Figure 7.13). 
 
 
Figure 7.12: SDS-PAGE and Gel Filtration Analysis of CKITAPITWPAYDGELEHHHHHH. A) SDS-PAGE of 
purified PatE precursor peptide B) Superdex 75 gel filtration UV trace of the precursor 
PatE C) Superdex 30 gel filtration UV trace of the mature peptide. 
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Figure 7.13: MALDI MS of CKITAPITWPAYDGELEHHHHHH. MALDI-TOF-MS of the mature peptide 
CKITAPITWPAYDGELEHHHHHH derived from full length PatE (Expected M+H = 2729.4). 
 
7.2.2.3 Thiol-mediated Cleavage 
 
PatE-intein-Full Length, PatE-intein-Small and PatE-intein-Large were all subjected to 
thiol cleavage by MESNA and MPAA. The full length PatE variant precipitated 
immediately on addition of the thiol and so work on this was stopped. PatE-intein-
Small and PatE-intein-Large were cleaved from the intein portion yielding an activated 
PatE leader sequence. These samples were purified on a Superdex S30 column with 
great difficulty due to a lack of absorbing residues at Abs280nm. A small bump on the gel 
filtration trace (Figure 7.14) was determined by MS to be the activated peptide. 
 
 
Figure 7.14: Gel Filtration of PatE-Large-MESNA. Gel filtration UV trace of PatE-Intein-Large post 
treatment with MESNA. (A) Full trace (B) Zoom view (red box). The small bump at an 
elution volume of 65 ml (indicated by black arrow) corresponds to activated PatE-Large-
MESNA. The large peak in the trace is the excised intein protein. 
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MSMS was carried out on both PatE-Small-MESNA and PatE-Large-MESNA complexes 
which confirmed the presence of the MESNA group (Figure 7.15). 
 
 
Figure 7.15: MSMS of Activated PatE Constructs. MALDI TOF MSMS and amino acid peak assignment of 
A) PatE-Small-MESNA and B) PatE-Large-MESNA. 
 
At this stage work on PatE-small-MESNA was halted as it was discovered at the same 
time that TruD could not process efficiently using the small leader sequence. TruD 
could however process efficiently peptides containing the larger leader sequence of 
PatE-large-MESNA and so this was carried forward to peptide ligation trials. 
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7.2.2.4 Peptide Ligation 
 
PatE-Large-MESNA was incubated separately with two fold excess of the C-terminal 
peptide ‘CIS[Bpa]CAYDGE’ and incubated at 37 °C for 48 hours. The reaction mixture 
was analysed by MS to identify peptide ligation. Very small levels of ligation were 
evident (Figure 7.16) however there remained significant amounts of the starting 
material (as judged by MS). The reaction was left for one week. However, no further 
ligation was evident suggesting that the reaction conditions require optimisation.  
 
 
 
Figure 7.16: MS of Ligated PatE-Large-CIS[Bpa]CAYDGE Peptide. MALDI-MS analysis of the product 
from the ligation of PatE-Large-MESNA plus CIS[Bpa]CAYDGE synthetic peptide 
showing [M+H]
+
 of 3337.5 at very low intensity.  
 
 
7.2.2.5 One Step Thiol Cleavage / Peptide Ligation 
 
Ligation as a two-step process was very inefficient giving low yields of ligated peptide. 
In order to assess a one-step ligation, a C-terminal peptide 
CKITAPITWPAYDGELEHHHHHH was created using a variant of the full length PatETEV 
created in Section 4.2.1. The addition of 200 mM MPAA and 20 mM TCEP yielded the 
most efficient ligation when peptides were in a 1:1 ratio (Figure 7.17).  
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Figure 7.17: MALDI MS of PatE-Intein-GLEA Ligation with CKITAPITWPAYDGELEHHHHHH. MALDI TOF 
MS of the resultant ligated peptide PatE-GLEA-CKITAPITWPAYDGELEHHHHHH 
(Expected M+H
+
 = 4355.05). 
 
In order to demonstrate that this procedure could be carried out on more than one 
peptide and with varying lengths of PatE-Leader/C-terminal peptide. PatE-Intein-Large 
was reacted with the C-terminal peptide CIS[Bpa]CAYDGE and analysed by MALDI MS 
(Figure 7.18). PatE-Intein-GLEA was reacted with the C-terminal peptide 
CKI[Thi]ACI[Hyp]APAYDG and analysed by MALDI MS (Figure 7.19). In both cases the 
predominant MS peaks corresponded to ligated peptide. These samples were purified 
from the remaining intein portion and any non-ligated C-terminal peptide by passing 
over a Superdex 30 column. 
 
 
 
Figure 7.18: MALDI MS of PatE-Intein-Large Ligation with CIS[Bpa]CAYDGE. MALDI TOF MS of the 
resultant ligated peptide PatE-Large-CIS[Bpa]CAYDGE with [M+H]
+ 
and [M+Na]
+
 peaks 
observed. 
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Figure 7.19: MALDI MS of PatE-Intein-GLEA Ligation with CKI[Thi]ACI[Hyp]APAYDG. MALDI TOF MS of 
the resultant ligated peptide PatE-GLEA-CKIT[Thi]ACI[Hyp]APAYDG. 
 
 
7.2.2.6 In Vitro Processing 
 
The ligation of PatE-GLEA with CKITAPITWPAYDGELEHHHHHH was instrumental in 
determining the correct conditions for the ligation. This peptide however does not 
contain any cysteines for heterocyclase treatment by TruD, therefore the two other 
ligated peptides were explored. 
 
PatE-Large was ligated with CIS[Bpa]CAYDGE and treated with TruD overnight and then 
analysed by MALDI MS (Figure 7.20). The loss of 36 Da (corresponding to the loss of 
two waters) confirms that two thiazolines have been made from the cysteines and that 
the ligated peptide is an active substrate. Unfortunately, due to the Large Bpa amino 
acid in the 7th position of the core peptide, macrocyclisation of this sample would be 
challenging due to a steric clash with the PatGmac enzyme (See Section 3) and so this 
peptide was not taken further. 
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Figure 7.20: MALDI MS of PatE-Large-CIS[Bpa]CAYDGE and TruD. MALDI TOF MS of (A) the ligated 
peptide PatE-Large-CIS[Bpa]CAYDGE and (B) PatE-Large-CIS[Bpa]CAYDGE following 
TruD treatment. The loss of 36 Da corresponds to two water losses and the formation 
of two thiazoline heterocycles derived from the cysteine residues. 
 
The final ligated peptide, PatE-GLEA-CKI[Thi]ACI[Hyp]APAYDG was subjected to TruD 
treatment overnight and a single water loss was observed in MALDI MS (Figure 7.21). 
The heterocyclised peptide was purified and cleaved with trypsin (Figure 7.22) and 
then incubated with PatGmac for one week to yield the final macrocyclic compound 
(Figure 7.23).  
 
 
 
Figure 7.21: MALDI MS of PatE-GLEA-CKI[Thi]ACI[Hyp]APAYDG and TruD. MALDI TOF MS of the ligated 
peptide PatE-GLEA-CKI[Thi]ACI[Hyp]APAYDG following TruD treatment. The loss of 18 
Da corresponds to one water loss and the formation of a single heterocycle. 
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Figure 7.22: MALDI MS of Heterocyclised I[Thi]ACI[Hyp]APAYDG. MALDI TOF MS of heterocyclised 
PatE-GLEA-CKI[Thi]ACI[Hyp]APAYDG following trypsin treatment to remove the leader 
peptide. The mass corresponds only to the core peptide and C-terminal ‘AYDG’ 
recognition sequence.  
 
 
 
 
Figure 7.23: Chemical Structure of cyclo[I[Thi]AC
Thn
I[Hyp]AP]. Expected chemical structure of 
cyclo[I[Thi]AC
Thn
I[Hyp]AP] with the unnatural amino acids Thienylalanine and 
Hydroxproline highlighted in magenta.  
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7.2.2.7 Mass Fragmentation 
 
Mass fragmentation analysis of cyclo[I[Thi]ACThnI[Hyp]AP] was carried out by Dr Sally 
Shirran (Figure 7.24). The fragments were assigned based on the hypothesised 
structure and were confirmed to correspond to the expected macrocycle. 
 
 
 
 
Figure 7.24: LC/MS/MS of cyclo[I[Thi]AC
Thn
I[Hyp]AP]. LC/MS/MS spectrum of cyclo[I[Thi]AC
Thn
I[Hyp]AP] 
with structures assigned to the primary peaks.  
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7.2.3 Discussion 
 
Intein-mediated protein ligation offers a method of generating semi-synthetic libraries 
of peptides containing unnatural entities. Four PatE-Intein constructs have been 
developed using the Mxe GyrA intein (1txb, NEB) with varying lengths of PatE leader 
sequence. Two of these have been ruled out; small (leader residues 36-43) and full 
length. The small PatE-intein has limited heterocyclase processing and the full length 
precipitates upon thiol cleavage. The remaining two constructs PatE-Intein Large and 
PatE-Intein GLEA have leader sequences of size which have been shown previously to 
be processed efficiently by TruD [67] and it has been demonstrated that they can be 
ligated in a one-step reaction to chemically synthesised C-terminal peptides.   
 
The heterologously expressed C-terminal peptide CKITAPITWPAYDGELEHHHHHH was 
used as a model substrate to allow the intein ligation step to be optimised. This was 
important as we could generate large quantities of the peptide at relatively low costs 
compared to chemically synthesised C-terminal peptides. The presence of the His6-tag 
allows for efficient isolation and the incorporation of the tryptophan residue enables 
ligation efficiency to be monitored by UV280nm. We estimate that in our system the 
ligation efficiency was greater than 80 %. 
 
The optimised one step ligation reaction was carried out using PatE-Intein-Large with 
the C-terminal peptide CIT[Bpa]CAYDG and PatE-Intein-GLEA with the C-terminal 
peptide CKI[Thi]ACI[Hyp]APAYDG and the resultant ligated peptides were shown to be 
fully active substrates for the heterocyclase enzyme TruD. The former peptide at this 
stage was abandoned as the Bpa amino acid in the 7th core peptide position doesn’t 
macrocyclise due to the bulky nature of the side chain. The latter peptide was, 
however, taken through the rest of the in vitro process with cleavage by trypsin and 
finally macrocyclisation with PatGmac. The final macrocycle cyclo[I[Thi]ACThnI[Hyp]AP] 
was characterised by MSMS, confirming that the intein-mediated peptide ligation (IPL) 
method is amenable to creating unnatural amino acid containing macrocycles. This 
7. Unnatural Amino Acid Incorporation into Cyclic Peptides 
 193 
opens up a wide range of chemical space with the only restriction in the core peptide 
being a C-terminal heterocycle or proline residue. 
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7.3 pEVOL technology 
 
7.3.1 Materials and methods 
 
7.3.1.1 Construct Design and DNA Cloning 
 
A PatE precursor peptide was designed and cloned based upon the PatE2K sequence to 
generate a PatE with a core peptide of ITA[AmberStopCodon]ITAC using methods 
described in section 4.2.1 with the primers listed in Table 7.2 (Figure 7.25). 
 
 
Table 7.2: PatE Amber Stop Codon Primers: PCR primer sequences used to generate PatE containing 
amber stop in the core peptide sequence. 
 
 
Figure 7.25: Schematic of PatE Amber Stop. Schematic of the PatE Amber Stop construct created with X 
representing the position where the unnatural amino acid is incorporated in response 
to the amber codon. This construct was derived from PatE2K (Section 4.2.1) with a 
lysine for efficient N-terminal cleavage and C-terminal His6-tag for isolation. 
 
The pEVOL-pBpF plasmid (expressing p-benzoyl-L-phenylalanyl-tRNA synthetase and 
tRNA pair), used to load the amino acid p-benzoyl-L-phenylalanine in response to the 
amber stop codon ‘TAG’, was a gift from Peter Schultz (Scripps Research Institute, 
Addgene plasmid # 31190) [183]. 
 
  
5’PatE cttccatggacaaaaaaaacattcta 
3’PatEAmberStop cttctcgagttcgccatcatacgcgcacgcggtaatctacgcggtgatttta
gatgcttccaaaccagc 
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7.3.1.2 Expression and Purification 
 
The two plasmids PatE-Amber-Stop and pEVOL-pBpF were used to co-transform 
(selected using two antibiotics) BL21 (DE3) E. coli cells, which were then grown at 37 °C 
to an OD600nm of 0.6 where they were then induced with 1 mM IPTG (PatE induction), 
0.02% L-arabinose (pEVOL-pBpF induction) and the addition of 0.3 mM Bpa amino acid 
(0.3 M stock solubilised in 1 M NaOH). The culture was them grown overnight at 37 °C, 
200 rpm before harvesting by centrifugation. 
 
Cell pellets of PatE-Bpa were purified using the same refolding technique described 
previously for PatE2/PatE2K (Section 4.2.2). The protein was visualised by SDS-PAGE 
and Bpa incorporation was confirmed by MALDI-TOF-MS analysis. 
 
7.3.1.3 In Vitro Processing 
 
The PatE-Bpa peptide was processed in vitro using the same methods as outlined for 
PatE2K (Sections 4.2.4 - 4.2.6), with cysteine heterocyclisation by TruD, N-terminal 
cleavage with bovine trypsin and finally macrocyclisation with PatGmac. 
 
7.3.1.4 Mass Fragmentation 
 
The final macrocycle containing the Bpa amino acid was subjected to LC/MS/MS using 
an AB SCIEX Triple TOF 5600 instrument and the fragment peaks were assigned 
confirming the structure. This work was carried out by Dr. Sally Shirran (University of St 
Andrews). 
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7.3.2 Results 
 
7.3.2.1 Expression and Purification 
 
PatE2K(ITA[Bpa]ITAC) was expressed from the pBMSCHis plasmid in BL21 DE3 with the  
p-benzoyl-l-phenylalanine (Bpa) amino acid loaded using the pEVOL-pBpF tRNA 
synthase/tRNA pair plasmid.  The peptide was solubilised from inclusion bodies in 
denaturing buffers, isolated by Ni-NTA chromatography and refolded using DTT. The 
peptide elutes off gel filtration as a single peak with a final yield of 10 - 15 mg L-1 
culture (Figure 7.26 A, B). The peptide was analysed by MALDI-TOF-MS confirming 100 
% incorporation of the Bpa amino acid (Figure 7.26 C). 
 
 
Figure 7.26: Purification of Bpa-containing PatE. (A) SDS-PAGE analysis of Ni Elution showing F.T (with 
no PatE present) and elution with PatE. (B) Gel filtration UV spectra of PatE-Bpa (C) 
MALDI TOF MS of final purified PatE-Bpa showing full incorporation of the Bpa amino 
acid into the peptide. 
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7.3.2.2 In vitro Processing 
 
The purified PatE was treated with TruD in order to heterocyclise the cysteine of the 
core peptide as described previously (Section 4.2.4) and then purified from the 
enzyme. MALDI-MS confirmed the majority (> 90 %) was heterocyclised (Figure 7.27). 
The sample was then cleaved by trypsin and purified on a Superdex S30 column.  
  
 
Figure 7.27: MS of TruD-treated PatE-ITA[Bpa]ITAC. MS spectra for PatE-ITA[Bpa]ITAC post 
heterocyclisation by TruD. A mass loss of 18 Da [7043 M+H
+
] from starting material 
confirms the formation of a thiazoline from the single cysteine residue.   
 
The sample was then cleaved by trypsin, purified on a Superdex S30 column and then 
incubated for one week with PatGmac in order to form the corresponding macrocycle 
(Figures 7.28, 7.29).  
 
 
Figure 7.28: Chemical Structure of cyclo[ITA[Bpa]ITAC
Thn
]. Expected chemical structure of 
cyclo[ITA[Bpa]ITAC
Thn
] with the unnatural amino acid Benzophenylalanine highlighted 
in magenta.  
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Figure 7.29 – MALDI TOF MS of cyclo[ITA[Bpa]ITAC
Thn
]. MALDI-TOF-MS of cyclo[ITA[Bpa]ITAC
Thn
] with 
peaks of [M+H]
+
 at 907.4, [M+Na]
+
 at 929.4 and [M+K]
+
 = 947.4.  
 
7.3.2.3 Mass Fragmentation 
 
Mass fragmentation analysis of cyclo[ITA[Bpa]ITACThn] was carried out by Dr Sally 
Shirran (Figure 7.30). The fragments were assigned based on the hypothesised 
structure and were confirmed to correspond to the expected macrocycle. 
 
 
 
Figure 7.30: LC/MS/MS Analysis of Bpa-containing macrocycle. LC/MS/MS spectrum of 
cyclo[ITA[Bpa]ITAC
Thn
] with peaks assigned based on the chemical structure.  
  
7. Unnatural Amino Acid Incorporation into Cyclic Peptides 
 199 
7.3.3 Discussion 
 
It has been demonstrated that macrocyclic peptides containing an unnatural amino 
acid can be derived in vitro from precursor peptides created in vivo using the pEVOL 
amber stop codon system which directly incorporates the unnatural amino acid on to 
the precursor peptide.  
 
The co-expression of the pEVOL and pBMS plasmids containing aminoacyl-tRNA 
synthase/suppressor tRNA pairs and PatE-AmberStop genes, respectively, efficiently 
allows the incorporation in vivo of the pBpa amino acid into the core peptide of  PatE. 
The resulting PatE variant was then purified and processed in vitro using the same 
enzymes and processes as for native PatE peptides (Chapter 4). This approach offers a 
very flexible method of producing cyclic peptides with unnatural amino acids as only 
the initial in vivo expression of the PatE is modified. Alternate unnatural amino acids 
could be used by exchanging the pEVOL co-expression plasmid enabling a range of 
amino acids to be incorporated into PatE proteins.  
 
The main disadvantage of this technique is that the expression levels with pBpa are 
between 10 and 20 % of a native PatE and as such expression conditions may have to 
be further optimised to improve yields.  
 
 
 
 
  
7. Unnatural Amino Acid Incorporation into Cyclic Peptides 
 200 
7.4 Conclusions and Future Work 
 
Two methods have been presented which allow the generation of precursor peptides 
containing unnatural amino acids, which are further processed in vitro to yield the 
corresponding macrocycles. Each of the methods has its own advantages and 
disadvantages.  The intein method offers wide diversity in the final product as it can 
incorporate several different unnatural amino acids per macrocycle. However, it 
requires  the synthetic C-terminal peptide to be soluble in aqueous buffer (up to 10 % 
DMSO can be tolerated). The pEVOL system allows a straight substitution for the 
standard PatE expression system. However, unlike the intein approach, only a single 
unnatural amino acid type can be incorporated per PatE (although, it can be 
incorporated at multiple sites) and at present only a small selection of unnatural amino 
acid tRNA/synthase pairs are commercially available. It should be possible to use both 
techniques in a complementary fashion to create an array of macrocycles containing a 
wide range of unnatural amino acids. 
 
The ability to make unnatural amino acid-containing macrocycles has been 
demonstrated by MSMS analyses. To further confirm the structures of the products, 
we aim to scale up to levels which will allow NMR spectroscopic analysis to be run on 
the final products and their structures to be fully assigned. 
 
Since the development of these protocols, the Naismith laboratory has developed the 
heterocyclase LynD (a homologue of PatD capable of heterocyclising cysteine residues 
only) with the PatE leader fused directly to its N-terminus [78]. This LynD fusion 
protein heterocyclises chemically synthesised peptides efficiently without the 
requirement of the leader sequence. While this new enzyme may reduce the 
requirement for the intein and pEVOL approaches, it is always important to have 
multiple approaches to a problem and the experience of using these techniques 
developed in this project could facilitate their use in other applications.  
  
8. Bibliography 
 201 
8. Bibliography 
 
[1]  F. P. Tally and M. F. DeBruin, "Development of daptomycin for Gram-positive 
infections," J. Antimicrob. Chemother., vol. 46, no. 4, pp. 523-526, 2000.  
[2]  L.-J. Ball, C. M. Goult, J. A. Donarski, J. Micklefield and V. Ramesh, "NMR 
structure determination and calcium binding effects of lipopeptide antibiotic 
daptomycin," Org. Biomol. Chem., vol. 2, pp. 1872-1878, 2004.  
[3]  A. R. Hamel, F. Huber, A. Carrupt, R. M. Wenger and M. Mutter, "Cyclosporin A 
prodrugs: design, synthesis and biophysical properties," J. Peptide Res., vol. 63, 
pp. 147-154, 2004.  
[4]  L. C. Sun and D. H. Coy, "Somatostatin receptor-targeted anti-cancer therapy," 
Curr. Drug Deliv., vol. 8, pp. 2-10, 2011.  
[5]  H. Ma, B. Zhou, Y. Kim and K. D. Janda, "A cyclic peptide-polymer probe for the 
detection of Clostridium botulinum neurotoxin serotype A," Toxicon, vol. 47, pp. 
901-8, 2006.  
[6]  P. Wipf, "Synthetic Studies of Biologically Active Marine Cyclopeptides," Chem. 
Rev., vol. 95, pp. 2115-2134, 1995.  
[7]  T. Ishida, H. Ohishi, M. Inoue, M. Kamigauchi, M. Sugiura, N. Takao, S. Kato, Y. 
Hamada and T. Shioiri, "Conformational properties of ulithiacyclamide, a strongly 
cytotoxic cyclic peptide from a marine tunicate, determined by 1H nuclear 
magnetic resonance and energy minimization calculations," J. Org. Chem., vol. 
54, pp. 5337-5343, 1989.  
[8]  C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, "Experimental and 
computational approaches to estimate solubility and permeability in drug 
discovery and development settings," Adv. Drug Deliv. Rev., vol. 46, pp. 3-26, 
2001.  
[9]  A. T. Bockus, C. M. McEwen and R. S. Lokey, "Form and function in cyclic Peptide 
natural products: a pharmacokinetic perspective," Curr. Top. Med. Chem., vol. 
13, pp. 821-836, 2013.  
[10]  A. Ehrlich, H.-U. Heyne, R. Winter, M. Beyermann, H. Haber, L. A. Carpino and M. 
Bienert, "Cyclization of all-L-Pentapeptides by Means of 1-Hydroxy-7-
azabenzotriazole-Derived Uronium and Phosphonium Reagents," J. Org. Chem., 
vol. 61, pp. 8831-8838, 1996.  
[11]  L. Zhang and J. P. Tam, "Synthesis and Application of Unprotected Cyclic Peptides 
as Building Blocks for Peptide Dendrimers," J. Am. Chem. Soc., vol. 119, pp. 2363-
2370, 1997.  
[12]  C. T. Wong, D. K. Rowlands, C.-H. Wong, T. W. C. Lo, G. K. T. Nguyen, H.-Y. Li and 
J. P. Tam, "Orally active peptidic bradykinin B1 receptor antagonists," Angew. 
Chem. Int. Ed., vol. 51, pp. 5620-5624, 2012.  
[13]  P. Hoogerhout, W. Kamphuis, H. F. Brugghe, J. A. Sluijs, H. A. Timmermans, J. 
8. Bibliography 
 202 
Westdijk, G. Zomer, C. J. Boog, E. M. Hol and G. P. van den Dobbelsteen, "A cyclic 
undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits 
antibodies against oligomeric and fibrillar amyloid and plaques," PLoS One, vol. 6, 
p. e19110, 2011.  
[14]  G. F. Gause and M. G. Brazhnikova, "Gramicidin S and its use in the treatment of 
infected wounds," Nature, vol. 154, p. 703, 1944.  
[15]  J. W. Blunt, B. R. Copp, R. A. Keyzers and M. H. G. Munro, "Marine natural 
products," Nat. Prod. Rep., vol. 29, pp. 144-222, 2012.  
[16]  P. A. Arnison, M. J. Bibb, G. Bierbaum, A. A. Bowers, T. S. Bugni, G. Bulaj, J. A. 
Camarero, D. J. Campopiano, G. L. Challis, J. Clardy, P. D. Cotter, D. J. Craik, M. 
Dawson, E. Dittmann, S. Donadio, P. C. Dorrestein, K.-D. Entian, M. A. Fischbach, 
J. S. Garavelli, U. Goransson, C. W. Gruber, D. H. Haft, T. K. Hemscheidt, C. 
Hertweck, C. Hill, A. R. Horswill, M. Jaspars, W. L. Kelly, J. P. Klinman, O. P. 
Kuipers, A. J. Link, W. Liu, M. A. Marahiel, D. A. Mitchell, G. N. Moll, B. S. Moore, 
R. Muller, S. K. Nair, I. F. Nes, G. E. Norris, B. M. Olivera, H. Onaka, M. L. Patchett, 
J. Piel, M. J. T. Reaney, S. Rebuffat, R. P. Ross, H.-G. Sahl, E. W. Schmidt, M. E. 
Selsted, K. Severinov, B. Shen, K. Sivonen, L. Smith, T. Stein, R. D. Sussmuth, J. R. 
Tagg, G.-L. Tang, A. W. Truman, J. C. Vederas, C. T. Walsh, J. D. Walton, S. C. 
Wenzel, J. M. Willey and W. A. van der Donk, "Ribosomally synthesized and post-
translationally modified peptide natural products: overview and 
recommendations for a universal nomenclature," Nat. Prod. Rep., vol. 30, pp. 
108-160, 2013.  
[17]  P. J. Knerr and W. A. van der Donk, "Discovery, biosynthesis, and engineering of 
lantipeptides," Annu. Rev. Biochem., vol. 81, pp. 479-505, 2012.  
[18]  J. M. Waisvisz, M. G. van der Hoeven, J. van Peppen and W. C. M. Zwennis, 
"Bottromycin. I. a new sulfur-containing antibiotic," J. Am. Chem. Soc., vol. 79, 
pp. 4520-4521, 1957.  
[19]  S. Duquesne, D. Destoumieux-Garzon, J. Peduzzi and S. Rebuffat, "Microcins, 
gene-encoded antibacterial peptides from enterobacteria," Nat. Prod. Rep., vol. 
24, pp. 708-34, 2007.  
[20]  J. O. Melby, M. J. Nard and D. A. Mitchell, "Thiazole/oxazole-modified microcins: 
complex natural products from ribosomal templates," Curr. Opin. Chem. Biol., 
vol. 15, pp. 369-378, 2011.  
[21]  J. D. Walton, H. E. Hallen-Adams and H. Luo, "Ribosomal biosynthesis of the 
cyclic peptide toxins of Amanita mushrooms," Biopolymers, vol. 94, pp. 659-664, 
2010.  
[22]  K. Sivonen, N. Leikoski, D. P. Fewer and J. Jokela, "Cyanobactins-ribosomal cyclic 
peptides produced by cyanobacteria," Appl. Microbiol. Biotechnol., vol. 86, pp. 
1213-1225, 2010.  
[23]  D. J. Craik, N. L. Daly, T. Bond and C. Waine, "Plant cyclotides: A unique family of 
cyclic and knotted proteins that defines the cyclic cystine knot structural motif," 
J. Mol. Biol., vol. 294, pp. 1327-1336, 1999.  
[24]  J. Lubelski, R. Rink, R. Khusainov, G. N. Moll and O. P. Kuipers, "Biosynthesis, 
8. Bibliography 
 203 
immunity, regulation, mode of action and engineering of the model lantibiotic 
nisin," Cell. Mol. Life Sci., vol. 65, pp. 455-476, 2008.  
[25]  K. R. Gustafson, T. C. McKee and H. R. Bokesch, "Anti-HIV cyclotides," Curr. 
Protein. Pep. Sci., vol. 5, pp. 331-340, 2004.  
[26]  B. Kaylon, S. E. Helaly, R. Scholz, J. Nachtigall, J. Vater, R. Borriss and R. D. 
Sussmuth, "Plantazolicin A and B: structure elucidation of ribosomally 
synthesized thiazole/oxazole peptides from Bacillus amyloliquefaciens FZB42," 
Org. Lett., vol. 13, pp. 2996-2999, 2011.  
[27]  "Structure determination and interception of biosynthetic intermediates for the 
Plantazolicin class of highly discriminating antibiotics," ACS Chem. Biol., vol. 6, 
pp. 1307-1313, 2011.  
[28]  H. Shimamura, H. Gouda, K. Nagai, T. Hirose, M. Ichioka, Y. Furuya, Y. Kobayashi, 
S. Hirono, T. Sunazuka and S. Omura, "Structure determination and total 
synthesis of Bottromycin A2: a potent antibiotic against MRSA and VRE," Angew. 
Chem. Int. Ed., vol. 48, pp. 914-917, 2009.  
[29]  T. Wieland, H. Faulstich and L. Fiume, "Amatoxins, Phallotoxins, Phallolysin, and 
Antamanide: The biologically active components of poisonous Amanita 
mushroom".  
[30]  M. A. Ortega, Y. Hao, Q. Zhang, M. C. Walker, W. A. van der Donk and S. K. Nair, 
"Structure and mechanism of the tRNA-dependent lantibiotic dehydratase NisB," 
Nature, vol. 517, pp. 509-512, 2015.  
[31]  A. Karakas-Sen, A. Narbad, N. Horn, H. M. Dodd, A. J. Parr, I. Colquhoun and M. J. 
Gasson, "Post-translational modification of nisin. The involvement of NisB in the 
dehydration process," Eur. J. Biochem., vol. 261, pp. 524-532, 1999.  
[32]  N. Garg, L. M. Salazar-Ocampo and W. A. van der Donk, "In vitro activity of the 
nisin dehydratase NisB," Proc. Natl. Acad. Sci. USA, vol. 110, pp. 7258-7263, 
2013.  
[33]  Schrodinger, LLC, "The PyMOL Molecular Graphics System," Version 1.5.0.4. 
[34]  N. Leikoski, D. P. Fewer, J. Jokela, M. Wahlsten, L. Rouhiainen and K. Sivonen, 
"Highly Diverse Cyanobactins in Strains of the Genus Anabaena," Appl. Environ. 
Microbiol., vol. 76, pp. 701-709, 2010.  
[35]  M. S. Donia and E. W. Schmidt, "Linking chemistry and genetics in the growning 
cyanobactin natural products family," Chem. Biol., vol. 18, pp. 508-519, 2011.  
[36]  R. Banker and S. Carmeli, "Tenuecyclamides A-D, cyclic hexapeptides from the 
cyanobacterium Nostoc spongiaeforme var. tenue," J. Nat. Prod., vol. 61, pp. 
1248-51, 1998.  
[37]  S. Sudek, M. G. Haygood, D. T. Youssef and E. W. Schmidt, "Structure of 
trichamide, a cyclic peptide from the bloom-forming cyanobacterium 
Trichodesmium erythraeum, predicted from the genome sequence," Appl. 
Environ. Microbiol., vol. 72, pp. 4382-4387, 2006.  
[38]  A. R. Carroll, J. C. Coll, D. J. Bourne, J. K. Macleod, T. M. Zabriskie, C. M. Ireland 
and B. F. Bowden, "Patellins 1-6 and Trunkamide A: Novel Cyclic Hexa-, Hepta- 
8. Bibliography 
 204 
and Octa-peptides From Colonial Ascidians, Lissoclinum sp.," Aus. J. Chem., vol. 
49, pp. 659-667, 1996.  
[39]  C. Ireland and P. J. Scheuer, "Ulicyclamide and ulithiacyclamide, two new small 
peptides from a marine tunicate," J. Am. Chem. Soc., vol. 102, pp. 5688-5691, 
1980.  
[40]  C. M. Ireland, A. R. Durso Jr, R. A. Newman and M. P. Hacker, "Antineoplastic 
cyclic peptides from the marine tunicate lissoclinum patella," J. Org. Chem., vol. 
47, pp. 1807-1811, 1982.  
[41]  K. Kohda, Y. Ohta, Y. Yokoyama, Y. Kawazoe, T. Kato, Y. Suzumura, Y. Hamada 
and T. Shioiri, "Mechanistic aspects of the cytocidal action of ulithiacyclamide on 
mouse leukemia L1210 cells in vitro," Biochem. Pharmacol., vol. 38, pp. 4497-
4500, 1989.  
[42]  B. M. Degnan, C. J. Hawkins, M. F. Lavin, E. J. McCaffrey, D. L. Parry, A. L. van den 
Brenk and D. J. Watters, "New cyclic peptides with cytotoxic activity from the 
ascidian lissoclinum patella," J. Med. Chem., vol. 32, pp. 1349-1354, 1989.  
[43]  X. Salvatella, J. M. Caba, F. Albericio and E. Giralt, "Solution structure of the 
antitumor candidate trunkamide A by 2D NMR and restrained simulated 
annealing methods," J. Org. Chem., vol. 24, pp. 211-215, 2003.  
[44]  R. G. Linington, J. Gonzalez, L. D. Urena, L. I. Romero, E. Ortega-Barria and W. H. 
Gerwick, "Venturamides A and B: antimalarial constituents of the panamanian 
marine Cyanobacterium Oscillatoria sp.," J. Nat. Prod, vol. 70, pp. 397-401, 2007.  
[45]  J. Ogino, R. E. Moore, G. M. Patterson and C. D. Smith, "Dendroamides, new 
cyclic hexapeptides from a blue-green alga. Multidrug-resistance reversing 
activity of dendroamide A," J. Nat. Prod., vol. 59, pp. 581-586, 1996.  
[46]  S. F. Brady, L. Simmons, J. H. Kim and E. W. Schmidt, "Metagenomic approaches 
to natural products from free-living and symbiotic organisms," Nat. Prod. Rep., 
vol. 26, pp. 1488-1503, 2009.  
[47]  E. W. Schmidt, J. T. Nelson, D. A. Rasko, S. Sudek, J. A. Eisen, M. G. Haygood and 
J. Ravel, "Patellamide A and C biosynthesis by a microcin-like pathway in 
Prochloron didemni, the cyanobacterial symbiont of lissoclinum patella," Proc. 
Natl. Acad. Sci. USA, vol. 17, pp. 7315-7320, 2005.  
[48]  T. S. Bibby, J. Nield, M. Chen, A. W. D. Larkum and J. Barber, "Structure of a 
photosystem II supercomplex isolated from Prochloron didemni retaining its 
chlorophyll a/b light-harvesting system," Proc. Natl. Acad. Sci. USA, vol. 100, pp. 
9050-9054, 2003.  
[49]  W. E. Houssen and M. Jaspars, "Azole-Based Cyclic Peptides from the Sea Squirt 
Lissoclinum Patella: Old Scaffolds, New Avenues," ChemBioChem, vol. 11, pp. 
1803-1815, 2010.  
[50]  F. J. Schmitz, M. B. Ksebati, C. J. L. Wang, M. B. Hossain and D. van der Helm, 
"Cyclic peptides from the ascidian Lissoclinum patella: conformational analysis of 
patellamide D by X-ray analysis and molecular modeling," J. Org. Chem., vol. 54, 
pp. 3463-3472, 1989.  
[51]  L. A. McDonald and C. M. Ireland, "Patellamide E: a New Cyclic Peptide from the 
8. Bibliography 
 205 
Ascidian Lissoclinum patella," J. Nat. Prod., vol. 55, pp. 376-379, 1992.  
[52]  M. A. Rashid, K. R. Gustafson, J. H. Cardellina II and M. R. Boyd, "Patellamide F, a 
New Cytotoxic Cyclic Peptide from the Colonial Ascidian Lissoclinum patella," J. 
Nat. Prod., vol. 58, pp. 594-597, 1995.  
[53]  X. Fu, T. Do, F. J. Schmitz, V. Andrusevich and M. H. Engel, "New Cyclic Peptides 
from the Ascidian Lissoclinum patella," J. Nat. Prod., vol. 61, pp. 1547-1551, 
1998.  
[54]  C. J. Hawkins, M. F. Lavin, K. A. Marshall, A. L. van den Brenk and D. J. Watters, 
"Structure-activity relationships of the lissoclinamides: cytotoxic cyclic peptides 
from the ascidian Lissoclinum patella," J. Med. Chem., vol. 33, pp. 1634-1638, 
1990.  
[55]  A. B. Williams and R. S. Jacobs, "A marine natural product, patellamide D, 
reverses multidrug resistance in a human leukemic cell line," Cancer Lett., vol. 
71, pp. 97-102, 1993.  
[56]  G. Szakacs, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe and M. M. Gottesman, 
"Targeting multidrug resistance in cancer," Nat. Rev. Drug Discov., vol. 5, pp. 
219-234, 2006.  
[57]  S. G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P. M. Harrell, Y. T. 
Trinh, Q. Zhang, I. L. Urbatsch and G. Chang, "Structure of P-glycoprotein Reveals 
a Molecular Basis for Poly-Specific Drug Binding," Science, vol. 323, pp. 1718-
1722, 2009.  
[58]  J. Li, K. F. Jaimes and S. G. Aller, "Refined structures of mouse P-glycoprotein," 
Protein Sci., vol. 23, pp. 34-36, 2014.  
[59]  P. Garcia-Reynaga and M. S. VanNieuwenhze, "A new total synthesis of 
patellamide A," Organic Letters, vol. 10, pp. 4621-4623, 2008.  
[60]  S.-L. You, H. Razavi and J. W. Kelly, "A Biomimetic Synthesis of Thiazolines Using 
Hexaphenyloxodiphosphonium Trifluoromethanesulfonate," Angew. Chem. Int. 
Ed., vol. 42, pp. 83-85, 2003.  
[61]  M. S. Donia, B. J. Hathaway, S. Sudek, M. G. Haygood, M. J. Rosovitz, J. Ravel and 
E. W. Schmidt, "Natural combinatorial peptide libraries in cyanobacterial 
symbionts of marine ascidians," Nat. Chem. Biol., vol. 2, pp. 729-735, 2006.  
[62]  M. S. Donia, J. Ravel and E. W. Schmidt, "A global assembly line for 
cyanobactins," Nat. Chem. Biol., vol. 4, pp. 341-343, 2008.  
[63]  J. Lee, J. McIntosh, B. J. Hathaway and E. W. Schmidt, "Using Marine Natural 
Products to Discover a Protease that Catalyzes Peptide Macrocyclization of 
Diverse Substrates," J. Am. Chem. Soc., vol. 131, pp. 2122-2124, 2009.  
[64]  J. A. McIntosh, M. S. Donia and E. W. Schmidt, "Insights into Heterocyclization 
from Two Highly Similar Enzymes," J. Am. Chem. Soc., vol. 132, pp. 4089-4091, 
2010.  
[65]  J. A. McIntosh, M. S. Donia, S. K. Nair and E. W. Schmidt, "Enzymatic Basis of 
Ribosomal Peptide Prenylation in Cyanobacteria," J. Am. Chem. Soc., vol. 133, pp. 
13698-13705, 2011.  
8. Bibliography 
 206 
[66]  V. Agarwal, E. Pierce, J. McIntosh, E. W. Schmidt and S. K. Nair, "Structures of 
cyanobactin maturation enzymes define a family of transamidating proteases," 
Chem. Biol., vol. 19, pp. 1411-1422, 2012.  
[67]  J. Koehnke, A. F. Bent, D. Zollman, K. Smith, W. E. Houssen, X. Zhu, G. Mann, T. 
Lebl, R. Scharff, S. Shirran, C. H. Botting, M. Jaspars, U. Schwarz-Linek and J. H. 
Naismith, "The cyanobactin heterocyclase enzyme: a processive adenylase that 
operates with a defined order of reaction," Angewandte Chemie, vol. 52, pp. 
13991-13996, 2013.  
[68]  Y. Goto, Y. Ito, Y. Kato, T. Tsunoda and H. Suga, "One-pot synthesis of azoline-
containing peptides in a cell-free translation system integrated with a 
posttranslational cyclodehydratase," Chemistry & Biology, vol. 21, pp. 766-744, 
2014.  
[69]  W. E. Houssen, A. F. Bent, A. R. McEwan, N. Pieiller, J. Tabudravu, J. Koehnke, G. 
Mann, R. I. Adaba, L. Thomas, U. W. Hawas, H. Liu, U. Schawrz-Linek, M. C. Smith, 
J. H. Naismith and M. Jaspars, "An efficient method for the in vitro production of 
azol(in)e-based cyclic peptides," Angewandte Chemie, vol. 126, pp. 14395-14398, 
2014.  
[70]  C. A. Regni, R. F. Roush, D. J. Miller, A. Nourse, C. T. Walsh and B. A. Schulman, 
"How the MccB bacterial ancestor of ubiquitin E1 initiates biosynthesis of the 
microcin C7 antibiotic," EMBO, vol. 28, pp. 1953-1964, 2009.  
[71]  J. Wang and Y. Chen, "Role of the Zn2+ motif of E1 in SUMO adenylation," J. Biol. 
Chem., vol. 285, pp. 23732-23738, 2010.  
[72]  M. A. Larkin, G. Blackshields, N. P. Brown, R. Chenna, P. A. McGettigan, H. 
McWilliam, F. Valentin, I. M. Wallace, A. Wilm, R. Lopez, J. D. Thompson, T. J. 
Gibson and D. G. Higgins, "Clustal W and Clustal X version 2.0," Bioinformatics, 
vol. 23, pp. 2947-2948, 2007.  
[73]  F. Sievers, A. Wilm, D. Dineen, T. J. Gibson, K. Karplus, W. Li, R. Lopez, H. 
McWililam, M. Remmert, J. Soding, J. D. Thompson and D. G. Higgins, "Fast, 
scalable generation of high-quality protein multiple sequence alignments using 
Clustal Omega," Molecular Systems Biology, vol. 7, p. 539, 2011.  
[74]  C. S. Bond and A. W. Schuttelkopf, "ALINE: a WYSIWYG protein-sequence 
alignment editor for publication-quality alignments," Acta Cryst., vol. D65, pp. 
510-512, 2009.  
[75]  W. E. Houssen, S. H. Wright, A. P. Kalverda, G. S. Thompson, S. M. Kelly and M. 
Jaspars, "Solution structure of the leader sequence of the patellamide precursor 
peptide, PatE1-34," ChemBioChem, vol. 11, pp. 1867-1873, 2010.  
[76]  R. S. Roy, S. Kim, J. D. Beleja and C. T. Walsh, "Role of the microcin B17 
propeptide in substrate recognition: solution structure and mutational analysis 
of McbA1−26," Chemistry & Biology, vol. 5, pp. 217-228, 1998.  
[77]  Y.-M. Li, J. C. Milne, L. L. Madison, R. Kolter and C. T. Walsh, "From Peptide 
Precursors to Oxazole and Thiazole-Containing Peptide Antibiotics: Microcin B17 
Synthase," Science, vol. 274, pp. 1188-1193, 1996.  
[78]  J. Koehnke, G. Mann, A. F. Bent, H. Ludewig, S. Shirran, C. Botting, T. Lebl, W. E. 
8. Bibliography 
 207 
Houssen, M. Jaspars and J. H. Naismith, "Structural analysis of leader peptide 
binding enables leader-free cyanobactin processing," Nat. Chem. Biol., vol. 11, 
pp. 558-563, 2015.  
[79]  J. A. McIntosh and E. W. Schmidt, "Marine molecular machines: heterocyclization 
in cyanobactin biosynthesis," ChemBioChem, vol. 11, pp. 1413-1421, 2010.  
[80]  K. L. Dunbar, J. O. Melby and D. A. Mitchell, "YcaO domains use ATP to activate 
amide backbones during peptide cyclodehydrations," Nat. Chem. Biol., vol. 8, pp. 
569-575, 2012.  
[81]  K. L. Dunbar and D. A. Mitchell, "Insights into the Mechanism of Peptide 
Cyclodehydrations Achieved," J. Am. Chem. Soc., vol. 135, pp. 8692-8701, 2013.  
[82]  K. L. Dunbar, J. R. Chekan, C. L. Cox, B. J. Burkhart, S. K. Nair and D. A. Mitchell, 
"Discovery of a new ATP-binding motif involved in peptidic azoline biosynthesis," 
Nat. Chem. Biol., vol. 10, pp. 823-829, 2014.  
[83]  K. L. Dunbar, J. I. Tietz, C. L. Cox, B. J. Burkhart and D. A. Mitchell, "Identification 
of an Auxiliary Leader Peptide-Binding Protein," J. Am. Chem. Soc., vol. 137, pp. 
7672-7677, 2015.  
[84]  R. J. Siezen, B. Renckens and J. Boekhorst, "Evolution of prokaryotic subtilases: 
Genome-wide analysis reveals novel subfamilies with different catalytic 
residues," Proteins: Structure, Function & Bioinformatics, vol. 67, pp. 681-694, 
2007.  
[85]  G. Dodson and A. Wlodawer, "Catalytic triads and their relatives," Trends in 
Biochem. Sci., vol. 23, pp. 347-352, 1998.  
[86]  J. M. Berg, J. L. Tymoczko and L. Stryer, Biochemistry, 5th ed., New York: W.H. 
Freeman and Co., 2002.  
[87]  W. E. Houssen, J. Koehnke, D. Zollman, J. Vendome, A. Raab, M. C. Smith, J. H. 
Naismith and M. Jaspars, "The discovery of new cyanobactins from Cyanothece 
PCC 7425 defines a new signature for processing of patellamides," 
ChemBioChem, vol. 21, pp. 2683-2689, 2012.  
[88]  J. A. McIntosh, C. R. Roberston, V. Agarwal, S. K. Nair, G. W. Bulaj and E. W. 
Schmidt, "Circular Logic: Nonribosomal Peptide-like Macrocyclization with a 
Ribosomal Peptide Catalyst," J. Am. Chem. Soc., vol. 132, pp. 15499-15501, 2010.  
[89]  J. W. Trauger, R. M. Kohli, H. D. Mootz, M. A. Marahiel and C. T. Walsh, "Peptide 
cyclization catalysed by the thioesterase domain of tyrocidine synthetase," 
Nature, vol. 407, pp. 215-218, 2000.  
[90]  D. E. Cane and C. T. Walsh, "The parallel and convergent universes of polyketide 
synthases and nonribosomal peptide synthetases," Chemistry & Biology, vol. 6, 
pp. R319-R325, 1999.  
[91]  C. J. S. Barber, P. T. Pujara, D. W. Reed, S. Chiwocha, H. Zhang and P. S. Covello, 
"The two-step biosynthesis of cyclic peptides from linear precursors in a member 
of the plant family caryophyllaceae involves cyclisation by a serine protease-like 
enzyme," J. Biol. Chem., vol. 288, pp. 12500-12510, 2013.  
[92]  H. Luo, S.-Y. Hong, R. M. Sgambelluri, E. Angelos, X. Li and J. D. Walton, "Peptide 
8. Bibliography 
 208 
macrocyclization catalyzed by a prolyl oligopeptidase involved in α-amanitin 
biosynthesis," Chemistry & Biology, vol. 21, pp. 1610-1617, 2014.  
[93]  G. K. T. Nguyen, S. Wang, Y. Qiu, X. Hemu, Y. Lian and J. P. Tam, "Butelase 1 is an 
Asx-specific ligase enabling peptide macrocyclization and synthesis," Nat. Chem. 
Biol., vol. 10, pp. 732-738, 2014.  
[94]  B. F. Milne, P. F. Long, A. Starcevic, D. Hranueli and M. Jaspars, "Spontaneity in 
the patellamide biosynthetic pathway," Org. Biomol. Chem., vol. 4, pp. 631-638, 
2006.  
[95]  G. Mann, J. Koehnke, A. F. Bent, R. Graham, W. E. Houssen, M. Jaspars and J. H. 
Naismith, "Structural studies of the cyanobactin DUF domains," Acta. Cryst., vol. 
F70, pp. 1597-1603, 2014.  
[96]  J. O. Melby, K. L. Dunbar, N. Q. Trinh and D. A. Mitchell, "Selectivity, 
Directionality and Promiscuity in Peptide Processing from a Bacillus sp. Al Hakam 
Cyclodehydratase," J. Am. Chem. Soc., vol. 134, pp. 5309-5316, 2012.  
[97]  T. L. Schneider, B. Shen and C. T. Walsh, "Oxidase Domains in Epothilone and 
Bleomycin Biosynthesis:  Thiazoline to Thiazole Oxidation during Chain 
Elongation," Biochemistry, vol. 42, pp. 9722-9730, 2003.  
[98]  P. J. Casey and M. C. Seabra, "Protein prenyltransferases," J. Biol. Chem., vol. 
271, pp. 5289-5292, 1996.  
[99]  N. Leikoski, D. P. Fewer, J. Jokela, P. Alakoski, M. Wahlsten and K. Sivonen, 
"Analysis of an inactive cyanobactin biosynthetic gene cluster leads to discovery 
of new natural products from strains of the genus Microcystis," PLoS One, vol. 7, 
pp. 1-9, 2012.  
[100] F. L. Zhang and P. J. Casey, "Protein Prenylation: Molecular Mechanisms and 
Functional Consequences," Ann. Rev. Biochem., vol. 65, pp. 241-269, 1996.  
[101] S. A. Holstein and R. A. Hohl, "Isoprenoids: remarkable diversity of form and 
function," Lipids, vol. 39, pp. 293-309, 2004.  
[102] J. A. McIntosh, Z. Lin, M. D. B. Tianero and E. W. Schmidt, "Aestuaramides, a 
natural library of cyanobactin cyclic peptides resulting from isoprene-derived 
Claisen rearrangements," ACS Chem. Biol., vol. 8, pp. 877-883, 2013.  
[103] M. D. B. Tianero, M. S. Donia, T. S. Young, P. G. Schultz and E. W. Schmidt, 
"Ribosomal Route to Small-Molecule Diversity," J. Am. Chem. Soc., vol. 134, pp. 
418-425, 2012.  
[104] J. D. Majmudar and R. A. Gibbs, "Pericyclic prenylation: peptide modification 
through a Claisen rearrangement," ChemBioChem, vol. 12, pp. 2723-2726, 2011.  
[105] S. Zhang, G. Zubay and E. Goldman, "Low-usage codons in Escherichia coli, yeast, 
fruit fly and primates," Gene, vol. 105, pp. 61-72, 1991.  
[106] H. Liu and J. H. Naismith, "An efficient one-step site-directed deletion, insertion, 
single and multiple-site plasmid mutagenesis protocol," BMC Biotechnol., vol. 8, 
pp. 1-10, 2008.  
[107] F. W. Studier, "Protein production by auto-induction in high density shaking 
cultures," Protein Expression & Purification, vol. 41, pp. 207-234, 2005.  
8. Bibliography 
 209 
[108] J. Jancarik and S.-H. Kim, "Sparse matrix sampling: a screening method for 
crystallization of proteins," J. Appl. Cryst., vol. 24, pp. 409-411, 1991.  
[109] A. McPherson, C. Nguyen, R. Cudney and S. B. Larson, "The Role of Small 
Molecule Additives and Chemical Modification in Protein Crystallization," Cryst. 
Growth Des., vol. 11, pp. 1469-1474, 2011.  
[110] G. Winter, "xia2: an expert system for macromolecular crystallography data 
reduction," J. Appl. Cryst., vol. 43, pp. 186-190, 2010.  
[111] W. Kabsch, "XDS," Acta Cryst., vol. D66, pp. 125-132, 2010.  
[112] P. Evans, "Scaling and assessment of data quality," Acta Cryst., vol. D62, pp. 72-
82, 2006.  
[113] G. M. Sheldrick, "Experimental phasing with SHELXC/D/E: combining chain 
tracing with density modification," Acta Cryst., vol. D66, pp. 479-485, 2010.  
[114] G. M. Sheldrick, "A short history of SHELX," Acta Cryst., vol. A64, pp. 112-122, 
2007.  
[115] P. D. Adams, P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J. 
Headd, L.-W. Jung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. 
Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. 
Terwilliger and P. H. Zwart, "PHENIX: a comprehensive Python-based system for 
macromolecular structure solution," Acta Cryst., vol. D66, pp. 213-221, 2010.  
[116] P. Emsley, B. Lohkamp, W. G. Scott and K. Cowtan, "Features and Development 
of Coot," Acta Cryst., vol. D66, pp. 486-501, 2010.  
[117] G. N. Murshudov, A. A. Vagin and E. J. Dodson, "Refinement of Macromolecular 
Structures by the Maximum-Likelihood Method," Acta Cryst., vol. D53, pp. 240-
255, 1997.  
[118] M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. 
Keegan, E. B. Krissinel, A. G. W. Leslie, A. McCoy, S. J. McNicholas, G. N. 
Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin and K. 
S. Wilson, "Overview of the CCP4 suite and current developments," Acta Cryst., 
vol. D67, pp. 235-242, 2011.  
[119] E. Krissinel and K. Henrick, "Inference of Macromolecular Assemblies from 
Crystalline State," J. Mol. Biol., vol. 372, pp. 774-797, 2007.  
[120] E. Krissinel, "Crystal contacts as nature's docking solutions," J. Comput. Chem., 
vol. 31, pp. 133-143, 2010.  
[121] J. Painter and E. A. Merritt, "Optimal description of a protein structure in terms 
of multiple groups undergoing TLS motion," Acta Cryst., vol. D62, pp. 439-450, 
2006.  
[122] J. Painter and E. A. Merritt, "TLSMD web server for the generation of multi-group 
TLS models," J. Appl. Cryst., vol. 39, pp. 109-111, 2006.  
[123] M. D. Winn, M. N. Isupov and G. N. Murshudov, "Use of TLS parameters to model 
anisotropic displacements in macromolecular refinement," Acta Cryst., vol. D57, 
pp. 122-133, 2001.  
[124] V. B. Chen, W. B. Arendall III, J. J. Headd, D. A. Keedy, R. M. Immormino, G. J. 
8. Bibliography 
 210 
Kapral, L. W. Murray, J. S. Richardson and D. C. Richardson, "MolProbity: all-atom 
structure validation for macromolecular crystallography," Acta Cryst., vol. D66, 
pp. 12-21, 2010.  
[125] L. A. Kelley and M. J. Sternberg, "Protein structure prediction on the web: a case 
study using the Phyre server," Nat. Protoc., vol. 4, pp. 363-371, 2009.  
[126] H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. 
Shindyalov and P. E. Bourne, "The Protein Data Bank," Nucl. Acids Res., vol. 28, 
pp. 235-242, 2000.  
[127] R. B. Kapust, J. Tozser, T. D. Copeland and D. S. Waugh, "The P1' specificity of 
tobacco etch virus protease," Biochem. Biophys., vol. 294, pp. 949-955, 2002.  
[128] N. Chayen, "Turning protein crystallisation from an art into a science," Curr. Opin. 
Struc. Biol., vol. 14, pp. 577-583, 2004.  
[129] G. L. Taylor, "Introduction to phasing," Acta Cryst., vol. D66, pp. 325-338, 2010.  
[130] E. E. Lattman and P. J. Loll, Protein crystallography; a concise guide, John Hopkins 
University Press, 2008.  
[131] G. Rhodes, Crystallography made clear, 3rd Edt., Academic Press, 2006.  
[132] H. Walden, "Selenium incorporation using recombination techniques," Acta 
Cryst., vol. D66, pp. 352-357, 2010.  
[133] P. D. Sun, S. Radaev and M. Kattah, "Generating isomorphous heavy-atom 
derivatives by a quick-soak method. Part I: test cases," Acta Cryst., vol. D58, pp. 
1092-1098, 2002.  
[134] B. W. Matthews, "Solvent content of protein crystals," J. Mol. Biol., vol. 33, pp. 
491-497, 1968.  
[135] T. Pape and T. R. Schneider, "HKL2MAP: a graphical user interface for 
macromolecular phasing with SHELX programs," J. Appl. Crystallogr., vol. 37, pp. 
843-844, 2004.  
[136] D. W. Banner, A. Bloomer, G. A. Petsko, D. C. Philliips and I. A. Wilson, "Atomic 
coordinates for triose phosphate isomerase from chicken muscle," Biochem. 
Biophys. Res. Commun., vol. 72, pp. 146-155, 1976.  
[137] A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni and 
R. J. Read, "Phaser crystallographic software," J. Appl. Cryst., vol. 40, pp. 658-
674, 2007.  
[138] E. Potterton, S. McNicholas, E. Krissinel, K. Cowtan and M. Noble, "The CCP4 
molecular-graphics project," Acta Cryst., vol. D58, pp. 1955-1957, 2002.  
[139] L. Potterton, S. McNicholas, E. Krissinel, J. Gruber, K. Cowtan, P. Emsley, G. N. 
Murshudov, S. Cohen, A. Perrakis and M. Noble, "Developments in the CCP4 
molecular-graphics project," Acta Cryst., vol. D60, pp. 2288-2294, 2004.  
[140] U. Metzger, C. Schall, G. Zocher, I. Unsold, E. Stec, S. M. Li, L. Heide and T. Stehle, 
"The structure of dimethylallyl tryptophan synthase reveals a common 
architecture of aromatic prenyltransferases in fungi and bacteria," Proc. Natl. 
Acad. Sci. USA, vol. 106, pp. 14309-14314, 2009.  
[141] J. Koehnke, A. Bent, W. E. Houssen, D. Zollman, F. Morawitz, S. Shirran, J. 
8. Bibliography 
 211 
Vendome, A. F. Nneoyiegbe, L. Trembleau, C. H. Botting, M. C. Smith, M. Jaspars 
and J. H. Naismith, "The machanism of patellamide macrocyclization revealed by 
the characterization of the PatG macrocyclase domain," Nat. Struct. Mol. Biol., 
vol. 19, pp. 767-772, 2012.  
[142] C. A. Smith, H. S. Toogood, H. M. Baker, R. M. Daniel and E. N. Baker, "Calcium-
mediated thermostability in the subtilisin superfamily: the crystal structure of 
Bacillus Ak.1 protease at 1.8 Å resolution," J. Mol. Biol., vol. 294, pp. 1027-1040, 
1999.  
[143] H. Liu and J. H. Naismith, "A simple and efficient expression and purification 
system using two newly constructed vectors," Protein Expr. Purif., vol. 63, pp. 
102-111, 2009.  
[144] R. A. Laskowski and M. B. Swindells, "LigPlot+: multiple ligand-protein interaction 
diagrams for drug discovery," J. Chem. Inf. Model., vol. 51, pp. 2778-2786, 2011.  
[145] G. Ramachandran and V. Sasisekharan, "Conformation of polypeptides and 
proteins," Adv. Protein. Chem, vol. 23, pp. 283-438, 1968.  
[146] D. E. Stewart, A. Sarkar and J. E. Wampler, "Occurence and role of cis peptide 
bonds in protein structures," J. Mol. Biol., vol. 214, pp. 253-260, 1990.  
[147] J. Koehnke, A. F. Bent, W. E. Houssen, G. Mann, M. Jaspars and J. H. Naismith, 
"The structural biology of patellamide biosynthesis," Current Opinion in 
Structural Biology, vol. 29, pp. 112-121, 2014.  
[148] A. C. Braisted, J. K. Judice and J. A. Wells, "Synthesis of proteins by subtiligase," 
Methods Enzymol., vol. 289, pp. 298-313, 1997.  
[149] T. K. Chang, D. Y. Jackson, J. P. Burnier and J. A. Wells, "Subtiligase: a tool for 
semisynthesis of proteins," Proc. Natl. Acad. Sci. USA, vol. 91, pp. 12544-12548, 
1994.  
[150] D. Y. Jackson, J. P. Burnier and J. A. Wells, "Enzymic cyclization of linear peptide 
esters using subtiligase," J. Am. Chem. Soc., vol. 117, pp. 819-820, 1995.  
[151] S. H. Joo, "Cyclic peptides as therapeutic agents and biochemical tools," Biomol. 
Ther. (Seoul)., vol. 20, pp. 19-26, 2012.  
[152] U. Schreiber, R. Gademann, P. J. Ralph and A. W. D. Larkum, "Assessment of 
photosynthetic performance of prochloron in Lissoclinum patella in hospite by 
chlorophyll fluorescence measurements," Plant Cell Physiol., vol. 38, pp. 945-
951, 1997.  
[153] E. J. Kim, D. C. Love, E. Darout, M. Abdo, B. Rempel, S. G. Withers, P. R. Rablen, J. 
A. Hanover and S. Knapp, "OGA inhibition by GlcNAc-selenazoline," Bioorg. Med. 
Chem., vol. 18, pp. 7058-7064, 2010.  
[154] A. Bodtke, M. Kandt, W.-D. Pfeiffer and P. Langer, "Synthesis of 4-Aryl-2-imino-
2H-selenazolines by a Reaction of α α-(Selenocyanato)acetophenones With 
Anilines," Phosphorus, Sulfur, and Silicon and the Related Elements, vol. 182, pp. 
209-217, 2007.  
[155] M. Koketsu, H. Tanaka and H. Ishihara, "A Facile Preparation of 2-Amino-1,3-
selenazoles by Reactions of N,N-Unsubstituted Selenoureas with 
8. Bibliography 
 212 
Chloroacetonitrile," Chemistry Letters, vol. 34, pp. 1260-1261, 2005.  
[156] H. Tao, Y. Weng, R. Zhuo, G. Chang, I. L. Urbatsch and Q. Zhang, "Design and 
Synthesis of Selenazole-Containing Peptides for Cocrystallization with P-
Glycoprotein," ChemBioChem, vol. 12, pp. 868-873, 2011.  
[157] P. S. Salgado, J. D. Taylor, E. Cota and S. J. Matthews, "Extending the usability of 
the phasing power of diselenide bonds: SeCys," Acta Cryst., vol. D67, pp. 8-13, 
2011.  
[158] F. W. Studier and B. A. Moffat, "Use of bacteriophage T7 RNA polymerase to 
direct selective high-level expression of cloned genes," J. Mol. Biol., vol. 189, pp. 
113-130, 1986.  
[159] D. E. Kim, D. Chivian and D. Baker, "Protein structure prediction and analysis 
using the Robetta server," Nucleic Acids Res., vol. 32, pp. W526-W531, 2004.  
[160] T. S. Young, I. Ahmad, J. A. Yin and P. G. Schultz, "An enhanced system for 
unnatural amino acid mutagenesis in E. coli," J. Mol. Biol., vol. 395, pp. 361-374, 
2010.  
[161] Y. Ryu and P. G. Schultz, "Efficient incorporation of unnatural amino acids into 
proteins in Escherichia coli," Nature Methods, vol. 3, pp. 263-265, 2006.  
[162] C. Cuevas and A. Francesch, "Development of Yondelis® (trabectedin, ET-743). A 
semisynthetic process solves the supply problem," Nat. Prod. Rep., vol. 26, pp. 
322-337, 2009.  
[163] C. Cuevas, M. Perez, M. J. Martin, J. L. Chicharro, C. Fernandez-Rivas, M. Flores, 
A. Francesch, P. Gallego, M. Zarzuelo, F. de la Calle, J. Garcia, C. Polanco, I. 
Rodriguez and I. Manzanares, "Synthesis of Ecteinascidin ET-743 and 
Phthalascidin Pt-650 from Cyanosafracin B," Org. Lett., vol. 2, pp. 2545-2548, 
2000.  
[164] M. Schnolzer and S. B. Kent, "Constructing proteins by dovetailing unprotected 
synthetic peptides: backbone-engineered HIV protease," Science, vol. 256, pp. 
221-225, 1992.  
[165] P. M. Kane, C. T. Yamashiro, D. F. Wolczyk, N. Neff, M. Goebl and T. H. Stevens, 
"Protein splicing converts the yeast TFP1 gene product to the 69-kD subunit of 
the vacuolar H(+)-adenosine triphosphatase," Science, vol. 250, pp. 651-657, 
1990.  
[166] S. Elleuche and S. Poggeler, "Inteins, valuable genetic elements in molecular 
biology and biotechnology," Appl. Microbiol. Biotechnol., vol. 87, pp. 479-489, 
2010.  
[167] F. B. Perler, E. O. Davis, G. E. Dean, F. S. Gimble, W. E. Jack, N. Neff, C. J. Noren, J. 
Thorner and M. Belfort, "Protein splicing elements: inteins and exteins--a 
definition of terms and recommended nomenclature," Nucleic Acids Res., vol. 22, 
pp. 1125-1127, 1994.  
[168] S. Chong, F. B. Mersha, D. G. Comb, M. E. Scott, D. Landry, L. M. Vence, F. B. 
Perler, J. Benner, R. B. Kucera, C. A. Hirvonen, J. J. Pelletier, H. Paulus and M.-Q. 
Xu, "Single-column purification of free recombinant proteins using a self-
cleavable affinity tag derived from a protein splicing element," Gene, vol. 192, 
8. Bibliography 
 213 
pp. 271-281, 1997.  
[169] T. C. Evans, J. Benner and M.-Q. Xu, "Semisynthesis of cytotoxic proteins using a 
modified protein splicing element," Protein Sci., vol. 7, pp. 2256-2264, 1998.  
[170] T. W. Muir, D. Sondhi and P. A. Cole, "Expressed protein ligation: A general 
method for protein engineering," Proc. Natl. Acad. Sci. USA, vol. 95, pp. 6705-
6710, 1998.  
[171] H. Sancheti and J. A. Camarero, ""Splicing up" drug discovery. Cell-based 
expression and screening of genetically-encoded libraries of backbone-cyclized 
polypeptides," Adv. Drug Deliv. Rev., vol. 61, pp. 908-917, 2009.  
[172] M.-Q. Xu and T. C. Evans, "Intein-Mediated Ligation and Cyclization of Expressed 
Proteins," Methods, vol. 24, pp. 257-277, 2001.  
[173] J. Normanly, L. G. Kleina, J.-M. Masson, J. Abelson and J. H. Miller, "Construction 
of escherichia coli amber suppressor tRNA genes," J. Mol. Biol., vol. 213, pp. 719-
726, 1990.  
[174] L. Wang, T. J. Magliery, D. R. Liu and P. G. Schultz, "A new functional suppressor 
tRNA/aminoacyl−tRNA synthetase pair for the in vivo incorpora on of unnatural 
amino acids into proteins," J. Am. Chem. Soc., vol. 122, pp. 5010-5011, 2000.  
[175] L. Wang, J. Xie and P. G. Schultz, "Expanding the genetic code," Annu. Rev. 
Biophys. Biomol. Struct., vol. 35, pp. 225-249, 2006.  
[176] M. Z. Lin and L. Wang, "Selective labeling of proteins with chemical probes in 
living cells," Physiology, vol. 23, pp. 131-141, 2008.  
[177] C. C. Liu and P. G. Schultz, "Adding new chemistries to the genetic code," Annu. 
Rev. Biochem., vol. 79, pp. 413-444, 2010.  
[178] J. Wang, J. Xie and P. G. Schultz, "A genetically encoded fluorescent amino acid," 
J. Am. Chem. Soc., vol. 128, pp. 8738-8739, 2006.  
[179] N. Hino, Y. Okazaki, A. Kobayashi, K. Sakamoto and S. Yokoyama, "Protein photo-
cross-linking in mammalian cells by site-specific incorporation of a photoreactive 
amino acid," Nat. Methods, vol. 2, pp. 201-206, 2005.  
[180] M. R. Fleissner, E. M. Brustad, T. Kalai, C. Altenbach, D. Cascio, F. B. Peters, K. 
Hideg, S. Peuker, P. G. Schultz and W. L. Hubbell, "Site-directed spin labeling of a 
genetically encoded unnatural amino acid," Proc. Natl. Acad. Sci. USA, vol. 106, 
pp. 21637-21642, 2009.  
[181] R. Xu, S. R. Hanson, Z. Zhang, Y. Y. Yang, P. G. Schultz and C. H. Wong, "Site-
specific incorporation of the mucin-type N-acetylgalactosamine-alpha-O-
threonine into protein in Escherichia coli," J. Am. Chem. Soc., vol. 126, pp. 15654-
15655, 2004.  
[182] J. Xie, L. Wang, N. Wu, A. Brock, G. Spraggon and P. G. Schultz, "The site-specific 
incorporation of p-iodo-L-phenylalanine into proteins for structure 
determination," Nat. Biotechnol., vol. 22, pp. 1297-1301, 2004.  
[183] J. W. Chin, A. B. Martin, D. S. King, L. Wang and P. G. Schultz, "Addition of a 
photocrosslinking amino acid to the genetic code of Escherichia coli," Proc. Natl. 
Acad. Sci. USA, vol. 99, pp. 11020-11024, 2002.  
8. Bibliography 
 214 
[184] M. W. Southworth, K. Amaya, T. C. Evans, M.-Q. Xu and F. B. Perler, "Purification 
of proteins fused to either the amino or carboxy terminus of the Mycobacterium 
xenopi gyrase A intein," Biotechniques, vol. 27, pp. 110-120, 1999.  
[185] A. Telenti, M. Southworth, F. Alcaide, S. Daugelat, W. R. Jacobs Jr and F. B. Perler, 
"The Mycobacterium xenopi GyrA protein splicing element: characterization of a 
minimal intein," J. Bacteriol., vol. 179, pp. 6378-6382, 1997.  
 
 
 
9. Appendices 
 215 
9. Appendices 
 
Appendix A. Media and Buffer Compositions 
 
A. 1 PatF 
 
Auto-Induction Medium ZY (10 g N-Z-amine AS, 5 g yeast extract, 925 ml H2O / 
litre culture) media supplemented with 1 mM MgSO4, 0.5 
% glycerol, 0.05 % glucose, 0.2 % -lactose, 25 mM 
(NH4)2SO4, 50 mM KH2PO4, 50 mM Na2HPO4     
Minimal Medium  19 mM NH4Cl, 22 mM KH2PO4, 22 mM Na2HPO4, 9 mM 
NaCl 
Lysis buffer 150 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 0.1 % Triton X-100, 3 mM BME  
Elution Buffer 150 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 0.1 % Triton X-100, 3 mM BME 
Desalt/Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP, 10 % 
glycerol. 
 
A. 2 LynF 
 
Auto-Induction Medium ZY (10 g N-Z-amine AS, 5 g yeast extract, 925 ml H2O / 
litre culture) media supplemented with 1 mM MgSO4, 0.5 
% glycerol, 0.05 % glucose, 0.2 % -lactose, 25 mM 
(NH4)2SO4, 50 mM KH2PO4, 50 mM Na2HPO4     
Lysis Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 3 mM BME  
Elution Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 3 mM BME 
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Desalt Buffer 150 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole pH 
8.0, 3 mM BME. 
Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP. 
 
A.3 PatGmac 
 
Auto-Induction Medium ZY (10 g N-Z-amine AS, 5 g yeast extract, 925 ml H2O) 
media supplemented with 1 mM MgSO4, 0.5 % glycerol, 
0.05 % glucose, 0.2 % -lactose, 25 mM (NH4)2SO4, 50 mM 
KH2PO4, 50 mM Na2HPO4.     
Lysis Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole  
 pH 8.0, 3 mM BME 
Elution Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM  
 imidazole pH 8.0, 3 mM BME  
Desalt Buffer  100 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 3 mM BME 
Mono-Q Buffer A  20 mM Tris-HCl pH 8.0, 3 mM BME  
Mono-Q Buffer B  1 M NaCl, 20 mM Tris-HCl pH 8.0, 3 mM BME 
Gel Filtration Buffer  150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
 
A.4 PatE 
 
Auto-Induction Medium ZY (10 g N-Z-amine AS, 5 g yeast extract, 925 ml H2O) 
media supplemented with 1 mM MgSO4, 0.5 % glycerol, 
0.05 % glucose, 0.2 % -lactose, 25 mM (NH4)2SO4, 50 mM 
KH2PO4, 50 mM Na2HPO4.     
Lysis Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 3 mM BME, 8 M Urea 
Elution Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 3 mM BME, 8 M Urea 
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Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
 
A.5 TruD 
 
Auto-Induction Medium ZY (10 g N-Z-amine AS, 5 g yeast extract, 925 ml H2O) 
media supplemented with 1 mM MgSO4, 0.5 % glycerol, 
0.05 % glucose, 0.2 % -lactose, 25 mM (NH4)2SO4, 50 
mM KH2PO4, 50 mM Na2HPO4.     
Lysis Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 3 mM BME 
Elution Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 3 mM BME 
Desalt Buffer 100 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 3 mM BME 
Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
 
A.6 PatApr 
 
Auto-Induction Medium ZY (10 g N-Z-amine AS, 5 g yeast extract, 925 ml H2O) 
media supplemented with 1 mM MgSO4, 0.5 % glycerol, 
0.05 % glucose, 0.2 % -lactose, 25 mM (NH4)2SO4, 50 
mM KH2PO4, 50 mM Na2HPO4.     
Lysis Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 3 mM BME 
Elution Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 3 mM BME 
Desalt Buffer 100 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 3 mM BME 
Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
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A.7 PatD 
 
Auto-Induction Medium ZY (10 g N-Z-amine AS, 5 g yeast extract, 925 ml H2O) 
media supplemented with 1 mM MgSO4, 0.5 % glycerol, 
0.05 % glucose, 0.2 % -lactose, 25 mM (NH4)2SO4, 50 
mM KH2PO4, 50 mM Na2HPO4.     
Lysis Buffer 500 mM NaCl, 20 mM Bis-Tris pH 6.8, 20 mM imidazole 
pH 8.0, 3 mM BME 
Elution Buffer 500 mM NaCl, 20 mM Bis-Tris pH 6.8, 250 mM imidazole 
pH 8.0, 3 mM BME 
Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
 
A.8 PatE SeCys 
 
Minimal Medium 19 mM NH4Cl, 22 mM KH2PO4, 22 mM Na2HPO4, 9mM 
NaCl 
Lysis Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 3 mM BME, 8 M Urea 
Elution Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 3 mM BME, 8 M Urea 
Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
 
Amino Acid Mixture for Selenocysteine Growth per 1 L SeCys Media: 
1.6 g  serine 
1 g leucine 
0.4 g  alanine, glutamate, glutamine, arginine, glycine 
0.25 g  aspartate 
0.1 g  lysine, threonine, phenylalanine, asparagine, histidine, proline, 
tyrosine, tryptophan, methionine 
0.05 g  isoleucine and valine  
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A.9 PatGox 
 
Lysis Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 3 mM BME 
Elution Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 3mM BME 
Capto-Q Buffer A 100 mM NaCl, 20 mM Tris-HCl pH 8.0, 3 mM BME  
Capto-Q Buffer B 1M NaCl, 20 mM Tris-HCl pH 8.0, 3 mM BME 
Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
 
A.10 PatGox Homologues (including ArtGox and CyaGox (PCC7425)) 
 
Auto-Induction Medium ZY (10 g N-Z-amine AS, 5 g yeast extract, 925 ml H2O) 
media supplemented with 1 mM MgSO4, 0.5 % glycerol, 
0.05 % glucose, 0.2 % -lactose, 25 mM (NH4)2SO4, 50 mM 
KH2PO4, 50 mM Na2HPO4, 50 µM FMN.     
Lysis Buffer 150 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 50 µM FMN, 3 mM BME 
Elution Buffer 150 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 50 µM FMN, 3 mM BME 
Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
 
 
A.11 Fourteen Buffer Screen 
 
For each lysis buffer, the equivalent elution buffer is the same with the exception of 
250 mM imidazole rather than 20 mM. 
 
Lysis Buffer 1:  150 mM NaCl, 20 mM Bis-Tris pH 6.8, 20 mM imidazole 
pH 8.0, 3 mM BME 
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Lysis Buffer 2:   150 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole  
pH 8.0, 3 mM BME 
Lysis Buffer 3: 500 mM NaCl, 20 mM Bis-Tris pH 6.8, 20 mM imidazole  
pH 8.0, 3 mM BME 
Lysis Buffer 4:   500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole  
pH 8.0, 3 mM BME 
Lysis Buffer 5:   150 mM NaCl, 20 mM Bis-Tris pH 6.8, 20 mM imidazole  
pH 8.0, 3 mM BME 
Lysis Buffer 6:   150 mM NaCl, 20 mM Tris-HCl pH 8.0, 0.1M arginine, 20  
mM imidazole pH 8.0, 3 mM BME 
Lysis Buffer 7:   150 mM NaCl, 20 mM Bis-Tris pH 6.8, 0.1M glycine, 20  
mM imidazole pH 8.0, 3 mM BME 
Lysis Buffer 8:   150 mM NaCl, 20 mM Tris-HCl pH 8.0, 0.1M glycine, 20  
mM imidazole pH 8.0, 3 mM BME 
Lysis Buffer 9:   150 mM NaCl, 20 mM Bis-Tris pH 6.8, 0.1 % NP-40, 20  
mM imidazole pH 8.0, 3 mM BME 
Lysis Buffer 10:  150 mM NaCl, 20 mM Tris-HCl pH 8.0, 0.1 % Triton X- 
100, 20 mM imidazole pH 8.0, 3 mM BME 
Lysis Buffer 11:  150 mM NaCl, 20 mM Bis-Tris pH 6.8, 0.1 % Triton X- 
100, 20 mM imidazole pH 8.0, 3 mM BME 
Lysis Buffer 12:  150 mM NaCl, 20 mM Tris-HCl pH 8.0, 0.1 % NP-40, 20  
mM imidazole pH 8.0, 3 mM BME 
Lysis Buffer 13:  150 mM NaCl, 20 mM Bis-Tris pH 6.8, 0.1 % -OG, 20  
mM imidazole pH 8.0, 3 mM BME 
Lysis Buffer 14:  150 mM NaCl, 20 mM Tris-HCl pH 8.0, 0.1 % -OG, 20  
mM imidazole pH 8.0, 3 mM BME 
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A.12 Full Length PatE - Intein  
 
Lysis Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 8 M Urea 
Elution Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 8 M Urea 
Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
Cleavage Buffer:  150 mM NaCl, 10 mM HEPES pH 7.4, 10 mM TCEP, 200 
mM MESNA/MPAA 
 
 
A.13 PatE – Intein (Small, Large, GLEA) 
 
Lysis Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole 
pH 8.0, 
Elution Buffer 500 mM NaCl, 20 mM Tris-HCl pH 8.0, 250 mM imidazole 
pH 8.0, 
Gel Filtration Buffer 150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP 
Cleavage Buffer:  150 mM NaCl, 10 mM HEPES pH 7.4, 10 mM TCEP, 200 
mM MESNA/MPAA 
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Appendix B. Sequence Alignment of Members of the PatF Family 
 
Figure B: Sequence Alignment of Members of the PatF Family. Absolutely conserved residues are 
shown in black. Secondary structure elements for PatF highlighted above (alpha helices – 
red, beta strands – yellow). Potential DMAPP binding residues are indicated by stars.  
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Appendix C. Sequence Alignment of Members of the PatG Macrocyclase Family 
 
 
 
Figure C: Sequence Alignment of Members of the PatG Macrocyclase Family. Secondary structure 
elements are shown in red (alpha helices) and yellow (beta strands). Active site residues 
are indicated by yellow stars, residues blocking the S3 and S4 sites as blue diamonds, 
lysines forming salt-bridges with the substrate as purple circles and His and Phe residues 
involved in substrate binding are marked by a magenta box. 
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Appendix D. Mass spectrometry data for in vitro derived cyclic compounds. 
 
 
Figure D.1: Mass Fragmentation of cyclo[VT
Oxn
VC
Thn
VT
Oxn
VC
Thn
].  
 
 
 
Figure D.2: Mass Fragmentation of cyclo[VTVC
Thn
VTVC
Thn
]. 
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Figure D.3: Mass Fragmentation of cyclo[IT
Oxn
AC
Thn
IT
Oxn
YC
Thn
].  
 
 
 
 Figure D.4: Mass Fragmentation of cyclo[ITAC
Thn
ITYC
Thn
].  
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Figure D.5: Mass Fragmentation of cyclo[IMAC
Thn
IMAC
Thn
].  
 
 
 
 
 
Figure D.6: Mass Fragmentation of cyclo[IDAC
Thn
IDFC
Thn
].  
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Figure D.7: Mass Fragmentation of cyclo[IITAC
Thn
IMAC
Thn
].  
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Figure D.8: MALDI-MS of in vitro Derived Cyclic Peptides. A) cyclo[VT
Oxn
VC
Thn
VT
Oxn
VC
Thn
], B) 
cyclo[VTVC
Thn
VTVC
Thn
], C) cyclo[IT
Oxn
AC
Thn
IT
Oxn
YC
Thn
], D) cyclo[IMAC
Thn
IMAC
Thn
]., E) 
cyclo[ITAC
Thn
ITAC
Thn
], F) cyclo[ATAC
Thn
ITAC
Thn
], G) cyclo[ITAC
Thn
ISFC
Thn
], H) 
cyclo[IC
Thn
AC
Thn
ITFC
Thn
], I) cyclo[IAAC
Thn
ITFC
Thn
] and J) cyclo[ITAAITFC
Thn
]. 
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Figure D.9: MALDI-MS of in vitro Derived Cyclic Peptides. A) cyclo[IITAC
Thn
IMAC
Thn
], B) 
cyclo[IC
Thn
FPT
Oxn
IC
Thn
] and C) cyclo[IT
Oxn
VC
Thn
IS
Oxn
VC
Thn
] 
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Appendix E. Stochastic Crystallisation Screen Composition Tables. 
 
E.1 Stochastic Screen 18 
- generated in-house  
 
No. Condition 
1 27.8 % PEG8000, 0.03 M Zinc chloride 
2 0.1 M HEPES pH 7.5, 26.4 % PEG6000, 0.09 M Calcium acetate, 1.91 % Ethylene glycol 
3 0.1 M Tris pH 8.0, 20.0 % PEGMME5000, 0.06 M Sodium chloride 
4 0.1 M Sodium citrate pH 5.0, 1.0 M Sodium citrate 
5 0.1 M Sodium cacodylate pH 7.0, 16.3 % PEG10000, 0.05 M Sodium potassium phosphate 
6 38.9 % PEG1500, 0.08 M Zinc acetate 
7 0.1 M HEPES pH 7.5, 52.8 % PEG400, 0.09 M Sodium bromide, 0.4 % Methanol 
8 0.1 M MES pH 6.0, 22.5 % PEGMME5000, 0.08 M Zinc acetate, 0.9 % Methanol 
9 25.5 % PEG3350, 0.03 M Zinc chloride 
10 0.1 M Tris pH 8.5, 31.8 % PEGMME2000, 0.09 M Calcium acetate 
11 0.1 M Sodium citrate pH 5.5, 1.8 M Sodium formate, 0.28 M Magnesium formate 
12 0.1 M Sodium acetate pH 5.0, 2.3 M Sodium chloride, 0.11 M Potassium thiocyanate, 3.5 % 
PEGMME350 
13 0.1 M CHES pH 9.5, 27.2 % PEG6000, 0.29 M Sodium chloride 
14 0.1 M Tris pH 8.0, 2.8 M Sodium malonate 
15 0.1 M Bicine pH 9.0, 51.6 % MPD 
16 24.5 % PEGMME2000, 0.09 M Sodium potassium tartrate 
17 0.1 M MOPS pH 6.5, 2.8 M Sodium acetate 
18 0.1 M Sodium citrate pH 5.0, 20.0 % Ethanol, 0.16 M Lithium chloride, 1.6 % PEG400 
19 0.1 M Bicine pH 8.5, 14.0 % PEG4000, 2.5 % PEGDME250 
20 0.1 M MES pH 6.5, 2.3 M Ammonium phosphate, 1.7 % Butanediol 
21 0.1 M Tris pH 8.5, 12.8 % Isopropanol, 0.11 M Calcium chloride 
22 0.1 M Tris pH 7.5, 2.0 M Sodium malate 
23 0.1 M Sodium acetate pH 5.5, 0.90 M Sodium citrate 
24 0.1 M Bicine pH 9.0, 44.0 % PEGMME550, 0.13 M Ammonium citrate 
25 0.1 M Bicine pH 9.5, 11.6 % PEG10000, 0.04 M Ammonium tartrate 
26 1.8 M Sodium potassium phosphate, 0.2 M Ammonium phosphate 
27 0.1 M Sodium acetate pH 5.0, 1.4 M Magnesium sulfate, 0.09 M Sodium citrate 
28 0.1 M MOPS pH 6.5, 2.1 M Sodium malate, 2.4 % PEG400 
29 0.1 M MOPS pH 7.0, 28.2 % PEG3350, 0.07 M Sodium citrate 
30 1.1 M Sodium tartrate, 0.13 M Ammonium citrate, 3.7 mM BME 
31 0.1 M Sodium acetate pH 4.5, 18.1 % PEGMME5000, 0.1 M Calcium chloride, 0.06 % LDAO 
32 0.1 M MES pH 6.0, 34.8 % PEG1500, 0.25 M Lithium sulfate 
33 17.1 % PEG4000, 0.09 M Zinc chloride 
34 0.1 M Bicine pH 9.0, 1.1 M Magnesium sulfate 
35 0.1 M CHES pH 9.0, 39.6 % PEG400, 0.29 M Lithium sulfate, 2.7 % PEG400 
36 0.1 M Bicine pH 9.5, 2.4 M Sodium malonate 
37 0.1 M Sodium acetate pH 5.5, 29.0 % PEG4000, 0.05 M Sodium potassium phosphate 
38 0.1 M Sodium acetate pH 5.5, 34.8 % PEGMME550, 0.03 M Calcium acetate 
39 0.1 M Sodium citrate pH 5.0, 2.1 M Sodium malonate, 0.22 M Potassium thiocyanate 
40 0.1 M MOPS pH 7.0, 2.2 M Sodium malate 
41 0.1 M Sodium cacodylate pH 6.5, 1.9 M Sodium potassium phosphate 
42 0.1 M Bicine pH 8.5, 1.9 M Ammonium sulfate 
43 0.1 M Sodium citrate pH 4.5, 2.4 M Sodium malate, 0.19 M Potassium nitrate 
44 0.1 M Tris pH 7.5, 1.7 M Ammonium phosphate, 0.29 M Potassium chloride 
45 0.1 M Sodium citrate pH 4.5, 30.8 % PEG1500, 0.08 % CHAPS 
46 0.1 M Tris pH 8.0, 16.2 % PEG10000, 0.05 M Zinc acetate 
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47 0.1 M MOPS pH 6.5, 34.5 % PEG3350, 0.09 M Sodium potassium tartrate 
48 53.9 % MPD, 0.15 M Ammonium sulfate, 3.0 % DMSO 
49 0.1 M Tris pH 8.0, 20.0 % Ethanol, 0.18 M Magnesium acetate, 0.08 % βOG 
50 0.1 M MES pH 6.0, 16.6 % PEG10000, 1.3 % Dioxane 
51 0.1 M BisTris pH 6.0, 27.0 % PEG3350, 0.08 M Zinc acetate, 0.05 % CHAPS 
52 0.1 M Bicine pH 9.0, 2.5 M Ammonium sulfate, 0.23 M Potassium nitrate, 0.9 % PEGMME350 
53 0.1 M CHES pH 9.0, 39.5 % MPD 
54 0.1 M Sodium cacodylate pH 7.0, 2.4 M Sodium malonate, 0.13 M Ammonium tartrate 
55 0.1 M Tris pH 8.5, 26.5 % PEG6000, 0.1 M Ammonium citrate 
56 0.1 M MES pH 6.0, 20.2 % PEGMME5000, 0.10 M Magnesium formate 
57 0.1 M MES pH 6.5, 1.1 M Sodium citrate, 0.29 M Magnesium sulfate, 2.2 % Hexanediol 
58 0.1 M MOPS pH 7.0, 20.5 % PEGMME5000 
59 0.1 M Bicine pH 8.5, 51.3 % PEG400, 0.11 M Sodium chloride 
60 0.1 M Sodium acetate pH 5.5, 22.0 % PEGMME2000 
61 0.1 M Tris pH 8.5, 2.7 M Sodium malonate, 0.10 M Potassium chloride 
62 24.8 % PEGMME2000, 0.17 M Sodium bromide 
63 0.1 M Sodium acetate pH 5.0, 19.0 % PEG6000, 0.11 M Lithium chloride 
64 0.1 M CHES pH 9.5, 2.1 M Sodium malate, 0.17 M Ammonium sulfate 
65 0.1 M Sodium citrate pH 5.0, 27.1 % PEG4000, 0.01 % LDAO 
66 0.1 M Tris pH 8.0, 24.3 % PEG8000, 0.05 M Ammonium phosphate 
67 0.1 M Sodium citrate pH 5.0, 1.6 M Ammonium sulfate, 0.14 M Ammonium acetate, 2.9 % Glycerol 
68 0.1 M BisTris pH 6.0, 2.4 M Sodium chloride, 0.08 M Calcium acetate 
69 0.1 M Sodium acetate pH 4.5, 53.0 % MPD, 0. 28 M Potassium thiocyanate, 1.3 % PEGDME250 
70 0.1 M Sodium citrate pH 5.5, 31.8 % PEGMME2000, 0.10 M Ammonium acetate, 2.7 % PEGMME350 
71 0.1 M Sodium acetate pH 4.5, 25.5 % PEG400, 0.24 M Potassium nitrate 
72 0.1 M Sodium citrate pH 4.5, 2.0 M Ammonium phosphate, 0.07 M Potassium chloride, 3.2 % 
Ethylene glycol 
73 0.1 M Sodium citrate pH 5.5, 38.0 % PEGMME550, 0.26 M Lithium sulfate, 0.1 % LDAO 
74 0.1 M MOPS pH 7.0, 37.8 % PEG1500, 0.19 M Potassium chloride, 6.3 mM EDTA 
75 0.1 M HEPES pH 8.0, 21.6 % PEGMME550, 0.07 M Magnesium chloride 
76 0.1 M Sodium cacodylate pH 7.0, 2.2 M Ammonium phosphate, 0.1 M Ammonium acetate 
77 0.1 M Tris pH 7.5, 2.4 M Sodium acetate, 0.11 M Potassium thiocyanate 
78 0.1 M CHES pH 9.0, 18.7 % PEGMME5000, 0.27 M Ammonium phosphate 
79 0.1 M Sodium cacodylate pH 7.0, 2.5 M Sodium formate 
80 0.1 M Bicine pH 9.5, 19.7 % PEG8000 
81 0.1 M BisTris pH 6.5, 2.0 M Sodium acetate 
82 0.1 M Sodium cacodylate pH 7.0, 2.0 M Sodium malate, 0.09 M Ammonium phosphate 
83 0.1 M Tris pH 8.6, 25.3 % PEG400, 0.17 M Magnesium acetate 
84 0.1 M Sodium citrate pH 5.5, 1.7 M ammonium phosphate, 0.10 M Sodium acetate 
85 0.1 M Tris pH 7.5, 1.7 M Magnesium sulfate, 0.16 M Magnesium chloride 
86 0.1 M Tris pH 7.5, 23.5 % PEG6000 
87 0.1 M BisTris pH 6.5, 22.8 PEG8000 
88 0.1 M Bicine pH 9.5, 11.2 % PEG10000, 0.11 M Sodium bromide 
89 0.1 M MOPS pH 6.5, 2.4 M Sodium chloride, 0.07 M Calcium chloride 
90 0.1 M Tris pH 8.0, 15.5 % PEGMME5000, 0.13 M Ammonium phosphate 
91 0.1 M HEPES pH 8.0, 1.8 M Sodium potassium phosphate 
92 0.1 M Sodium citrate pH 4.5, 30.3 % PEG1500, 0.20 M Ammonium sulfate  
93 0.1 M CHES pH 9.0, 0.70 M Sodium citrate, 0.23 M Sodium chloride 
94 0.1 M HEPES pH 8.0, 2.7 M Sodium chloride, 0.08 M Calcium chloride 
95 0.1 M HEPES pH 7.5, 2.2 M Sodium malonate, 0.30 M Potassium chloride 
96 0.1 M Sodium acetate pH 5.5, 29.8 % PEG1500 
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E.2 Stochastic Screen 20 
-  generated in-house 
 
No. Condition 
1 2.4 M Sodium acetate, 0.11 M Zinc acetate, 0.06 % LDAO 
2 0.1 M Sodium acetate pH 5.5, 14.7 % Isopropanol, 0.29 M Magnesium acetate 
3 0.1 M MES pH 6.0, 28.8 % PEG3350, 0.04 M Calcium chloride 
4 0.1 M Bicine pH 9.0, 23.4 % PEG4000, 0.15 M Ammonium acetate, 1.0 % MPD 
5 0.1 M MES pH 6.0, 22.8 % PEGMME2000, 0.13 M Lithium sulfate 
6 0.1 M Sodium acetate pH 5.0, 2.5 M Ammonium sulfate, 0.13 M Lithium sulfate 
7 0.1 M Sodium acetate pH 5.5, 1.7 M Ammonium phosphate, 0.08 M Ammonium citrate 
8 0.1 M CHES pH 9.5, 2.5 M Ammonium phosphate 
9 0.1 M Bicine pH 9.0, 2.3 M Sodium malate, 0.24 M Sodium chloride 
10 0.1 M MES pH 6.5, 2.2 M Sodium acetate, 0.11 M Calcium acetate 
11 0.1 M Sodium acetate pH 5.0, 18.0 % PEG3350, 0.05 M Zinc chloride 
12 0.1 M MES pH 60, 2.7 M Sodium chloride, 0.13 M calcium chloride 
13 0.1 M Bicine pH 9.0, 2.3 M Sodium malate, 0.24 M Sodium chloride 
14 0.1 M MES pH 6.5, 2.2 M Sodium acetate, 0.11 M Calcium acetate 
15 0.1 M Sodium acetate pH 5.0, 18.0 % PEG3350, 0.05 M Zinc chloride 
16 0.1 M MES pH 6.0, 2.7 M Sodium chloride, 0.13 M Calcium chloride 
17 0.1 M Sodium citrate pH 5.5, 0.65 M Sodium citrate, 0.06 M Sodium bromide 
18 0.1 M BisTris pH 6.0, 15.8 % PEG4000, 0.07 M Magnesium sulfate, 2.0 % PEG400 
19 0.1 M Sodium acetate pH 5.0, 1.3 M Magnesium sulfate, 0.05 % CHAPS 
20 0.1 M BisTris pH 6.5, 24.8 % PEG8000, 0.07 M Magnesium formate 
21 0.1 M Bicine pH 8.5, 12.7 % PEG6000, 0.05 M Sodium acetate 
22 2.3 M Sodium acetate, 0.16 M Lithium chloride 
23 0.1 M CHES pH 9.0, 28.0 % PEG4000 
24 0.1 M Sodium citrate pH 5.5, 36.7 % PEGMME2000, 0.03 M Sodium citrate 
25 0.1 M CHES pH 9.0, 18.3 % PEG10000, 0.07 M Sodium citrate 
26 0.1 M HEPES pH 7.5, 2.7 M Sodium potassium phosphate, 0.05 % CHAPS 
27 0.1 M BisTris pH 6.0, 25.6 % PEGMME5000, 1.3 % Butanediol 
28 0.1 M Sodium acetate pH 5.0, 25.1 % PEGMME2000, 0.17 M Potassium chloride, 0.9 % DMSO 
29 0.1 M Sodium cacodylate pH 6.5, 25.9 % PEG6000, 0.08 M Lithium sulfate 
30 0.1 M Sodium acetate pH 4.5, 22.6 % PEGMME2000, 0.25 M Lithium sulfate 
31 0.1 M Bicine pH 9.5, 2.5 M Sodium malonate, 0.07 M Sodium potassium tartrate 
32 0.1 M Sodium acetate pH 5.5, 14.8 % PEGMME5000, 0.07 M Lithium chloride 
33 0.1 M Tris pH 7.5, 3.2 M Sodium chloride, 0.14 M Ammonium citrate 
34 0.1 M MOPS pH 7.0, 24.5 % PEGMME550, 0.24 M Ammonium phosphate 
35 0.1 M HEPES pH 8.0, 1.7 M Magnesium sulfate, 0.18 M Potassium nitrate 
36 0.1 M Bicine pH 9.5, 19.4 % Ethanol, 0.29 M Magnesium chloride 
37 0.1 M Tris pH 7.5, 34.2 % PEGMME2000 
38 0.1 M Sodium acetate pH 5.0, 21.7 % PEG3350, 0.11 M Zinc acetate 
39 0.1 M Sodium citrate pH 4.5, 1.6 M Sodium formate 
40 0.1 M BisTris pH 6.0, 2.7 M Ammonium phosphate, 0.08 M Ammonium sulfate 
41 0.1 M MOPS pH 7.0, 32.0 % PEGMME550, 0.27 M Sodium potassium phosphate, 2.8 % Glycerol 
42 0.1 M MOPS pH 7.0, 53.3 % MPD, 0.8 % Methanol 
43 0.1 M Sodium citrate pH 4.5, 18.4 % PEGMME5000, 2.4 % PEGMME350 
44 0.1 M Sodium cacodylate pH 7.0, 2.3 M Sodium malate 
45 0.1 M MOPS pH 6.5, 16.9 % PEGMME5000, 0.08 M Zinc acetate 
46 0.1 M MES pH 6.0, 2.1 M Sodium formate, 0.05 M Sodium bromide 
47 0.1 M CHES pH 9.5, 2.1 M Sodium malate 
48 0.1 M CHES pH 9.5, 32.3 % PEG1500, 0.08 M Sodium bromide, 0.4 % Ethylene glycol 
9. Appendices 
 233 
49 12.8 % PEG8000, 0.1 M Calcium acetate 
50 0.1 M Bicine pH 8.5, 18.6 % PEG8000, 0.04 M Ammonium tartrate 
51 0.1 M Tris pH 8.5, 31.8 % PEG400 
52 0.1 M Tris pH 8.5, 41.0 % PEGMME550, 0.14 M Magnesium acetate 
53 0.1 M HEPES pH 8.0, 14.8 % PEG4000, 0.04 M Ammonium citrate, 0.01 % LDAO 
54 0.1 M BisTris pH 6.5, 2.2 M Ammonium sulfate 
55 0.1 M BisTris pH 6.5, 32.2 % PEG3350, 0.09 M Sodium chloride, 7.8 mM BME 
56 0.1 M Sodium acetate pH 5.0, 12.0 % Isopropanol 
57 0.1 M HEPES pH 7.5, 0.72 M Sodium citrate, 0.04 M Magnesium formate, 2.9 % Ethylene glycol 
58 0.1 M HEPES pH 7.5, 1.9 M Sodium potassium phosphate, 0.24 M Ammonium phosphate, 4.0 
% PEGDME250 
59 0.1 M Sodium acetate pH 4.5, 1.3 M Sodium tartrate 
60 16.3 % Isopropanol 
61 0.1 M Sodium cacodylate pH 6.5, 14.2 % PEG4000, 0.04 M Zinc acetate 
62 0.1 M Sodium acetate pH 4.5, 21.8 % PEG4000, 0.08 M Lithium chloride 
63 0.1 M HEPES pH 7.5, 1.3 M Sodium citrate 
64 0.1 M MOPS pH 7.0, 2.0 M Sodium potassium phosphate, 0.22 M Sodium bromide 
65 0.1 M BisTris pH 6.0, 1.8 M Sodium formate, 0.13 M Ammonium tartrate 
66 0.1 M CHES pH 9.0, 1.3 M Magnesium sulfate, 0.2 M Magnesium acetate 
67 0.1 M Bicine pH 9.5, 20.5 % PEG3350, 0.14 M Potassium thiocyanate 
68 0.1 M MES pH 6.0, 19.6 % PEG6000, 0.11 M Ammonium acetate 
69 1.0 M Sodium citrate, 0.11 M Sodium acetate 
70 11.3 % PEG10000 
71 0.1 M Sodium cacodylate pH 6.5, 2.3 % Ethanol, 0.13 M Magnesium chloride 
72 0.1 M Bicine pH 9.0, 23.2 % PEG1500, 0.05 M Magnesium formate, 4.6 mM BME 
73 0.1 M Sodium citrate pH 5.5, 2.7 M Sodium potassium phosphate, 0.06 M Potassium nitrate 
74 0.1 M Sodium cacodylate pH 7.0, 14.7 % PEGMME5000, 0.07 M Calcium acetate 
75 0.1 M Tris pH 8.5, 4.1 M Sodium chloride 
76 0.1 M Sodium citrate pH 5.5, 47.3 % PEGMME550, 3.7 % Hexanediol 
77 17.4 % Isopropanol, 0.1 M Sodium potassium tartrate 
78 0.1 M Bicine pH 8.5, 9.3 % PEG10000, 0.26 M Lithium sulfate 
79 0.1 M Sodium cacodylate pH 7.0, 25.1 % PEGMME5000, 0.09 M Ammonium tartrate 
80 0.1 M Tris pH 8.0, 36.0 % PEGMME550, 0.18 M Magnesium acetate 
81 0.1 M CHES pH 9.0, 38.3 % PEG400, 0.13 M Sodium bromide 
82 0.1 M Sodium acetate pH 5.5, 1.9 M Sodium malonate 
83 0.1 M Bicine pH 8.5, 0.90 M Sodium tartrate, 0.05 M Sodium potassium phosphate 
84 0.1 M Tris pH 8.5, 2.8 M Sodium chloride, 0.1 M Zinc acetate 
85 0.1 M Tris pH 8.5, 0.90 M Sodium citrate, 0.27 M Magnesium chloride 
86 0.1 M BisTris pH 6.0, 31.4 % PEG1500, 0.06 M Calcium chloride 
87 0.1 M HEPES pH 7.5, 9.3 % Ethanol, 0.13 M Ammonium sulfate, 0.03 % βOG 
88 0.1 M Tris pH 8.0, 20.8 % PEG4000, 0.14 M Potassium chloride 
89 0.1 M Sodium acetate pH 4.5, 2.2 M Sodium malate, 4.4 mM EDTA 
90 0.1 M HEPES pH 8.0, 19.0 % PEG10000 
91 32.0 % PEGMME2000, 0.06 M Zinc chloride, 3.5 % Hexanediol 
92 0.1 M Sodium acetate pH 5.5, 20.7 % PEG1500, 0.29 M Sodium chloride 
93 0.1 M Sodium citrate pH 5.0, 0.89 M Sodium citrate, 0.12 M Ammonium acetate 
94 0.1 M CHES pH 9.5, 29.8 % PEG400 
95 0.1 M HEPES pH 8.0, 20.4 % PEG3350, 0.26 M Sodium acetate 
96 0.1 M Sodium cacodylate pH 7.0, 1.1 M Sodium tartrate, 0.13 M Ammonium citrate, 3.4 % 
DMSO 
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E.3 Stochastic Screen Pegs 4 
- generated in-house 
 
No. Condition 
1 0.1 M HEPES pH 8.0, 25.2 % PEG400 
2 0.1 M Sodium acetate pH 5.0, 31.5 % PEGMME550, 0.13 M Zinc acetate 
3 34.6 % PEGMME2000, 1.0 mM EDTA 
4 0.1 M Sodium citrate pH 4.5, 19.3 % PEG10000, 0.07 M Magnesium formate 
5 0.1 M Sodium cacodylate pH 6.5, 35.6 % PEGMME2000, 0.14 M Magnesium formate 
6 0.1 M Sodium acetate pH 5.0, 48.4 % PEGMME550, 0.08 M Ammonium acetate 
7 0.1 M Sodium cacodylate pH 7.0, 24.2 % PEGMME5000, 0.29 M Sodium chloride, 3.2 % 
PEGDME250 
8 12.1 % PEG10000 
9 23.1 % PEG3350, 0.05 M Calcium acetate 
10 0.1 M Sodium acetate pH 5.5, 21.4 % PEG4000, 0.20 M Magnesium chloride 
11 0.1 M MES pH 6.5, 32.2 % PEG1500, 0.15 M Calcium chloride 
12 23.9 % PEG8000, 0.11 M Sodium potassium phosphate 
13 0.1 M Tris pH 7.5, 30.2 % PEGMME550 
14 0.1 M Sodium cacodylate pH 6.5, 27.2 % PEG3350 
15 0.1 M Tris pH 8.0, 19.5 % PEG3350, 0.10 M Potassium nitrate 
16 0.1 M HEPES pH 7.5, 21.8 % PEG1500, 0.09 M Zinc chloride 
17 0.1 M Bicine pH 8.5, 17.9 % PEG10000, 0.26 M Lithium chloride, 3.9 % Ethylene glycol 
18 0.1 M Sodium citrate pH 5.5, 31.8 % PEGMME550, 0.16 M Ammonium sulfate 
19 0.1 M Sodium acetate pH 5.5, 24.3 % PEG400, 0.11 M Sodium chloride 
20 0.1 M Sodium citrate pH 5.5, 14.6 % PEG6000, 0.08 M Lithium chloride, 1.6 % Dioxane 
21 24.2 % PEG3350, 0.04 M Sodium potassium tartrate 
22 0.1 M CHES pH 9.0, 14.7 % PEG6000, 0.07 M Sodium acetate 
23 0.1 M BisTris pH 6.5, 19.7 % PEG1500, 0.17 M Ammonium phosphate, 4.0 % PEGMME350 
24 0.1 M BisTris pH 6.0, 37.8 % PEG400, 0.08 M Potassium chloride, 0.1 % LDAO 
25 0.1 M Sodium acetate pH 5.5, 24.1 % PEG8000, 0.14 M Sodium citrate, 0.01 % βOG 
26 0.1 M Bicine pH 9.5, 27.8 % PEGMME2000, 0.22 M Magnesium sulfate, 2.1 % Ethylene glycol 
27 0.1 M HEPES pH 7.5, 27.3 % PEG6000, 0.22 M Ammonium phosphate, 3.1 % DMSO 
28 0.1 M HEPES pH 7.5, 13.1 % PEGMME5000 
29 0.1 M HEPES pH 7.5, 41.8 % PEG400, 0.10 M Calcium acetate 
30 0.1 M CHES pH 9.0, 21.3 % PEG8000, 0.22 M Sodium potassium phosphate 
31 0.1 M CHES pH 9.5, 9.8 % PEG10000, 0.14 M Ammonium acetate 
32 26.3 % PEG400, 0.15 M Sodium chloride 
33 0.1 M Sodium acetate pH 4.5, 22.8 % PEGMME5000, 0.05 M Zinc chloride, 3.6 % PEG400 
34 0.1 M CHES pH 9.5, 27.1 % PEG3350, 0.10 M Potassium chloride 
35 0.1 M Sodium citrate pH 5.0, 30.6 % PEG3350, 0.10 M Sodium potassium phosphate, 0.8 % 
MPD 
36 0.1 M MES pH 6.0, 30.4 % PEGMME2000, 0.06 M Sodium acetate 
37 0.1 M Sodium cacodylate pH 7.0, 21.2 % PEG6000, 0.09 M Calcium chloride 
38 0.1 MOPS pH 7.0, 25.2 % PEG6000, 0.15 M Potassium chloride, 1.8 % PEG400 
39 0.1 M Tris pH 8.0, 29.0 % PEG3350, 0.03 M Ammonium citrate 
40 0.1 M MES pH 6.0, 42.7 % PEGMME550 
41 0.1 M MOPS pH 7.0, 26.7 % PEGMME2000 
42 0.1 M Tris pH 8.0, 13.9 % PEG4000 
43 44.0 % PEG400, 0.05 M Sodium potassium tartrate 
44 0.1 M Sodium acetate pH 4.5, 47.6 % PEGMME550, 0.18 M Magnesium chloride 
45 0.1 M BisTris pH 6.0, 15.6 % PEGMME5000, 0.22 M Magnesium acetate 
46 0.1 M Sodium acetate pH 5.0, 36.1 % PEG1500, 0.09 M Sodium chloride 
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47 0.1 M MES pH 6.0, 47.0 % PEGMME550, 0.26 M Potassium thiocyanate 
48 0.1 M Bicine pH 9.0, 18.5 % PEGMME5000, 1.6 % Methanol 
49 0.1 M Sodium citrate pH 5.0, 22.8 % PEG4000, 0.05 M Magnesium formate 
50 0.1 M Sodium cacodylate pH 7.0, 15.8 % PEG6000, 0.07 M Zinc acetate, 3.0 % Methanol 
51 0.1 M Sodium citrate pH 4.5, 32.4 % PEG3350, 0.06 M Magnesium chloride 
52 0.1 M Sodium acetate pH 5.0, 25.4 % PEGMME2000, 0.12 M Zinc acetate 
53 0.1 M Sodium acetate pH 5.0, 18.5 % PEG4000, 0.13 M Sodium chloride 
54 0.1 M Tris pH 8.0, 23.8 % PEG3350 
55 0.1 M Tris pH 7.5, 25.3 % PEG8000, 0.04 M Ammonium tartrate 
56 0.1 M HEPES pH 8.0, 15.9 % PEG6000, 0.03 M Calcium chloride 
57 0.1 M BisTris pH 6.0, 21.3 % PEG1500, 0.17 M Ammonium sulfate, 0.08 % CHAPS 
58 0.1 M Bicine pH 9.0, 16.5 % PEGMME5000 
59 0.1 M Sodium cacodylate pH 7.0, 24.8 % PEG4000, 0.03 M Zinc chloride 
60 0.1 M MOPS pH 7.0, 15.1 % PEG10000, 0.09 M Potassium chloride 
61 0.1 M Bicine pH 9.5, 15.7 % PEG8000, 0.12 M Magnesium sulfate 
62 34.8 % PEG1500, 0.25 M Lithium sulfate 
63 0.1 Bicine pH 9.5, 19.3 % PEG10000 
64 0.1 M Tris pH 8.5, 15.1 % PEGMME5000, 0.10 M Ammonium citrate 
65 0.1 M BisTris pH 6.0, 20.5 % PEG1500, 0.28 M Lithium sulfate 
66 0.1 M Sodium citrate pH 4.5, 42.8 % PEGMME550 
67 0.1 M Bicine pH 8.5, 33.2 % PEGMME2000, 0.07 M Calcium chloride 
68 0.1 M Sodium citrate pH 5.0, 24.6 % PEG4000, 0.05 M Ammonium sulfate 
69 0.1 M HEPES pH 8.0, 14.5 % PEG10000, 0.01 % CHAPS 
70 0.1 M MOPS pH 6.0, 24.3 % PEG8000, 0.07 M Zinc chloride, 0.1 % CHAPS 
71 0.1 M Tris pH 8.5, 34.3 % PEGMME550, 1.4 % PEGDME250 
72 0.1 M MOPS pH 7.0, 24.0 % PEG6000, 3.0 % PEGMME350 
73 24.1 % PEGMME550, 0.06 M Sodium bromide, 0.5 % Hexanediol 
74 0.1 M MES pH 6.0, 18.4 % PEG1500, 6.1 mM BME 
75 0.1 M Sodium citrate pH 4.5, 12.9 % PEGMME5000, 0.09 M Lithium sulfate 
76 0.1 M Sodium acetate pH 4.5, 55.4 % PEG400 
77 0.1 M Bicine pH 8.5, 25.8 % PEGMME2000, 0.11 M Calcium acetate 
78 0.1 M MES pH 6.5, 30.1 % PEG4000 
79 0.1 M BisTris pH 6.0, 26.7 % PEGMME5000, 0.14 M Sodium acetate 
80 23.3 % PEGMME2000, 0.12 M Sodium potassium tartrate 
81 0.1 M MOPS pH 7.0, 29.6 % PEG3350, 0.08 M Ammonium phosphate 
82 0.1 M Bicine pH 9.5, 29.6 % PEG10000 
83 0.1 M CHES pH 9.0, 23.3 % PEG6000, 0.11 M Sodium potassium tartrate 
84 0.1 M MES pH 6.5, 9.5 % PEG10000, 0.07 M Potassium thiocyanate 
85 0.1 M Sodium acetate pH 5.5, 24.5 % PEG400, 0.07 M Zinc chloride, 3.4 % PEGDME250 
86 0.1 M HEPES pH 7.5, 32.1 % PEG1500, 0.21 M Magnesium acetate 
87 0.1 M Sodium acetate pH 5.5, 15.0 % PEG10000, 0.25 M Magnesium chloride 
88 0.1 M Sodium citrate pH 5.5, 23.3 % PEG6000, 0.06 M Ammonium tartrate 
89 0.1 M Bicine pH 9.5, 11.7 % PEG10000, 0.06 M Sodium citrate 
90 0.1 M Sodium cacodylate pH 7.0, 22.6 % PEG3350, 0.27 M Magnesium sulfate 
91 0.1 M Tris pH 8.5, 31.2 % PEG4000, 0.19 M Sodium potassium phosphate, 3.9 % Glycerol 
92 0.1 M Bicine pH 9.0, 50.6 % PEG400 
93 0.1 M CHES PH 9.0, 17.6 % PEG4000, 0.8 % Glycerol 
94 0.1 M MES pH 6.0, 39.0 % PEGMME2000, 0.14 M Potassium nitrate 
95 0.1 M CHES pH 9.5, 20.7 % PEGMME5000, 1.9 % PEGMME350 
96 0.1 M Sodium acetate pH 5.5, 26.8 % PEG8000, 0.22 M Sodium bromide 
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E.4 Commercial Screens 
 
JCSG+ Screen, PEGS I Suite and PEGS II Suite were purchased from Qiagen 
 
Compositions can be found at: 
http://www.qiagen.com/products/protein/crystallization/compositiontables/default.a
spx 
 
Wizard Classics Screen was purchased from Rigaku Reagents 
 
Compositions can be found at: 
http://www.rigakureagents.com/p-1-wizard-classic-crystallization-screen-series.aspx 
 
